{"c938865b11b14c7106a80798336fc2b4c68f1814": [["IntroductionThe human \"channelome\" contains over 300 known channels [1] that selectively and rapidly transport ions across biological membranes in response to specific stimuli.", [["membranes", "ANATOMY", 134, 143], ["human", "ORGANISM", 16, 21], ["membranes", "CELLULAR_COMPONENT", 134, 143], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["The human \"channelome\"", "TREATMENT", 12, 34], ["specific stimuli", "TEST", 159, 175]]], ["Ion channels are present on the plasma membranes and organelles of all cells, where they regulate organelle ion homeostasis, mitochondrial function, inflammasome activation, action potential firing, membrane potential, cell volume, and autophagy [2] [3] [4] [5] .", [["plasma membranes", "ANATOMY", 32, 48], ["organelles", "ANATOMY", 53, 63], ["cells", "ANATOMY", 71, 76], ["organelle ion", "ANATOMY", 98, 111], ["mitochondrial", "ANATOMY", 125, 138], ["membrane", "ANATOMY", 199, 207], ["cell", "ANATOMY", 219, 223], ["Ion", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma membranes", "CELLULAR_COMPONENT", 32, 48], ["organelles", "CELLULAR_COMPONENT", 53, 63], ["cells", "CELL", 71, 76], ["organelle ion", "CELLULAR_COMPONENT", 98, 111], ["mitochondrial", "CELLULAR_COMPONENT", 125, 138], ["membrane", "CELLULAR_COMPONENT", 199, 207], ["cell", "CELL", 219, 223], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 246, 261], ["mitochondrial function", "TEST", 125, 147], ["inflammasome activation", "PROBLEM", 149, 172], ["cell volume", "TEST", 219, 230], ["autophagy", "TEST", 236, 245], ["all cells", "ANATOMY", 67, 76], ["ion homeostasis", "OBSERVATION", 108, 123]]], ["Given their importance, it follows that their dysfunctions leads to human diseases, termed channelopathies [6] .", [["channelopathies", "DISEASE", 91, 106], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["their dysfunctions", "PROBLEM", 40, 58], ["human diseases", "PROBLEM", 68, 82], ["termed channelopathies", "PROBLEM", 84, 106]]], ["These include disease states of the nervous [2] , musculoskeletal [5] , cardiovascular [7] , and immune systems [8] .", [["nervous", "ANATOMY", 36, 43], ["musculoskeletal", "ANATOMY", 50, 65], ["cardiovascular", "ANATOMY", 72, 86], ["nervous", "ANATOMICAL_SYSTEM", 36, 43], ["disease", "OBSERVATION", 14, 21], ["musculoskeletal", "ANATOMY", 50, 65]]], ["This has motivated research on compounds that can modulate ion channel activity;~19% of current FDA-approved drugs are ion channel modulators, second only to drugs targeting G-protein coupled receptors [9, 10] .IntroductionMany viruses encode their own ion channels [11] [12] [13] termed \"viroporins,\" highlighting the importance of ionic balance during viral infection.", [["viral infection", "DISEASE", 354, 369], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 174, 201], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 266, 280], ["viroporins", "SIMPLE_CHEMICAL", 289, 299], ["G-protein coupled receptors", "PROTEIN", 174, 201], ["current FDA", "TREATMENT", 88, 99], ["drugs", "TREATMENT", 109, 114], ["ion channel modulators", "TREATMENT", 119, 141], ["G-protein coupled receptors", "TREATMENT", 174, 201], ["viroporins", "TREATMENT", 289, 299], ["viral infection", "PROBLEM", 354, 369], ["viral infection", "OBSERVATION", 354, 369]]], ["This field has spurred intense research and several drugs that target viroporins have emerged (reviewed in [11] ).", [["viroporins", "GENE_OR_GENE_PRODUCT", 70, 80], ["viroporins", "PROTEIN", 70, 80], ["several drugs", "TREATMENT", 44, 57], ["spurred", "OBSERVATION_MODIFIER", 15, 22], ["intense", "OBSERVATION_MODIFIER", 23, 30]]], ["More recent evidence highlights how viruses can regulate and/or depend on the ion channels expressed by host cells, highlighting them as new host targets for therapeutic intervention (reviewed by Hover et al., 2017) [14] .", [["cells", "ANATOMY", 109, 114], ["host cells", "CELL", 104, 114], ["ion channels", "PROTEIN", 78, 90], ["host cells", "CELL_TYPE", 104, 114], ["therapeutic intervention", "TREATMENT", 158, 182]]], ["Given recent and important advances in this field, we herein provide an up-to-date review of the virus-ion channel literature and discuss the future prospects of ion channel drugs as anti-viral agents.", [["ion channel drugs", "SIMPLE_CHEMICAL", 162, 179], ["ion channel drugs", "TREATMENT", 162, 179], ["anti-viral agents", "TREATMENT", 183, 200]]], ["Firstly, we highlight recent evidence that suggests that viruses have adapted to take advantage of endolysosomal ionic balance as a cue for viral entry.", [["endolysosomal", "ANATOMY", 99, 112], ["viruses", "PROBLEM", 57, 64], ["endolysosomal ionic balance", "TREATMENT", 99, 126], ["viruses", "OBSERVATION", 57, 64]]], ["We then discuss how intracellular ion channels contribute to the Two-pore channels 1 and 2 (TPC1/2) Gunaratne et al., 2018 [34] Severe fever with thrombocytopenia syndrome virus (SFTSV) Unknown channel Li et al., 2019 [35] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Two-pore channel 2 (TPC2) Ou et al., 2020 [36] Bunyamwera orthobunyavirus (BUNV) Two-pore domain K + (K 2P ) Hover et al., 2016/18 [28, 37] Hazara orthonairovirus (HAZV) Unknown K + channel Punch et al., 2017 [38] Charlton et al., 2019 [39] Human immunodeficiency virus (HIV) G-Protein coupled inwardly rectifying K + (GIRK) ATP-sensitive K + K ATP Dubey et al., 2019 [40] Merkel cell polyomavirus (MCPyV)Ca 2+ Channels and Viral EntryThe involvement of Ca 2+ channels during viral entry is now well-documented [26] .", [["intracellular", "ANATOMY", 20, 33], ["fever", "DISEASE", 135, 140], ["thrombocytopenia syndrome", "DISEASE", 146, 171], ["acute respiratory syndrome coronavirus", "DISEASE", 230, 268], ["K", "CHEMICAL", 381, 382], ["K", "CHEMICAL", 462, 463], ["Human immunodeficiency virus", "DISEASE", 525, 553], ["K", "CHEMICAL", 598, 599], ["ATP", "CHEMICAL", 609, 612], ["K", "CHEMICAL", 623, 624], ["K", "CHEMICAL", 627, 628], ["ATP", "CHEMICAL", 629, 632], ["Ca", "CHEMICAL", 689, 691], ["Ca", "CHEMICAL", 738, 740], ["ATP", "CHEMICAL", 609, 612], ["K +", "CHEMICAL", 623, 626], ["ATP", "CHEMICAL", 629, 632], ["Ca 2+", "CHEMICAL", 689, 694], ["Ca 2+", "CHEMICAL", 738, 743], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 33], ["Human immunodeficiency virus", "ORGANISM", 525, 553], ["G-Protein coupled inwardly rectifying K +", "GENE_OR_GENE_PRODUCT", 560, 601], ["GIRK", "GENE_OR_GENE_PRODUCT", 603, 607], ["ATP", "SIMPLE_CHEMICAL", 609, 612], ["MCPyV", "ORGANISM", 683, 688], ["Ca 2+", "SIMPLE_CHEMICAL", 738, 743], ["GIRK", "PROTEIN", 603, 607], ["Ca 2+ channels", "PROTEIN", 738, 752], ["Human immunodeficiency virus", "SPECIES", 525, 553], ["Severe fever with thrombocytopenia syndrome virus", "SPECIES", 128, 177], ["SFTSV", "SPECIES", 179, 184], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 223, 268], ["SARS-CoV", "SPECIES", 272, 280], ["Human immunodeficiency virus", "SPECIES", 525, 553], ["HIV", "SPECIES", 555, 558], ["pore channels", "TEST", 69, 82], ["Severe fever", "PROBLEM", 128, 140], ["thrombocytopenia syndrome virus (SFTSV", "PROBLEM", 146, 184], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 223, 268], ["SARS", "TEST", 272, 276], ["CoV", "TEST", 277, 280], ["Two-pore channel", "TREATMENT", 284, 300], ["Bunyamwera orthobunyavirus", "TEST", 331, 357], ["BUNV", "TEST", 359, 363], ["K", "TEST", 381, 382], ["K 2P", "TEST", 386, 390], ["et al.", "TEST", 399, 405], ["Hazara orthonairovirus", "TEST", 424, 446], ["HAZV", "TEST", 448, 452], ["K", "TEST", 462, 463], ["channel Punch et al.", "TEST", 466, 486], ["Charlton et al.", "TEST", 498, 513], ["Human immunodeficiency virus", "PROBLEM", 525, 553], ["Protein", "TEST", 562, 569], ["rectifying", "TEST", 587, 597], ["K", "TEST", 598, 599], ["GIRK", "TEST", 603, 607], ["ATP", "TEST", 609, 612], ["K", "TEST", 623, 624], ["K ATP", "TEST", 627, 632], ["Dubey", "TEST", 633, 638], ["et al.", "TEST", 639, 645], ["Merkel cell polyomavirus", "TEST", 657, 681], ["MCPyV", "TEST", 683, 688], ["Ca", "TEST", 689, 691], ["thrombocytopenia syndrome", "OBSERVATION", 146, 171], ["Severe", "OBSERVATION_MODIFIER", 223, 229], ["acute", "OBSERVATION_MODIFIER", 230, 235], ["respiratory syndrome", "OBSERVATION", 236, 256]]], ["Fujioka et al. showed that influenza virus (IAV) hemagglutinin (HA) triggers intracellular [Ca 2+ ] oscillations that are required for viral infection [30] .", [["intracellular", "ANATOMY", 77, 90], ["Ca", "CHEMICAL", 92, 94], ["viral infection", "DISEASE", 135, 150], ["Ca 2+", "CHEMICAL", 92, 97], ["influenza virus", "ORGANISM", 27, 42], ["IAV) hemagglutinin", "ORGANISM", 44, 62], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["influenza virus", "SPECIES", 27, 42], ["IAV", "SPECIES", 44, 47], ["influenza virus", "PROBLEM", 27, 42], ["hemagglutinin (HA)", "TREATMENT", 49, 67], ["intracellular [Ca 2+ ] oscillations", "TREATMENT", 77, 112], ["viral infection", "PROBLEM", 135, 150], ["influenza virus", "OBSERVATION", 27, 42]]], ["The initial modulation of Ca 2+ by IAV was demonstrated using F\u00f6rster resonance energy transfer (FRET)-based imaging of the Ca 2+ sensor Yellow Cameleon (YC3.60).", [["Ca", "CHEMICAL", 26, 28], ["Ca", "CHEMICAL", 124, 126], ["Ca 2+", "CHEMICAL", 26, 31], ["Ca 2+", "CHEMICAL", 124, 129], ["Ca 2+", "SIMPLE_CHEMICAL", 26, 31], ["Ca 2", "PROTEIN", 26, 30], ["Ca", "TEST", 26, 28], ["IAV", "PROBLEM", 35, 38], ["based imaging", "TEST", 103, 116], ["the Ca", "TEST", 120, 126]]], ["These oscillations in Ca 2+ were mediated by a specific voltage-gated Ca 2+ channel (Ca V 1.2) identified through siRNA silencing approaches.", [["Ca", "CHEMICAL", 22, 24], ["Ca", "CHEMICAL", 70, 72], ["Ca", "CHEMICAL", 85, 87], ["Ca 2+", "CHEMICAL", 22, 27], ["Ca 2+", "CHEMICAL", 70, 75], ["Ca V 1.2", "CHEMICAL", 85, 93], ["Ca 2+", "SIMPLE_CHEMICAL", 22, 27], ["Ca V 1.2", "GENE_OR_GENE_PRODUCT", 85, 93], ["Ca 2+ channel", "PROTEIN", 70, 83], ["Ca V 1.2", "PROTEIN", 85, 93], ["These oscillations in Ca", "TEST", 0, 24], ["a specific voltage", "TEST", 45, 63], ["gated Ca", "TEST", 64, 72], ["channel (Ca V", "TEST", 76, 89], ["siRNA silencing approaches", "TREATMENT", 114, 140], ["siRNA silencing", "OBSERVATION", 114, 129]]], ["Assays subsequently revealed that IAV directly binds to Ca V 1.2 via the interaction of HA and a sialylated site on Ca V 1.2.", [["Ca", "CHEMICAL", 56, 58], ["Ca", "CHEMICAL", 116, 118], ["Ca V 1.2", "CHEMICAL", 56, 64], ["Ca V 1.2", "CHEMICAL", 116, 124], ["IAV", "ORGANISM", 34, 37], ["Ca V 1.2", "GENE_OR_GENE_PRODUCT", 56, 64], ["HA", "GENE_OR_GENE_PRODUCT", 88, 90], ["Ca V 1.2", "PROTEIN", 56, 64], ["HA", "PROTEIN", 88, 90], ["sialylated site", "PROTEIN", 97, 112], ["IAV", "SPECIES", 34, 37], ["Assays", "TEST", 0, 6], ["IAV", "PROBLEM", 34, 37], ["Ca V", "TEST", 56, 60], ["HA", "PROBLEM", 88, 90], ["a sialylated site", "PROBLEM", 95, 112], ["Ca V", "TEST", 116, 120], ["IAV", "OBSERVATION", 34, 37]]], ["Accordingly, IAV entry could be inhibited by diltiazem, a clinically available Ca 2+ blocker, highlighting the potential of these compounds for drug repurposing.Ca 2+ Channels and Viral EntryEbola virus (EBOV) also requires Ca 2+ channels for its entry into host cells.", [["cells", "ANATOMY", 263, 268], ["diltiazem", "CHEMICAL", 45, 54], ["Ca", "CHEMICAL", 79, 81], ["Ca", "CHEMICAL", 161, 163], ["Ca", "CHEMICAL", 224, 226], ["diltiazem", "CHEMICAL", 45, 54], ["Ca 2+", "CHEMICAL", 79, 84], ["Ca 2+", "CHEMICAL", 161, 166], ["Ca 2+", "CHEMICAL", 224, 229], ["IAV", "ORGANISM", 13, 16], ["diltiazem", "SIMPLE_CHEMICAL", 45, 54], ["Ca 2+ blocker", "SIMPLE_CHEMICAL", 79, 92], ["Ca 2", "GENE_OR_GENE_PRODUCT", 161, 165], ["Viral EntryEbola virus", "ORGANISM", 180, 202], ["EBOV", "ORGANISM", 204, 208], ["Ca 2+", "SIMPLE_CHEMICAL", 224, 229], ["cells", "CELL", 263, 268], ["Ca 2+ channels", "PROTEIN", 224, 238], ["host cells", "CELL_TYPE", 258, 268], ["Viral EntryEbola virus", "SPECIES", 180, 202], ["EBOV", "SPECIES", 204, 208], ["IAV entry", "TREATMENT", 13, 22], ["diltiazem", "TREATMENT", 45, 54], ["Ca 2+ blocker", "TREATMENT", 79, 92], ["drug repurposing", "TREATMENT", 144, 160], ["Ca", "TEST", 161, 163], ["Channels", "TEST", 167, 175], ["Viral EntryEbola virus", "PROBLEM", 180, 202], ["Ca 2+ channels", "TREATMENT", 224, 238], ["Viral EntryEbola virus", "OBSERVATION", 180, 202], ["host cells", "OBSERVATION", 258, 268]]], ["EBOV enters cells through endolysosomes positive for both Niemann-Pick C1 (NPC1) and two-pore Ca 2+ channel 2 (TPC2) [32] .", [["cells", "ANATOMY", 12, 17], ["Ca", "CHEMICAL", 94, 96], ["Ca 2+", "CHEMICAL", 94, 99], ["EBOV", "ORGANISM", 0, 4], ["cells", "CELL", 12, 17], ["endolysosomes", "GENE_OR_GENE_PRODUCT", 26, 39], ["Niemann-Pick C1", "GENE_OR_GENE_PRODUCT", 58, 73], ["NPC1", "GENE_OR_GENE_PRODUCT", 75, 79], ["Ca 2+ channel 2", "GENE_OR_GENE_PRODUCT", 94, 109], ["Niemann-Pick C1", "PROTEIN", 58, 73], ["NPC1", "PROTEIN", 75, 79], ["Ca 2+ channel 2", "PROTEIN", 94, 109], ["TPC2", "PROTEIN", 111, 115], ["EBOV", "SPECIES", 0, 4], ["EBOV enters cells", "TEST", 0, 17], ["endolysosomes", "TEST", 26, 39], ["Niemann", "TEST", 58, 65], ["NPC1", "TEST", 75, 79], ["two-pore Ca", "TREATMENT", 85, 96]]], ["To further characterise this pathway, Penny et al. expanded the pharmacology of TPCs using a virtual screen of~1500 FDA-approved drugs.", [["TPCs", "SIMPLE_CHEMICAL", 80, 84], ["a virtual screen", "TEST", 91, 107]]], ["All identified TPC modulators were cross-referenced with two recent anti-EBOV screens, with four dopamine receptor antagonists and five oestrogen receptor modulators identified.", [["dopamine", "CHEMICAL", 97, 105], ["dopamine", "CHEMICAL", 97, 105], ["oestrogen", "CHEMICAL", 136, 145], ["TPC", "CANCER", 15, 18], ["dopamine receptor antagonists", "GENE_OR_GENE_PRODUCT", 97, 126], ["oestrogen receptor", "GENE_OR_GENE_PRODUCT", 136, 154], ["TPC modulators", "TREATMENT", 15, 29], ["two recent anti-EBOV screens", "TEST", 57, 85], ["four dopamine receptor antagonists", "TREATMENT", 92, 126], ["five oestrogen receptor modulators", "TREATMENT", 131, 165], ["TPC modulators", "OBSERVATION", 15, 29]]], ["As such, it was reasoned that these drugs exert their inhibitory effects on EBOV through the blockade of TPCs ( Figure 1E ), subsequently confirmed through EBOV virus-like particle (VLP) assays [33] .", [["EBOV", "ORGANISM", 76, 80], ["TPCs", "GENE_OR_GENE_PRODUCT", 105, 109], ["Figure 1E", "GENE_OR_GENE_PRODUCT", 112, 121], ["EBOV virus-like particle", "GENE_OR_GENE_PRODUCT", 156, 180], ["TPCs", "PROTEIN", 105, 109], ["EBOV", "SPECIES", 76, 80], ["EBOV virus", "SPECIES", 156, 166], ["these drugs", "TREATMENT", 30, 41], ["EBOV", "TREATMENT", 76, 80], ["the blockade of TPCs", "TREATMENT", 89, 109], ["EBOV virus", "PROBLEM", 156, 166]]], ["Das et al. further characterised the role of Ca 2+ in EBOV entry using single-molecule FRET (smFRET)-imaging.", [["Ca", "CHEMICAL", 45, 47], ["Ca 2+", "CHEMICAL", 45, 50], ["Ca 2+", "SIMPLE_CHEMICAL", 45, 50], ["EBOV", "ORGANISM", 54, 58], ["EBOV", "SPECIES", 54, 58], ["Ca", "TEST", 45, 47], ["imaging", "TEST", 101, 108]]], ["It was shown that Ca 2+ and pH synergistically induce a conformational change in the EBOV glycoprotein GP2 (a key mediator of receptor binding and viral entry) to form a reversible intermediate state primed for NPC1 binding.", [["Ca", "CHEMICAL", 18, 20], ["Ca 2+", "CHEMICAL", 18, 23], ["Ca 2+", "SIMPLE_CHEMICAL", 18, 23], ["EBOV", "ORGANISM", 85, 89], ["GP2", "GENE_OR_GENE_PRODUCT", 103, 106], ["NPC1", "GENE_OR_GENE_PRODUCT", 211, 215], ["EBOV glycoprotein GP2", "PROTEIN", 85, 106], ["NPC1", "PROTEIN", 211, 215], ["Ca", "TEST", 18, 20], ["pH synergistically", "PROBLEM", 28, 46], ["a conformational change", "PROBLEM", 54, 77], ["the EBOV glycoprotein GP2", "PROBLEM", 81, 106], ["receptor binding", "TREATMENT", 126, 142], ["a reversible intermediate state", "PROBLEM", 168, 199], ["NPC1 binding", "PROBLEM", 211, 223]]], ["NPC1 binding then further promotes the conformational transition into a fusion-ready \"primed\" state of invading EBOV virions [43] .Ca 2+ Channels and Viral EntryOf importance to the current pandemic, it has been shown that Middle East respiratory syndrome coronavirus (MERS) [44] is dependent on TPCs to escape endosomes [34] .", [["endosomes", "ANATOMY", 311, 320], ["Middle East respiratory syndrome coronavirus", "DISEASE", 223, 267], ["NPC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["EBOV", "ORGANISM", 112, 116], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 223, 267], ["TPCs", "GENE_OR_GENE_PRODUCT", 296, 300], ["endosomes", "CELLULAR_COMPONENT", 311, 320], ["NPC1", "PROTEIN", 0, 4], ["TPCs", "PROTEIN", 296, 300], ["Middle East respiratory syndrome coronavirus", "SPECIES", 223, 267], ["NPC1 binding", "PROBLEM", 0, 12], ["a fusion", "TREATMENT", 70, 78], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 223, 267], ["Middle", "ANATOMY_MODIFIER", 223, 229], ["respiratory syndrome", "OBSERVATION", 235, 255]]], ["As an enveloped virus, MERS must fuse its envelope with host membranes to enter cells.", [["membranes", "ANATOMY", 61, 70], ["cells", "ANATOMY", 80, 85], ["MERS", "GENE_OR_GENE_PRODUCT", 23, 27], ["host membranes", "CELLULAR_COMPONENT", 56, 70], ["cells", "CELL", 80, 85], ["MERS", "PROTEIN", 23, 27], ["an enveloped virus", "PROBLEM", 3, 21], ["MERS", "PROBLEM", 23, 27], ["host membranes", "TREATMENT", 56, 70], ["enveloped", "OBSERVATION_MODIFIER", 6, 15], ["virus", "OBSERVATION", 16, 21]]], ["Following receptor attachment, MERS particles can fuse at either the cell surface or intracellularly in the endosomal network.", [["cell surface", "ANATOMY", 69, 81], ["endosomal network", "ANATOMY", 108, 125], ["cell surface", "CELLULAR_COMPONENT", 69, 81], ["endosomal network", "CELLULAR_COMPONENT", 108, 125], ["receptor attachment", "PROBLEM", 10, 29], ["MERS particles", "PROBLEM", 31, 45], ["endosomal network", "OBSERVATION", 108, 125]]], ["Fusion is mediated by the proteolytic cleavage of the viral spike (S) protein at its S1/S2 site.", [["S2", "GENE_OR_GENE_PRODUCT", 88, 90], ["viral spike (S) protein", "PROTEIN", 54, 77], ["S1/S2 site", "DNA", 85, 95], ["Fusion", "TREATMENT", 0, 6], ["the proteolytic cleavage", "PROBLEM", 22, 46], ["the viral spike", "PROBLEM", 50, 65], ["viral spike", "OBSERVATION", 54, 65], ["S1", "ANATOMY", 85, 87], ["S2", "ANATOMY", 88, 90]]], ["At the surface of the cell, this proteolytic event is facilitated by TMPRSS2, which in turn precludes exposure of the fusion loop and coalescence of host and viral membranes [45] .", [["surface", "ANATOMY", 7, 14], ["cell", "ANATOMY", 22, 26], ["membranes", "ANATOMY", 164, 173], ["surface", "CELLULAR_COMPONENT", 7, 14], ["cell", "CELL", 22, 26], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 69, 76], ["TMPRSS2", "PROTEIN", 69, 76], ["this proteolytic event", "PROBLEM", 28, 50], ["TMPRSS2", "PROBLEM", 69, 76], ["the fusion loop", "TREATMENT", 114, 129], ["host and viral membranes", "PROBLEM", 149, 173], ["cell", "ANATOMY", 22, 26], ["fusion loop", "OBSERVATION", 118, 129], ["host", "OBSERVATION_MODIFIER", 149, 153], ["viral membranes", "OBSERVATION", 158, 173]]], ["Alternatively, fusion can occur in late endosomes following translocation through the endocytic network and proteolytic processing by proprotein convertases, including furin, in a process regulated by Ca 2+ [46, 47] .", [["late endosomes", "ANATOMY", 35, 49], ["Ca", "CHEMICAL", 201, 203], ["Ca 2+", "CHEMICAL", 201, 206], ["late endosomes", "CELLULAR_COMPONENT", 35, 49], ["endocytic network", "CELLULAR_COMPONENT", 86, 103], ["furin", "GENE_OR_GENE_PRODUCT", 168, 173], ["Ca 2+", "SIMPLE_CHEMICAL", 201, 206], ["proprotein convertases", "PROTEIN", 134, 156], ["furin", "PROTEIN", 168, 173], ["fusion", "PROBLEM", 15, 21], ["proteolytic processing", "TREATMENT", 108, 130], ["proprotein convertases", "TREATMENT", 134, 156], ["furin", "TREATMENT", 168, 173], ["fusion", "OBSERVATION", 15, 21]]], ["In studies by Gunaratne et al., genetic silencing of TPC1 and TPC2 prevented the entry of pseudotyped MERS ( Figure 1F ).", [["TPC1", "GENE_OR_GENE_PRODUCT", 53, 57], ["TPC2", "GENE_OR_GENE_PRODUCT", 62, 66], ["pseudotyped", "ORGANISM", 90, 101], ["TPC1", "PROTEIN", 53, 57], ["TPC2", "PROTEIN", 62, 66], ["pseudotyped MERS", "PROTEIN", 90, 106], ["TPC1", "TREATMENT", 53, 57], ["TPC2", "TREATMENT", 62, 66]]], ["The dependence of MERS upon TPCs was further demonstrated through its inhibition by tetrandrine and fangchinoline (TPC inhibitors), which prevented a post-internalisation but pre-fusion entry event.", [["TPCs", "ANATOMY", 28, 32], ["tetrandrine", "CHEMICAL", 84, 95], ["fangchinoline", "CHEMICAL", 100, 113], ["TPC", "CHEMICAL", 115, 118], ["tetrandrine", "CHEMICAL", 84, 95], ["fangchinoline", "CHEMICAL", 100, 113], ["MERS", "GENE_OR_GENE_PRODUCT", 18, 22], ["TPCs", "SIMPLE_CHEMICAL", 28, 32], ["tetrandrine", "SIMPLE_CHEMICAL", 84, 95], ["fangchinoline", "SIMPLE_CHEMICAL", 100, 113], ["TPC", "SIMPLE_CHEMICAL", 115, 118], ["MERS", "PROTEIN", 18, 22], ["TPCs", "CELL_TYPE", 28, 32], ["MERS upon TPCs", "PROBLEM", 18, 32], ["tetrandrine", "TREATMENT", 84, 95], ["fangchinoline (TPC inhibitors", "TREATMENT", 100, 129], ["dependence", "OBSERVATION_MODIFIER", 4, 14]]], ["The mechanism through which TPC blockade inhibited MERS was multi-faceted: TPC1 and TPC2 silencing impaired furin activity, whilst pharmacological and genetic inhibition of TPC1 impaired endosomal motility.", [["endosomal", "ANATOMY", 187, 196], ["TPC", "CHEMICAL", 28, 31], ["TPC", "SIMPLE_CHEMICAL", 28, 31], ["MERS", "GENE_OR_GENE_PRODUCT", 51, 55], ["TPC1", "GENE_OR_GENE_PRODUCT", 75, 79], ["TPC2", "GENE_OR_GENE_PRODUCT", 84, 88], ["furin", "GENE_OR_GENE_PRODUCT", 108, 113], ["TPC1", "GENE_OR_GENE_PRODUCT", 173, 177], ["endosomal", "CELLULAR_COMPONENT", 187, 196], ["MERS", "PROTEIN", 51, 55], ["TPC2", "PROTEIN", 84, 88], ["furin", "PROTEIN", 108, 113], ["TPC1", "PROTEIN", 173, 177], ["TPC blockade", "TREATMENT", 28, 40], ["TPC1", "TREATMENT", 75, 79], ["TPC2 silencing", "TREATMENT", 84, 98], ["impaired furin activity", "PROBLEM", 99, 122], ["TPC1 impaired endosomal motility", "PROBLEM", 173, 205], ["furin activity", "OBSERVATION", 108, 122], ["endosomal motility", "OBSERVATION", 187, 205]]], ["Of note, the related SARS-CoV-2, the causative agent of COVID-19 [48, 49] , was similarly inhibited by TPC blockade.", [["SARS", "DISEASE", 21, 25], ["TPC", "CHEMICAL", 103, 106], ["COVID-19", "CHEMICAL", 56, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["TPC", "SIMPLE_CHEMICAL", 103, 106], ["SARS-CoV", "SPECIES", 21, 29], ["COVID", "TEST", 56, 61], ["TPC blockade", "TREATMENT", 103, 115], ["TPC blockade", "OBSERVATION", 103, 115]]], ["Specifically, treatment of cells with tetrandrine reduced the entry of a lentiviral vector pseudotyped with the SARS-CoV-2 S (spike) [36] .Ca 2+ Channels and Viral EntryThe bunyavirus severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging arbovirus with fatality rates of 12-50% and the potential to cause future pandemics [35] .", [["cells", "ANATOMY", 27, 32], ["tetrandrine", "CHEMICAL", 38, 49], ["fever", "DISEASE", 191, 196], ["thrombocytopenia syndrome", "DISEASE", 202, 227], ["SFTSV", "DISEASE", 235, 240], ["arbovirus", "DISEASE", 257, 266], ["tetrandrine", "CHEMICAL", 38, 49], ["cells", "CELL", 27, 32], ["tetrandrine", "SIMPLE_CHEMICAL", 38, 49], ["lentiviral", "ORGANISM", 73, 83], ["Viral", "ORGANISM", 158, 163], ["bunyavirus", "ORGANISM", 173, 183], ["bunyavirus severe fever with thrombocytopenia syndrome virus", "SPECIES", 173, 233], ["SFTSV", "SPECIES", 235, 240], ["cells", "PROBLEM", 27, 32], ["tetrandrine", "TREATMENT", 38, 49], ["a lentiviral vector pseudotyped", "TREATMENT", 71, 102], ["the SARS", "TEST", 108, 116], ["CoV", "TEST", 117, 120], [".Ca", "TEST", 138, 141], ["The bunyavirus severe fever", "PROBLEM", 169, 196], ["thrombocytopenia syndrome virus", "PROBLEM", 202, 233], ["SFTSV", "PROBLEM", 235, 240], ["an emerging arbovirus", "PROBLEM", 245, 266], ["fatality rates", "TEST", 272, 286], ["bunyavirus", "OBSERVATION_MODIFIER", 173, 183], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["fever", "OBSERVATION", 191, 196], ["thrombocytopenia syndrome", "OBSERVATION", 202, 227], ["arbovirus", "OBSERVATION", 257, 266]]], ["Using a library of FDA-approved drugs, the Ca 2+ channel blockers benidipine hydrochloride and nifedipine were shown to inhibit SFTSV infection ( Figure 1C) , with in vivo activity confirmed using C57BL/6 and humanised mouse models.", [["Ca", "CHEMICAL", 43, 45], ["benidipine hydrochloride", "CHEMICAL", 66, 90], ["nifedipine", "CHEMICAL", 95, 105], ["SFTSV infection", "DISEASE", 128, 143], ["Ca 2+", "CHEMICAL", 43, 48], ["benidipine hydrochloride", "CHEMICAL", 66, 90], ["nifedipine", "CHEMICAL", 95, 105], ["Ca 2+ channel blockers benidipine hydrochloride", "SIMPLE_CHEMICAL", 43, 90], ["nifedipine", "SIMPLE_CHEMICAL", 95, 105], ["SFTSV", "SIMPLE_CHEMICAL", 128, 133], ["C57BL/6", "ORGANISM", 197, 204], ["mouse", "ORGANISM", 219, 224], ["mouse", "SPECIES", 219, 224], ["SFTSV", "SPECIES", 128, 133], ["mouse", "SPECIES", 219, 224], ["FDA-approved drugs", "TREATMENT", 19, 37], ["the Ca 2+ channel blockers benidipine hydrochloride", "TREATMENT", 39, 90], ["nifedipine", "TREATMENT", 95, 105], ["SFTSV infection", "PROBLEM", 128, 143], ["C57BL/6 and humanised mouse models", "TREATMENT", 197, 231]]], ["Through a retrospective analysis of human SFTSV cases, clinical evidence of the efficacy of nifedipine as an anti-SFTSV therapeutic was also demonstrated.", [["nifedipine", "CHEMICAL", 92, 102], ["nifedipine", "CHEMICAL", 92, 102], ["human", "ORGANISM", 36, 41], ["SFTSV", "CANCER", 42, 47], ["nifedipine", "SIMPLE_CHEMICAL", 92, 102], ["anti-SFTSV", "CANCER", 109, 119], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["a retrospective analysis", "TEST", 8, 32], ["human SFTSV cases", "TEST", 36, 53], ["nifedipine", "TREATMENT", 92, 102], ["an anti-SFTSV therapeutic", "TREATMENT", 106, 131]]], ["A cohort of patients receiving nifedipine prior to and during hospital admission showed enhanced viral clearance and reduced frequency of neurological syndromes, often associated with fatal outcomes [50, 51] .", [["neurological", "ANATOMY", 138, 150], ["nifedipine", "CHEMICAL", 31, 41], ["neurological syndromes", "DISEASE", 138, 160], ["nifedipine", "CHEMICAL", 31, 41], ["patients", "ORGANISM", 12, 20], ["nifedipine", "SIMPLE_CHEMICAL", 31, 41], ["patients", "SPECIES", 12, 20], ["nifedipine", "TREATMENT", 31, 41], ["enhanced viral clearance", "PROBLEM", 88, 112], ["neurological syndromes", "PROBLEM", 138, 160], ["viral clearance", "OBSERVATION", 97, 112], ["neurological syndromes", "OBSERVATION", 138, 160]]], ["The fatality rate of patients receiving nifedipine was reduced 5-fold compared to untreated patients, which corresponded to abnormal serum Ca 2+ levels at admission.", [["serum", "ANATOMY", 133, 138], ["nifedipine", "CHEMICAL", 40, 50], ["Ca", "CHEMICAL", 139, 141], ["nifedipine", "CHEMICAL", 40, 50], ["Ca 2+", "CHEMICAL", 139, 144], ["patients", "ORGANISM", 21, 29], ["nifedipine", "SIMPLE_CHEMICAL", 40, 50], ["patients", "ORGANISM", 92, 100], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["Ca 2+", "SIMPLE_CHEMICAL", 139, 144], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 92, 100], ["nifedipine", "TREATMENT", 40, 50], ["abnormal serum Ca", "PROBLEM", 124, 141]]], ["The viral processes through which SFTSV requires Ca 2+ channels were subsequently shown to be during virus internalisation and genome replication.K + Channels and Viral EntryThe involvement of K + channels in viral entry has been extensively characterised for the model bunyaviruses Bunyamwera orthobunyavirus (BUNV); and Hazara orthononairovirus (HAZV), a model for Crimean Congo haemorrhagic fever virus, which causes severe viral haemorrhagic fever outbreaks, with a case fatality rate of up to 40%.", [["Ca", "CHEMICAL", 49, 51], ["K", "CHEMICAL", 146, 147], ["K", "CHEMICAL", 193, 194], ["Crimean Congo haemorrhagic fever", "DISEASE", 367, 399], ["viral haemorrhagic fever", "DISEASE", 427, 451], ["Ca 2+", "CHEMICAL", 49, 54], ["K +", "CHEMICAL", 146, 149], ["K +", "CHEMICAL", 193, 196], ["SFTSV", "GENE_OR_GENE_PRODUCT", 34, 39], ["Ca 2+", "SIMPLE_CHEMICAL", 49, 54], ["K +", "SIMPLE_CHEMICAL", 146, 149], ["K +", "SIMPLE_CHEMICAL", 193, 196], ["Bunyamwera orthobunyavirus", "ORGANISM", 283, 309], ["BUNV", "ORGANISM", 311, 315], ["Hazara orthononairovirus", "ORGANISM", 322, 346], ["Crimean Congo haemorrhagic fever virus", "ORGANISM", 367, 405], ["SFTSV", "PROTEIN", 34, 39], ["Ca 2+ channels", "PROTEIN", 49, 63], ["K + channels", "PROTEIN", 193, 205], ["Bunyamwera orthobunyavirus", "SPECIES", 283, 309], ["Congo haemorrhagic fever virus", "SPECIES", 375, 405], ["viral haemorrhagic fever", "SPECIES", 427, 451], ["Bunyamwera orthobunyavirus", "SPECIES", 283, 309], ["BUNV", "SPECIES", 311, 315], ["Hazara orthononairovirus", "SPECIES", 322, 346], ["HAZV", "SPECIES", 348, 352], ["Crimean Congo haemorrhagic fever virus", "SPECIES", 367, 405], ["The viral processes", "PROBLEM", 0, 19], ["Ca 2+ channels", "TREATMENT", 49, 63], ["virus internalisation", "TREATMENT", 101, 122], ["genome replication", "TREATMENT", 127, 145], ["K", "TEST", 146, 147], ["K + channels", "PROBLEM", 193, 205], ["viral entry", "PROBLEM", 209, 220], ["the model bunyaviruses", "TEST", 260, 282], ["Crimean Congo haemorrhagic fever virus", "PROBLEM", 367, 405], ["severe viral haemorrhagic fever outbreaks", "PROBLEM", 420, 461], ["a case fatality rate", "TEST", 468, 488], ["viral processes", "OBSERVATION", 4, 19], ["Viral Entry", "OBSERVATION", 163, 174], ["viral entry", "OBSERVATION", 209, 220], ["severe", "OBSERVATION_MODIFIER", 420, 426], ["viral", "OBSERVATION_MODIFIER", 427, 432], ["haemorrhagic", "OBSERVATION_MODIFIER", 433, 445]]], ["Initial work using known K + channel pharmacology suggested that the blockade of two-pore K + channels (K 2P ) inhibited the early stages of the BUNV lifecycle ( Figure 1D ) [37] .", [["K", "CHEMICAL", 25, 26], ["K", "CHEMICAL", 90, 91], ["K", "CHEMICAL", 104, 105], ["K +", "CHEMICAL", 25, 28], ["K +", "CHEMICAL", 90, 93], ["K + channel", "GENE_OR_GENE_PRODUCT", 25, 36], ["K +", "SIMPLE_CHEMICAL", 90, 93], ["K 2P", "SIMPLE_CHEMICAL", 104, 108], ["K + channel", "PROTEIN", 25, 36], ["-pore K + channels", "PROTEIN", 84, 102], ["K 2P", "PROTEIN", 104, 108], ["the blockade", "TREATMENT", 65, 77]]], ["Subsequent work identified both acidic pH and K + in endosomes as crucial biochemical cues for the endosomal escape of BUNV [28] .", [["endosomes", "ANATOMY", 53, 62], ["endosomal", "ANATOMY", 99, 108], ["K", "CHEMICAL", 46, 47], ["K +", "CHEMICAL", 46, 49], ["K +", "SIMPLE_CHEMICAL", 46, 49], ["endosomes", "CELLULAR_COMPONENT", 53, 62], ["endosomal", "CELLULAR_COMPONENT", 99, 108], ["acidic pH", "TEST", 32, 41], ["K", "TEST", 46, 47]]], ["Similar studies in HAZV highlighted a dependence on K + channels for infection, and that K + primarily accumulated in cholesterol-rich endosomes ( Figure 1B) [28, 38, 39] .", [["cholesterol-rich endosomes", "ANATOMY", 118, 144], ["K", "CHEMICAL", 52, 53], ["infection", "DISEASE", 69, 78], ["K", "CHEMICAL", 89, 90], ["cholesterol", "CHEMICAL", 118, 129], ["K +", "CHEMICAL", 52, 55], ["K +", "CHEMICAL", 89, 92], ["cholesterol", "CHEMICAL", 118, 129], ["K +", "SIMPLE_CHEMICAL", 52, 55], ["K +", "SIMPLE_CHEMICAL", 89, 92], ["cholesterol", "SIMPLE_CHEMICAL", 118, 129], ["endosomes", "CELLULAR_COMPONENT", 135, 144], ["K + channels", "PROTEIN", 52, 64], ["HAZV", "SPECIES", 19, 23], ["Similar studies", "TEST", 0, 15], ["a dependence", "PROBLEM", 36, 48], ["K + channels", "TREATMENT", 52, 64], ["infection", "PROBLEM", 69, 78], ["K", "TEST", 89, 90], ["cholesterol", "TEST", 118, 129], ["infection", "OBSERVATION", 69, 78]]], ["The K + dependence of HAZV involves the glycoprotein spikes; a change in K + concentration triggers conformational changes in the glycoproteins, as revealed through cryo-electron tomography of HAZV virions incubated with K + that \"primed\" them for insertion into target membranes (Figure 2A ).", [["membranes", "ANATOMY", 270, 279], ["K", "CHEMICAL", 4, 5], ["HAZV", "CHEMICAL", 22, 26], ["K", "CHEMICAL", 73, 74], ["K", "CHEMICAL", 221, 222], ["K +", "CHEMICAL", 4, 7], ["K +", "CHEMICAL", 73, 76], ["K +", "CHEMICAL", 221, 224], ["K +", "SIMPLE_CHEMICAL", 4, 7], ["HAZV", "SIMPLE_CHEMICAL", 22, 26], ["K +", "SIMPLE_CHEMICAL", 73, 76], ["K +", "SIMPLE_CHEMICAL", 221, 224], ["membranes", "CELLULAR_COMPONENT", 270, 279], ["HAZV", "PROTEIN", 22, 26], ["glycoproteins", "PROTEIN", 130, 143], ["The K", "TEST", 0, 5], ["HAZV", "PROBLEM", 22, 26], ["the glycoprotein spikes", "PROBLEM", 36, 59], ["a change in K + concentration", "PROBLEM", 61, 90], ["conformational changes in the glycoproteins", "PROBLEM", 100, 143], ["cryo-electron tomography", "TEST", 165, 189], ["HAZV virions", "PROBLEM", 193, 205], ["K", "TEST", 221, 222], ["dependence", "OBSERVATION_MODIFIER", 8, 18], ["glycoprotein spikes", "OBSERVATION", 40, 59]]], ["Moreover, it was shown that both BUNV and HAZV could be \"primed\" in vitro in buffers containing high [K + ], which expedited entry and subsequent viral gene expression.", [["K", "CHEMICAL", 102, 103], ["BUNV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HAZV", "GENE_OR_GENE_PRODUCT", 42, 46], ["BUNV", "PROTEIN", 33, 37], ["HAZV", "PROTEIN", 42, 46], ["BUNV", "SPECIES", 33, 37], ["HAZV", "SPECIES", 42, 46], ["vitro in buffers", "TREATMENT", 68, 84], ["subsequent viral gene expression", "PROBLEM", 135, 167], ["viral gene expression", "OBSERVATION", 146, 167]]], ["This phenomenon was analogous to earlier studies for IAV, in which acid bypass in the presence of K + revealed that the exposure of IAV virions to low pH and high [K + ] weakened interactions between the M1 matrix protein and ribonucleoprotein (RNP) bundles, a pre-requisite for genome release ( Figure 2B ).", [["K", "CHEMICAL", 98, 99], ["K", "CHEMICAL", 164, 165], ["K +", "CHEMICAL", 98, 101], ["[K + ]", "CHEMICAL", 163, 169], ["IAV", "ORGANISM", 53, 56], ["K +", "SIMPLE_CHEMICAL", 98, 101], ["IAV", "ORGANISM", 132, 135], ["M1 matrix protein", "GENE_OR_GENE_PRODUCT", 204, 221], ["RNP", "CELLULAR_COMPONENT", 245, 248], ["M1 matrix protein", "PROTEIN", 204, 221], ["ribonucleoprotein (RNP) bundles", "PROTEIN", 226, 257], ["IAV", "SPECIES", 53, 56], ["earlier studies", "TEST", 33, 48], ["IAV", "PROBLEM", 53, 56], ["acid bypass", "TREATMENT", 67, 78], ["K", "TEST", 98, 99], ["IAV virions", "PROBLEM", 132, 143], ["low pH", "PROBLEM", 147, 153], ["high [K +", "PROBLEM", 158, 167], ["weakened interactions", "PROBLEM", 170, 191], ["ribonucleoprotein (RNP) bundles", "TREATMENT", 226, 257], ["M1", "ANATOMY_MODIFIER", 204, 206]]], ["The exposure of IAV virions to K + therefore drives viral uncoating and expedites IAV infection [31] .K + Channels and Viral EntryRecent work also highlights a requirement for K + channels during human immunodeficiency virus (HIV) infection.", [["K", "CHEMICAL", 31, 32], ["infection", "DISEASE", 86, 95], ["K", "CHEMICAL", 176, 177], ["human immunodeficiency virus (HIV) infection", "DISEASE", 196, 240], ["K +", "CHEMICAL", 31, 34], ["K +", "CHEMICAL", 176, 179], ["IAV", "ORGANISM", 16, 19], ["K +", "SIMPLE_CHEMICAL", 31, 34], ["K +", "SIMPLE_CHEMICAL", 176, 179], ["human immunodeficiency virus", "ORGANISM", 196, 224], ["HIV", "ORGANISM", 226, 229], ["K + channels", "PROTEIN", 176, 188], ["human immunodeficiency virus (HIV", "SPECIES", 196, 229], ["IAV", "SPECIES", 16, 19], ["IAV", "SPECIES", 82, 85], ["human immunodeficiency virus", "SPECIES", 196, 224], ["HIV", "SPECIES", 226, 229], ["IAV virions", "TREATMENT", 16, 27], ["K", "TEST", 31, 32], ["viral uncoating", "PROBLEM", 52, 67], ["IAV infection", "PROBLEM", 82, 95], ["Viral EntryRecent work", "TEST", 119, 141], ["K + channels", "PROBLEM", 176, 188], ["human immunodeficiency virus", "PROBLEM", 196, 224], ["HIV) infection", "PROBLEM", 226, 240], ["IAV", "OBSERVATION_MODIFIER", 82, 85], ["infection", "OBSERVATION", 86, 95], ["infection", "OBSERVATION", 231, 240]]], ["Using pharmacological approaches ( Figure 1A ) [40] HIV entry could be blocked with ifenprodil and the broad spectrum K + channel blocker tetraethylammonium (TEA).", [["ifenprodil", "CHEMICAL", 84, 94], ["K", "CHEMICAL", 118, 119], ["tetraethylammonium", "CHEMICAL", 138, 156], ["TEA", "CHEMICAL", 158, 161], ["ifenprodil", "CHEMICAL", 84, 94], ["K +", "CHEMICAL", 118, 121], ["tetraethylammonium", "CHEMICAL", 138, 156], ["TEA", "CHEMICAL", 158, 161], ["ifenprodil", "SIMPLE_CHEMICAL", 84, 94], ["K + channel", "SIMPLE_CHEMICAL", 118, 129], ["tetraethylammonium", "SIMPLE_CHEMICAL", 138, 156], ["TEA", "SIMPLE_CHEMICAL", 158, 161], ["HIV", "SPECIES", 52, 55], ["HIV entry", "TREATMENT", 52, 61], ["ifenprodil", "TREATMENT", 84, 94], ["the broad spectrum K + channel blocker tetraethylammonium (TEA", "TREATMENT", 99, 161]]], ["Khan et al. also showed that the pharmacological activation of the endolysosome-resident transient receptor potential mucolipin 1 channel (TRPML1) enhanced the degradation of HIV-Tat (a multi-function viral protein involved in transcription, splicing, capping, and translation), which in turn reduced the transition from viral latency [52] .", [["transient receptor potential mucolipin 1", "GENE_OR_GENE_PRODUCT", 89, 129], ["TRPML1", "GENE_OR_GENE_PRODUCT", 139, 145], ["HIV-Tat", "GENE_OR_GENE_PRODUCT", 175, 182], ["endolysosome-resident transient receptor potential mucolipin 1 channel", "PROTEIN", 67, 137], ["TRPML1", "PROTEIN", 139, 145], ["HIV-Tat", "PROTEIN", 175, 182], ["multi-function viral protein", "PROTEIN", 186, 214], ["HIV", "SPECIES", 175, 178], ["mucolipin 1 channel (TRPML1)", "TREATMENT", 118, 146], ["HIV-Tat", "TREATMENT", 175, 182], ["a multi-function viral protein", "TREATMENT", 184, 214], ["splicing, capping", "TREATMENT", 242, 259], ["viral latency", "PROBLEM", 321, 334], ["viral latency", "OBSERVATION", 321, 334]]], ["TRPML1 activates large conductance Ca 2+ -activated potassium (BK) channels in endosomes [53] , implying that this channel is required for HIV infection.K + Channels and Viral EntryThe reliance of viruses upon ion channels is not restricted to RNA viruses.", [["endosomes", "ANATOMY", 79, 88], ["Ca", "CHEMICAL", 35, 37], ["potassium", "CHEMICAL", 52, 61], ["HIV infection", "DISEASE", 139, 152], ["K", "CHEMICAL", 153, 154], ["Ca 2+", "CHEMICAL", 35, 40], ["potassium", "CHEMICAL", 52, 61], ["K +", "CHEMICAL", 153, 156], ["TRPML1", "GENE_OR_GENE_PRODUCT", 0, 6], ["large conductance Ca 2+ -activated potassium (BK)", "GENE_OR_GENE_PRODUCT", 17, 66], ["endosomes", "CELLULAR_COMPONENT", 79, 88], ["HIV", "ORGANISM", 139, 142], ["K +", "SIMPLE_CHEMICAL", 153, 156], ["TRPML1", "PROTEIN", 0, 6], ["large conductance Ca 2+ -activated potassium (BK) channels", "PROTEIN", 17, 75], ["HIV", "SPECIES", 139, 142], ["large conductance Ca", "TEST", 17, 37], ["-activated potassium", "TEST", 41, 61], ["HIV infection", "PROBLEM", 139, 152], ["K", "TEST", 153, 154], ["viruses upon ion channels", "TREATMENT", 197, 222], ["RNA viruses", "PROBLEM", 244, 255], ["large", "OBSERVATION_MODIFIER", 17, 22], ["infection", "OBSERVATION", 143, 152], ["Viral Entry", "OBSERVATION", 170, 181], ["viruses", "OBSERVATION", 197, 204]]], ["It was recently shown that both K + and Ca 2+ channels are important host factors for polyomavirus infection [41] .", [["K", "CHEMICAL", 32, 33], ["Ca", "CHEMICAL", 40, 42], ["polyomavirus infection", "DISEASE", 86, 108], ["K +", "CHEMICAL", 32, 35], ["Ca 2+", "CHEMICAL", 40, 45], ["K +", "SIMPLE_CHEMICAL", 32, 35], ["Ca 2+", "SIMPLE_CHEMICAL", 40, 45], ["polyomavirus", "ORGANISM", 86, 98], ["K", "PROTEIN", 32, 33], ["Ca 2+ channels", "PROTEIN", 40, 54], ["K", "TEST", 32, 33], ["Ca", "TEST", 40, 42], ["polyomavirus infection", "PROBLEM", 86, 108], ["infection", "OBSERVATION", 99, 108]]], ["Using a panel of ion channel modulators, the entry of Merkel cell polyomavirus (MCPyV), the causative agent of Merkel cell carcinoma (MCC), was shown to be sensitive to 4-aminopyridine (4-AP), a blocker of voltage-gated K + (K V ) channels ( Figure 1G ).", [["Merkel cell", "ANATOMY", 54, 65], ["Merkel cell carcinoma", "ANATOMY", 111, 132], ["MCC", "ANATOMY", 134, 137], ["Merkel cell carcinoma", "DISEASE", 111, 132], ["4-aminopyridine", "CHEMICAL", 169, 184], ["4-AP", "CHEMICAL", 186, 190], ["K", "CHEMICAL", 220, 221], ["4-aminopyridine", "CHEMICAL", 169, 184], ["4-AP", "CHEMICAL", 186, 190], ["K +", "CHEMICAL", 220, 223], ["Merkel cell polyomavirus", "ORGANISM", 54, 78], ["MCPyV", "ORGANISM", 80, 85], ["Merkel cell carcinoma", "CANCER", 111, 132], ["MCC", "CANCER", 134, 137], ["4-aminopyridine", "SIMPLE_CHEMICAL", 169, 184], ["4-AP", "SIMPLE_CHEMICAL", 186, 190], ["K + (K V )", "GENE_OR_GENE_PRODUCT", 220, 230], ["voltage-gated K + (K V ) channels", "PROTEIN", 206, 239], ["ion channel modulators", "TREATMENT", 17, 39], ["Merkel cell polyomavirus", "PROBLEM", 54, 78], ["Merkel cell carcinoma", "PROBLEM", 111, 132], ["aminopyridine", "TREATMENT", 171, 184], ["voltage", "TEST", 206, 213], ["gated K", "TEST", 214, 221], ["Merkel cell polyomavirus", "OBSERVATION", 54, 78], ["Merkel cell carcinoma", "OBSERVATION", 111, 132]]], ["Moreover, both MCPyV and Simian virus 40 (SV40) ( Figure 1H ) were sensitive to verapamil, a broad-spectrum Ca 2+ channel blocker.", [["verapamil", "CHEMICAL", 80, 89], ["Ca", "CHEMICAL", 108, 110], ["verapamil", "CHEMICAL", 80, 89], ["Ca 2+", "CHEMICAL", 108, 113], ["MCPyV", "ORGANISM", 15, 20], ["Simian virus 40", "ORGANISM", 25, 40], ["SV40", "ORGANISM", 42, 46], ["verapamil", "SIMPLE_CHEMICAL", 80, 89], ["Ca 2+ channel blocker", "SIMPLE_CHEMICAL", 108, 129], ["Simian virus", "SPECIES", 25, 37], ["Simian virus 40", "SPECIES", 25, 40], ["Simian virus", "TEST", 25, 37], ["verapamil", "TREATMENT", 80, 89], ["a broad-spectrum Ca 2+ channel blocker", "TREATMENT", 91, 129]]], ["The identities of the Ca 2+ channels involved in polyomavirus entry were further explored, revealing a requirement for transient (T-type, low-voltage activated) channel family members in MCPyV infection but not SV40.", [["Ca", "CHEMICAL", 22, 24], ["MCPyV infection", "DISEASE", 187, 202], ["Ca 2+", "CHEMICAL", 22, 27], ["Ca 2+", "SIMPLE_CHEMICAL", 22, 27], ["polyomavirus", "ORGANISM", 49, 61], ["MCPyV", "ORGANISM", 187, 192], ["SV40", "ORGANISM", 211, 215], ["Ca 2+ channels", "PROTEIN", 22, 36], ["low-voltage activated) channel family members", "PROTEIN", 138, 183], ["polyomavirus entry", "PROBLEM", 49, 67], ["transient (T-type", "PROBLEM", 119, 136], ["MCPyV infection", "PROBLEM", 187, 202], ["Ca", "OBSERVATION", 22, 24], ["MCPyV", "ANATOMY", 187, 192], ["infection", "OBSERVATION", 193, 202]]], ["Tetrandrine, a TPC blocker, restricted both viruses.", [["Tetrandrine", "CHEMICAL", 0, 11], ["Tetrandrine", "CHEMICAL", 0, 11], ["Tetrandrine", "SIMPLE_CHEMICAL", 0, 11], ["TPC", "SIMPLE_CHEMICAL", 15, 18], ["Tetrandrine", "TREATMENT", 0, 11], ["a TPC blocker", "TREATMENT", 13, 26], ["viruses", "OBSERVATION", 44, 51]]], ["The role of TPCs was found to be during endoplasmic reticulum (ER) disassembly and/or ER docking for SV40 [54] , which may be explained by the recent demonstration that Ca 2+ ions mediate the stabilization of SV40 capsids and contribute to its disassembly [55] .", [["endoplasmic reticulum", "ANATOMY", 40, 61], ["ER", "ANATOMY", 63, 65], ["Ca", "CHEMICAL", 169, 171], ["Ca 2+", "CHEMICAL", 169, 174], ["TPCs", "GENE_OR_GENE_PRODUCT", 12, 16], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 40, 61], ["ER", "GENE_OR_GENE_PRODUCT", 63, 65], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["SV40", "ORGANISM", 101, 105], ["Ca 2+ ions", "SIMPLE_CHEMICAL", 169, 179], ["SV40", "ORGANISM", 209, 213], ["TPCs", "PROTEIN", 12, 16], ["ER", "PROTEIN", 86, 88], ["SV40", "TEST", 101, 105], ["Ca", "TEST", 169, 171], ["the stabilization of SV40 capsids", "TREATMENT", 188, 221]]], ["Time of addition assays using the CFTR inhibitors CFTR 172 and glibenclamide, combined with the assessment of exposure of VP2/VP3 minor capsid proteins, indicated a role for CFTR in the trafficking of BKPyV to the ER.", [["ER", "ANATOMY", 214, 216], ["CFTR 172", "CHEMICAL", 50, 58], ["glibenclamide", "CHEMICAL", 63, 76], ["glibenclamide", "CHEMICAL", 63, 76], ["CFTR", "GENE_OR_GENE_PRODUCT", 34, 38], ["glibenclamide", "SIMPLE_CHEMICAL", 63, 76], ["VP2", "GENE_OR_GENE_PRODUCT", 122, 125], ["VP3 minor capsid proteins", "GENE_OR_GENE_PRODUCT", 126, 151], ["CFTR", "GENE_OR_GENE_PRODUCT", 174, 178], ["BKPyV", "GENE_OR_GENE_PRODUCT", 201, 206], ["ER", "GENE_OR_GENE_PRODUCT", 214, 216], ["VP2", "PROTEIN", 122, 125], ["VP3 minor capsid proteins", "PROTEIN", 126, 151], ["CFTR", "PROTEIN", 174, 178], ["BKPyV", "PROTEIN", 201, 206], ["ER", "PROTEIN", 214, 216], ["assays", "TEST", 17, 23], ["the CFTR inhibitors CFTR", "TREATMENT", 30, 54], ["glibenclamide", "TREATMENT", 63, 76], ["the assessment", "TEST", 92, 106], ["VP2/VP3 minor capsid proteins", "PROBLEM", 122, 151], ["CFTR", "PROBLEM", 174, 178], ["BKPyV", "OBSERVATION", 201, 206]]], ["Whilst the mechanism of CFTR involvement in BKPyV ER trafficking remains unclear, it is hypothesised that the channel may be important in the acidification and ER docking of BKPyV-containing endosomes.", [["BKPyV ER", "ANATOMY", 44, 52], ["endosomes", "ANATOMY", 191, 200], ["CFTR", "GENE_OR_GENE_PRODUCT", 24, 28], ["BKPyV ER", "GENE_OR_GENE_PRODUCT", 44, 52], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["BKPyV", "GENE_OR_GENE_PRODUCT", 174, 179], ["endosomes", "CELLULAR_COMPONENT", 191, 200], ["CFTR", "PROTEIN", 24, 28], ["ER", "PROTEIN", 50, 52], ["ER", "PROTEIN", 160, 162], ["BKPyV", "PROTEIN", 174, 179], ["CFTR involvement", "PROBLEM", 24, 40], ["BKPyV", "PROBLEM", 174, 179], ["CFTR", "OBSERVATION", 24, 28], ["BKPyV", "OBSERVATION", 44, 49]]], ["CFTR has been implicated in the fusion of endosomes [56] , and co-localises with vacuolar ATPase (vATPase) to provide the counter-charge during endosomal acidification [57] .", [["endosomes", "ANATOMY", 42, 51], ["vacuolar", "ANATOMY", 81, 89], ["endosomal", "ANATOMY", 144, 153], ["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["endosomes", "CELLULAR_COMPONENT", 42, 51], ["vacuolar ATPase", "GENE_OR_GENE_PRODUCT", 81, 96], ["vATPase", "GENE_OR_GENE_PRODUCT", 98, 105], ["endosomal", "CELLULAR_COMPONENT", 144, 153], ["CFTR", "PROTEIN", 0, 4], ["vacuolar ATPase", "PROTEIN", 81, 96], ["vATPase", "PROTEIN", 98, 105], ["vacuolar ATPase (vATPase)", "TREATMENT", 81, 106]]], ["Time of addition assays using the CFTR inhibitors CFTR172 and glibenclamide, combined with the assessment of exposure of VP2/VP3 minor capsid proteins, indicated a role for CFTR in the trafficking of BKPyV to the ER.", [["ER", "ANATOMY", 213, 215], ["CFTR172", "CHEMICAL", 50, 57], ["glibenclamide", "CHEMICAL", 62, 75], ["CFTR172", "CHEMICAL", 50, 57], ["glibenclamide", "CHEMICAL", 62, 75], ["CFTR", "GENE_OR_GENE_PRODUCT", 34, 38], ["CFTR172", "SIMPLE_CHEMICAL", 50, 57], ["glibenclamide", "SIMPLE_CHEMICAL", 62, 75], ["VP2", "GENE_OR_GENE_PRODUCT", 121, 124], ["VP3 minor capsid proteins", "GENE_OR_GENE_PRODUCT", 125, 150], ["CFTR", "GENE_OR_GENE_PRODUCT", 173, 177], ["BKPyV", "GENE_OR_GENE_PRODUCT", 200, 205], ["ER", "GENE_OR_GENE_PRODUCT", 213, 215], ["VP2", "PROTEIN", 121, 124], ["VP3 minor capsid proteins", "PROTEIN", 125, 150], ["CFTR", "PROTEIN", 173, 177], ["BKPyV", "PROTEIN", 200, 205], ["ER", "PROTEIN", 213, 215], ["assays", "TEST", 17, 23], ["the CFTR inhibitors", "TREATMENT", 30, 49], ["glibenclamide", "TREATMENT", 62, 75], ["the assessment", "TEST", 91, 105], ["VP2/VP3 minor capsid proteins", "PROBLEM", 121, 150], ["CFTR", "PROBLEM", 173, 177]]], ["Whilst the mechanism of CFTR involvement in BKPyV ER trafficking remains unclear, it is hypothesised that the channel may be important in the acidification and ER docking of BKPyV-containing endosomes.Ion Channels in Viral ReplicationOnce viral genomes are released inside the host cell, replication can commence.", [["BKPyV ER", "ANATOMY", 44, 52], ["endosomes", "ANATOMY", 191, 200], ["cell", "ANATOMY", 282, 286], ["CFTR", "GENE_OR_GENE_PRODUCT", 24, 28], ["BKPyV ER", "GENE_OR_GENE_PRODUCT", 44, 52], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["BKPyV", "GENE_OR_GENE_PRODUCT", 174, 179], ["endosomes", "CELLULAR_COMPONENT", 191, 200], ["cell", "CELL", 282, 286], ["CFTR", "PROTEIN", 24, 28], ["ER", "PROTEIN", 50, 52], ["ER", "PROTEIN", 160, 162], ["BKPyV", "PROTEIN", 174, 179], ["Viral ReplicationOnce viral genomes", "DNA", 217, 252], ["CFTR involvement", "PROBLEM", 24, 40], ["BKPyV", "PROBLEM", 174, 179], ["Ion Channels", "TREATMENT", 201, 213], ["Viral ReplicationOnce viral genomes", "TREATMENT", 217, 252], ["CFTR", "OBSERVATION", 24, 28], ["BKPyV", "OBSERVATION", 44, 49], ["Viral", "OBSERVATION_MODIFIER", 217, 222], ["viral genomes", "OBSERVATION", 239, 252], ["host cell", "OBSERVATION", 277, 286]]], ["Recent evidence suggests that this process is partially controlled by ion concentrations and can therefore be targeted by ion channel drugs.Ca 2+ Channels and Viral ReplicationFlaviviruses establish replication complexes in modified intracellular membranes, often derived from the ER.", [["intracellular membranes", "ANATOMY", 233, 256], ["ER", "ANATOMY", 281, 283], ["Ca", "CHEMICAL", 140, 142], ["Ca 2+", "CHEMICAL", 140, 145], ["ion", "SIMPLE_CHEMICAL", 70, 73], ["Ca 2", "GENE_OR_GENE_PRODUCT", 140, 144], ["intracellular membranes", "CELLULAR_COMPONENT", 233, 256], ["ER", "GENE_OR_GENE_PRODUCT", 281, 283], ["replication complexes", "PROTEIN", 199, 220], ["ER", "PROTEIN", 281, 283], ["this process", "PROBLEM", 30, 42], ["ion channel drugs", "TREATMENT", 122, 139], ["Ca", "TEST", 140, 142], ["Viral ReplicationFlaviviruses", "TREATMENT", 159, 188], ["replication complexes in modified intracellular membranes", "PROBLEM", 199, 256], ["Viral ReplicationFlaviviruses", "OBSERVATION", 159, 188], ["replication complexes", "OBSERVATION", 199, 220], ["intracellular membranes", "OBSERVATION", 233, 256]]], ["The ER stores the majority of intracellular Ca 2+ , and so it is perhaps unsurprising that an array of flaviviruses depend on intracellular Ca 2+ ion channels for their replication (Table 2) .", [["ER", "ANATOMY", 4, 6], ["intracellular", "ANATOMY", 30, 43], ["intracellular", "ANATOMY", 126, 139], ["Ca", "CHEMICAL", 44, 46], ["Ca", "CHEMICAL", 140, 142], ["Ca 2+", "CHEMICAL", 44, 49], ["Ca 2+", "CHEMICAL", 140, 145], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["ER", "PROTEIN", 4, 6], ["intracellular Ca 2+ ion channels", "PROTEIN", 126, 158], ["intracellular Ca", "PROBLEM", 30, 46], ["flaviviruses", "PROBLEM", 103, 115], ["intracellular Ca", "TREATMENT", 126, 142], ["Ca", "OBSERVATION", 44, 46], ["flaviviruses", "OBSERVATION", 103, 115]]], ["Japanese encephalitis virus (JEV) is an arthropod-borne virus linked to acute encephalitis.", [["Japanese encephalitis", "DISEASE", 0, 21], ["JEV", "DISEASE", 29, 32], ["encephalitis", "DISEASE", 78, 90], ["Japanese encephalitis virus", "ORGANISM", 0, 27], ["JEV", "ORGANISM", 29, 32], ["arthropod-borne virus", "ORGANISM", 40, 61], ["Japanese encephalitis virus", "SPECIES", 0, 27], ["Japanese encephalitis virus", "SPECIES", 0, 27], ["JEV", "SPECIES", 29, 32], ["Japanese encephalitis virus (JEV", "PROBLEM", 0, 32], ["an arthropod-borne virus", "PROBLEM", 37, 61], ["acute encephalitis", "PROBLEM", 72, 90], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["encephalitis", "OBSERVATION", 78, 90]]], ["Wang et al. performed a screen of FDA-approved drugs to assess in vitro activity against JEV [58] .", [["JEV", "ORGANISM", 89, 92], ["JEV", "SPECIES", 89, 92], ["a screen", "TEST", 22, 30], ["FDA", "TEST", 34, 37], ["drugs", "TREATMENT", 47, 52]]], ["Within the screen, three of the five most potent inhibitors were blockers of voltage-gated Ca 2+ channels (VGCCs), including manidipine, cilnidipine, and benidipine hydrochloride.", [["Ca", "CHEMICAL", 91, 93], ["manidipine", "CHEMICAL", 125, 135], ["cilnidipine", "CHEMICAL", 137, 148], ["benidipine hydrochloride", "CHEMICAL", 154, 178], ["Ca 2+", "CHEMICAL", 91, 96], ["manidipine", "CHEMICAL", 125, 135], ["cilnidipine", "CHEMICAL", 137, 148], ["benidipine hydrochloride", "CHEMICAL", 154, 178], ["Ca 2+", "SIMPLE_CHEMICAL", 91, 96], ["manidipine", "SIMPLE_CHEMICAL", 125, 135], ["cilnidipine", "SIMPLE_CHEMICAL", 137, 148], ["benidipine hydrochloride", "SIMPLE_CHEMICAL", 154, 178], ["voltage-gated Ca 2+ channels", "PROTEIN", 77, 105], ["VGCCs", "PROTEIN", 107, 112], ["the screen", "TEST", 7, 17], ["voltage", "TEST", 77, 84], ["VGCCs", "TEST", 107, 112], ["manidipine", "TREATMENT", 125, 135], ["cilnidipine", "TREATMENT", 137, 148], ["benidipine hydrochloride", "TREATMENT", 154, 178]]], ["Time of addition assays suggested that these three drugs did not act during viral entry, nor were they virucidal, but specifically inhibited virus replication.", [["these three drugs", "TREATMENT", 39, 56]]], ["The potential of these drugs as broad-acting anti-flavivirus treatments was further assessed and each led to a concentration-dependent inhibition of Dengue virus DENV), West Nile virus, and Zika virus (ZIKV) replication.", [["Dengue virus DENV", "DISEASE", 149, 166], ["Dengue virus DENV", "ORGANISM", 149, 166], ["West Nile virus", "ORGANISM", 169, 184], ["Zika virus", "ORGANISM", 190, 200], ["Dengue virus DENV", "SPECIES", 149, 166], ["West Nile virus", "SPECIES", 169, 184], ["Zika virus", "SPECIES", 190, 200], ["Dengue virus DENV", "SPECIES", 149, 166], ["West Nile virus", "SPECIES", 169, 184], ["Zika virus", "SPECIES", 190, 200], ["ZIKV", "SPECIES", 202, 206], ["these drugs", "TREATMENT", 17, 28], ["broad-acting anti-flavivirus treatments", "TREATMENT", 32, 71], ["a concentration-dependent inhibition", "TREATMENT", 109, 145], ["Dengue virus DENV", "PROBLEM", 149, 166], ["West Nile virus", "PROBLEM", 169, 184], ["Zika virus (ZIKV) replication", "TREATMENT", 190, 219]]], ["Yellow fever virus (YFV) was, however, insensitive to manidipine.", [["Yellow fever", "DISEASE", 0, 12], ["manidipine", "CHEMICAL", 54, 64], ["manidipine", "CHEMICAL", 54, 64], ["Yellow fever virus", "ORGANISM", 0, 18], ["YFV", "ORGANISM", 20, 23], ["manidipine", "SIMPLE_CHEMICAL", 54, 64], ["Yellow fever virus", "SPECIES", 0, 18], ["Yellow fever virus", "SPECIES", 0, 18], ["YFV", "SPECIES", 20, 23], ["Yellow fever virus (YFV", "PROBLEM", 0, 23], ["manidipine", "TREATMENT", 54, 64], ["fever virus", "OBSERVATION", 7, 18]]], ["Interestingly, the in vitro selection of a manidipine-resistant JEV identified a Q130R mutation in the non-structural protein NS4B.", [["manidipine", "CHEMICAL", 43, 53], ["JEV", "DISEASE", 64, 67], ["manidipine", "CHEMICAL", 43, 53], ["manidipine", "SIMPLE_CHEMICAL", 43, 53], ["JEV", "ORGANISM", 64, 67], ["Q130R", "GENE_OR_GENE_PRODUCT", 81, 86], ["non-structural protein NS4B", "PROTEIN", 103, 130], ["JEV", "SPECIES", 64, 67], ["a manidipine", "TREATMENT", 41, 53], ["resistant JEV", "PROBLEM", 54, 67], ["a Q130R mutation", "PROBLEM", 79, 95], ["the non-structural protein NS4B", "PROBLEM", 99, 130], ["non-structural protein NS4B", "OBSERVATION", 103, 130]]], ["Sequence alignments confirmed that the Q130 site was conserved in each of the flaviviruses susceptible to manidipine, but not YFV.", [["manidipine", "CHEMICAL", 106, 116], ["manidipine", "CHEMICAL", 106, 116], ["Q130", "GENE_OR_GENE_PRODUCT", 39, 43], ["manidipine", "SIMPLE_CHEMICAL", 106, 116], ["YFV", "ORGANISM", 126, 129], ["Q130 site", "DNA", 39, 48], ["YFV", "SPECIES", 126, 129], ["Sequence alignments", "TEST", 0, 19], ["the Q130 site", "PROBLEM", 35, 48], ["the flaviviruses", "PROBLEM", 74, 90], ["manidipine", "TREATMENT", 106, 116], ["YFV", "PROBLEM", 126, 129], ["flaviviruses", "OBSERVATION", 78, 90]]], ["The efficacy of manidipine against JEV was further confirmed in in vivo mouse models, with manidipine-treated mice exhibiting significantly higher survival rates compared to untreated mice challenged with JEV.Ca 2+ Channels and Viral ReplicationA role for Ca 2+ channels during DENV replication was further revealed by Dionicio et al. [59] .", [["manidipine", "CHEMICAL", 16, 26], ["JEV", "DISEASE", 35, 38], ["manidipine", "CHEMICAL", 91, 101], ["Ca", "CHEMICAL", 256, 258], ["manidipine", "CHEMICAL", 16, 26], ["manidipine", "CHEMICAL", 91, 101], ["JEV.Ca 2+", "CHEMICAL", 205, 214], ["Ca 2+", "CHEMICAL", 256, 261], ["manidipine", "SIMPLE_CHEMICAL", 16, 26], ["JEV", "ORGANISM", 35, 38], ["mouse", "ORGANISM", 72, 77], ["manidipine", "SIMPLE_CHEMICAL", 91, 101], ["mice", "ORGANISM", 110, 114], ["mice", "ORGANISM", 184, 188], ["Viral", "ORGANISM", 228, 233], ["Ca 2+", "SIMPLE_CHEMICAL", 256, 261], ["DENV", "ORGANISM", 278, 282], ["Ca 2+ channels", "PROTEIN", 256, 270], ["mouse", "SPECIES", 72, 77], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 184, 188], ["JEV", "SPECIES", 35, 38], ["mouse", "SPECIES", 72, 77], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 184, 188], ["DENV", "SPECIES", 278, 282], ["manidipine", "TREATMENT", 16, 26], ["JEV", "PROBLEM", 35, 38], ["manidipine", "TREATMENT", 91, 101], ["significantly higher survival rates", "PROBLEM", 126, 161], ["JEV.Ca", "TEST", 205, 211], ["Viral ReplicationA role", "TREATMENT", 228, 251], ["Ca 2+ channels", "TREATMENT", 256, 270], ["DENV replication", "TREATMENT", 278, 294]]], ["DENV was shown to inhibit intracellular Ca 2+ release from the ER, which in turn activated the store-operated Ca 2+ (SOCE) pathway.", [["intracellular", "ANATOMY", 26, 39], ["ER", "ANATOMY", 63, 65], ["Ca", "CHEMICAL", 40, 42], ["Ca", "CHEMICAL", 110, 112], ["Ca 2+", "CHEMICAL", 40, 45], ["Ca 2+", "CHEMICAL", 110, 115], ["DENV", "ORGANISM", 0, 4], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 39], ["Ca 2+", "SIMPLE_CHEMICAL", 40, 45], ["ER", "GENE_OR_GENE_PRODUCT", 63, 65], ["Ca 2+", "SIMPLE_CHEMICAL", 110, 115], ["SOCE", "GENE_OR_GENE_PRODUCT", 117, 121], ["ER", "PROTEIN", 63, 65], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4], ["intracellular Ca", "TEST", 26, 42]]], ["In addition, specialised Ca 2+ release activated Ca 2+ channels (CRACs) were identified as a requirement for DENV replication.", [["Ca", "CHEMICAL", 25, 27], ["Ca", "CHEMICAL", 49, 51], ["Ca 2+", "CHEMICAL", 25, 30], ["Ca 2+", "CHEMICAL", 49, 54], ["Ca 2+", "SIMPLE_CHEMICAL", 25, 30], ["Ca 2+", "SIMPLE_CHEMICAL", 49, 54], ["CRACs", "GENE_OR_GENE_PRODUCT", 65, 70], ["DENV", "ORGANISM", 109, 113], ["Ca 2+ release activated Ca 2+ channels", "PROTEIN", 25, 63], ["CRACs", "PROTEIN", 65, 70], ["DENV", "SPECIES", 109, 113], ["specialised Ca", "TEST", 13, 27], ["DENV replication", "TREATMENT", 109, 125]]], ["Small molecule blockers of these channels resulted in a 70% reduction in virus yield.", [["Small molecule blockers", "TREATMENT", 0, 23], ["these channels", "PROBLEM", 27, 41], ["a 70% reduction in virus yield", "TREATMENT", 54, 84], ["molecule blockers", "OBSERVATION", 6, 23]]], ["Additionally, yeast two-hybrid screens identified the Ca 2+ -permeable non-selective transient receptor potential vanilloid 4 (TRPV4) in complex with the DEAD-box helicase (DDX3X) as a key regulator of viral mRNA translation for ZIKV [60] .Ca 2+ Channels and Viral ReplicationThe hepatitis B virus (HBV) X protein is an oncoprotein that regulates cytosolic [Ca 2+ ] [61] .", [["cytosolic", "ANATOMY", 347, 356], ["Ca", "CHEMICAL", 54, 56], ["hepatitis B", "DISEASE", 280, 291], ["Ca", "CHEMICAL", 358, 360], ["Ca 2+", "CHEMICAL", 54, 59], ["Ca 2+ ]", "CHEMICAL", 358, 365], ["transient receptor potential vanilloid 4", "GENE_OR_GENE_PRODUCT", 85, 125], ["TRPV4", "GENE_OR_GENE_PRODUCT", 127, 132], ["DEAD-box helicase", "GENE_OR_GENE_PRODUCT", 154, 171], ["DDX3X", "GENE_OR_GENE_PRODUCT", 173, 178], ["Viral", "ORGANISM", 259, 264], ["hepatitis B virus", "ORGANISM", 280, 297], ["HBV", "ORGANISM", 299, 302], ["Ca 2+ -permeable non-selective transient receptor potential vanilloid 4", "PROTEIN", 54, 125], ["TRPV4", "PROTEIN", 127, 132], ["DEAD-box helicase", "PROTEIN", 154, 171], ["DDX3X", "PROTEIN", 173, 178], ["viral mRNA", "RNA", 202, 212], ["hepatitis B virus (HBV) X protein", "PROTEIN", 280, 313], ["oncoprotein", "PROTEIN", 320, 331], ["yeast", "SPECIES", 14, 19], ["hepatitis B virus", "SPECIES", 280, 297], ["yeast", "SPECIES", 14, 19], ["hepatitis B virus", "SPECIES", 280, 297], ["HBV", "SPECIES", 299, 302], ["yeast", "TEST", 14, 19], ["hybrid screens", "TEST", 24, 38], ["the Ca", "TEST", 50, 56], ["permeable non-selective transient receptor potential vanilloid 4 (TRPV4)", "TREATMENT", 61, 133], ["the DEAD-box helicase", "TREATMENT", 150, 171], ["viral mRNA translation", "TREATMENT", 202, 224], ["ZIKV", "PROBLEM", 229, 233], ["Channels", "TEST", 246, 254], ["Viral Replication", "TREATMENT", 259, 276], ["The hepatitis B virus (HBV) X protein", "TEST", 276, 313], ["an oncoprotein", "TEST", 317, 331], ["cytosolic [Ca", "TEST", 347, 360]]], ["Recently, Yao et al. characterised this mechanism, revealing its interaction with ORAI1, a critical component of the SOCE pathway [62] .", [["ORAI1", "GENE_OR_GENE_PRODUCT", 82, 87], ["SOCE", "GENE_OR_GENE_PRODUCT", 117, 121], ["ORAI1", "PROTEIN", 82, 87]]], ["HBV replication was also dependent on K + in studies by Chakraborty et al. [63] .", [["K", "CHEMICAL", 38, 39], ["K +", "CHEMICAL", 38, 41], ["HBV", "ORGANISM", 0, 3], ["K +", "SIMPLE_CHEMICAL", 38, 41], ["HBV", "SPECIES", 0, 3], ["HBV replication", "TREATMENT", 0, 15], ["K", "TEST", 38, 39]]], ["They reported that K + -dependent nucleolytic activity in the presence of HBV RNA mediates the self-cleavage of a 53 nt oligomer with ribozyme activity that is required for viral replication.Cl \u2212 Channels or Other Anions and Vials ReplicationChikungunya virus (CHIKV) is a re-emerging arbovirus associated with long-term complications and high morbidity.", [["K", "CHEMICAL", 19, 20], ["Cl", "CHEMICAL", 191, 193], ["Chikungunya virus (CHIKV)", "DISEASE", 242, 267], ["arbovirus", "DISEASE", 285, 294], ["K +", "CHEMICAL", 19, 22], ["Cl", "CHEMICAL", 191, 193], ["K + -dependent", "GENE_OR_GENE_PRODUCT", 19, 33], ["HBV", "ORGANISM", 74, 77], ["Vials Replication", "ORGANISM", 225, 242], ["Chikungunya virus", "ORGANISM", 242, 259], ["CHIKV", "ORGANISM", 261, 266], ["HBV RNA", "RNA", 74, 81], ["53 nt oligomer", "DNA", 114, 128], ["Chikungunya virus", "SPECIES", 242, 259], ["HBV", "SPECIES", 74, 77], ["Chikungunya virus", "SPECIES", 242, 259], ["CHIKV", "SPECIES", 261, 266], ["K", "TEST", 19, 20], ["-dependent nucleolytic activity", "PROBLEM", 23, 54], ["HBV RNA", "PROBLEM", 74, 81], ["a 53 nt oligomer with ribozyme activity", "TREATMENT", 112, 151], ["viral replication", "TREATMENT", 173, 190], ["Other Anions", "TREATMENT", 208, 220], ["Chikungunya virus", "PROBLEM", 242, 259], ["CHIKV", "PROBLEM", 261, 266], ["a re-emerging arbovirus", "PROBLEM", 271, 294], ["long-term complications", "PROBLEM", 311, 334], ["high morbidity", "PROBLEM", 339, 353], ["nucleolytic activity", "OBSERVATION", 34, 54], ["HBV", "OBSERVATION", 74, 77], ["Chikungunya virus", "OBSERVATION", 242, 259], ["high", "OBSERVATION_MODIFIER", 339, 343], ["morbidity", "OBSERVATION", 344, 353]]], ["Using siRNA silencing of the Cl \u2212 intracellular channels (CLIC) 1 and 4, M\u00fcller et al. demonstrated a requirement for both channels during the replication of a CHIKV sub-genomic replicon in mammalian and invertebrate cells [65] .", [["intracellular", "ANATOMY", 34, 47], ["cells", "ANATOMY", 217, 222], ["Cl", "CHEMICAL", 29, 31], ["mammalian", "CELL", 190, 199], ["invertebrate cells", "CELL", 204, 222], ["Cl \u2212 intracellular channels", "PROTEIN", 29, 56], ["CHIKV sub-genomic replicon", "DNA", 160, 186], ["mammalian and invertebrate cells", "CELL_TYPE", 190, 222], ["CHIKV", "SPECIES", 160, 165], ["siRNA silencing", "TREATMENT", 6, 21], ["the replication", "TREATMENT", 139, 154], ["a CHIKV sub-genomic replicon", "TREATMENT", 158, 186]]], ["The voltage-dependent anion channel 1 (VDAC1) is also implicated in viral replication; it is upregulated by infectious bursal disease virus (IBDV).", [["infectious bursal disease", "DISEASE", 108, 133], ["voltage-dependent anion channel 1", "GENE_OR_GENE_PRODUCT", 4, 37], ["VDAC1", "GENE_OR_GENE_PRODUCT", 39, 44], ["infectious bursal disease virus", "ORGANISM", 108, 139], ["IBDV", "ORGANISM", 141, 145], ["voltage-dependent anion channel 1", "PROTEIN", 4, 37], ["VDAC1", "PROTEIN", 39, 44], ["infectious bursal disease virus", "SPECIES", 108, 139], ["IBDV", "SPECIES", 141, 145], ["The voltage-dependent anion channel", "PROBLEM", 0, 35], ["viral replication", "PROBLEM", 68, 85], ["infectious bursal disease virus", "PROBLEM", 108, 139], ["dependent", "OBSERVATION_MODIFIER", 12, 21], ["anion channel", "OBSERVATION", 22, 35], ["viral replication", "OBSERVATION", 68, 85], ["infectious", "OBSERVATION_MODIFIER", 108, 118]]], ["Han et al. showed that knockdown of VDAC1 inhibited IBDV replication through the reduction of viral polymerase activity, and that the overexpression of VDAC1 promotes polymerase activity.", [["VDAC1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IBDV", "ORGANISM", 52, 56], ["VDAC1", "GENE_OR_GENE_PRODUCT", 152, 157], ["VDAC1", "PROTEIN", 36, 41], ["viral polymerase", "PROTEIN", 94, 110], ["VDAC1", "PROTEIN", 152, 157], ["IBDV", "SPECIES", 52, 56], ["VDAC1", "TREATMENT", 36, 41], ["IBDV replication", "TREATMENT", 52, 68], ["viral polymerase activity", "PROBLEM", 94, 119], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["viral polymerase activity", "OBSERVATION", 94, 119], ["polymerase activity", "OBSERVATION", 167, 186]]], ["Immunoprecipitation (IP) experiments showed that VDAC1 interacts with IBDV VP1 and VP3, components of RNPs, indicating a role for this channel in RNP formation [64] .Viruses as Causative Agents of Acquired ChannelopathiesViral pathologies are becoming increasingly linked to the dysregulation of host ion channels (Table 3 ).", [["RNP", "ANATOMY", 146, 149], ["Viral pathologies", "DISEASE", 221, 238], ["VDAC1", "GENE_OR_GENE_PRODUCT", 49, 54], ["IBDV VP1", "ORGANISM", 70, 78], ["VP3", "GENE_OR_GENE_PRODUCT", 83, 86], ["RNPs", "GENE_OR_GENE_PRODUCT", 102, 106], ["RNP", "CELLULAR_COMPONENT", 146, 149], ["VDAC1", "PROTEIN", 49, 54], ["IBDV VP1", "PROTEIN", 70, 78], ["VP3", "PROTEIN", 83, 86], ["RNPs", "PROTEIN", 102, 106], ["RNP", "PROTEIN", 146, 149], ["IBDV", "SPECIES", 70, 74], ["Immunoprecipitation (IP) experiments", "TEST", 0, 36], ["VDAC1 interacts", "PROBLEM", 49, 64], ["IBDV VP1", "TREATMENT", 70, 78], ["Viruses", "PROBLEM", 166, 173], ["Acquired ChannelopathiesViral pathologies", "PROBLEM", 197, 238], ["RNPs", "OBSERVATION", 102, 106]]], ["This reveals an interesting and new avenue for ion channel drugs, as the pharmacological manipulation of virus-targeted channels may not only impair viral infection at the cellular level, but may circumvent virus-induced channelopathies.Viral Channelopathies and Ca 2+ ChannelsRecent studies have linked viral infection to neuronal pathologies through the dysregulation of Ca 2+ signalling.", [["cellular", "ANATOMY", 172, 180], ["neuronal", "ANATOMY", 323, 331], ["infection", "DISEASE", 155, 164], ["channelopathies", "DISEASE", 221, 236], ["Ca", "CHEMICAL", 263, 265], ["viral infection", "DISEASE", 304, 319], ["neuronal pathologies", "DISEASE", 323, 343], ["Ca", "CHEMICAL", 373, 375], ["Ca 2+", "CHEMICAL", 263, 268], ["Ca 2+", "CHEMICAL", 373, 378], ["cellular", "CELL", 172, 180], ["neuronal", "CELL", 323, 331], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 373, 378], ["ion channel drugs", "TREATMENT", 47, 64], ["virus", "PROBLEM", 105, 110], ["viral infection at the cellular level", "PROBLEM", 149, 186], ["circumvent virus-induced channelopathies", "PROBLEM", 196, 236], ["Viral Channelopathies", "PROBLEM", 237, 258], ["Ca", "TEST", 263, 265], ["ChannelsRecent studies", "TEST", 269, 291], ["viral infection", "PROBLEM", 304, 319], ["neuronal pathologies", "PROBLEM", 323, 343], ["the dysregulation of Ca", "PROBLEM", 352, 375], ["new", "OBSERVATION_MODIFIER", 32, 35], ["viral", "OBSERVATION_MODIFIER", 149, 154], ["infection", "OBSERVATION", 155, 164], ["Channelopathies", "OBSERVATION", 243, 258], ["viral", "OBSERVATION_MODIFIER", 304, 309], ["infection", "OBSERVATION", 310, 319]]], ["The FDA-approved Alzheimer's drug memantine protected against neuronal cell death induced by ZIKV infection [66] .", [["neuronal cell", "ANATOMY", 62, 75], ["Alzheimer", "DISEASE", 17, 26], ["memantine", "CHEMICAL", 34, 43], ["neuronal cell death", "DISEASE", 62, 81], ["infection", "DISEASE", 98, 107], ["memantine", "CHEMICAL", 34, 43], ["memantine", "SIMPLE_CHEMICAL", 34, 43], ["neuronal cell", "CELL", 62, 75], ["ZIKV", "SPECIES", 93, 97], ["The FDA", "TREATMENT", 0, 7], ["Alzheimer's drug memantine", "TREATMENT", 17, 43], ["neuronal cell death", "PROBLEM", 62, 81], ["ZIKV infection", "PROBLEM", 93, 107]]], ["Memantine acts upon the N-methyl-d-aspartate receptor (NMDAR), which mediates Ca 2+ signalling to govern synaptic plasticity [67] .", [["synaptic", "ANATOMY", 105, 113], ["Memantine", "CHEMICAL", 0, 9], ["N-methyl-d-aspartate", "CHEMICAL", 24, 44], ["Ca", "CHEMICAL", 78, 80], ["Memantine", "CHEMICAL", 0, 9], ["N-methyl-d-aspartate", "CHEMICAL", 24, 44], ["Ca 2+", "CHEMICAL", 78, 83], ["Memantine", "SIMPLE_CHEMICAL", 0, 9], ["N-methyl-d-aspartate receptor", "GENE_OR_GENE_PRODUCT", 24, 53], ["NMDAR", "GENE_OR_GENE_PRODUCT", 55, 60], ["Ca 2+", "SIMPLE_CHEMICAL", 78, 83], ["N-methyl-d-aspartate receptor", "PROTEIN", 24, 53], ["NMDAR", "PROTEIN", 55, 60], ["Memantine acts", "TREATMENT", 0, 14], ["d-aspartate receptor (NMDAR)", "TREATMENT", 33, 61]]], ["The overstimulation of NMDAR is linked to neurodegeneration, a pathology commonly associated with ZIKV.", [["neurodegeneration", "DISEASE", 42, 59], ["NMDAR", "GENE_OR_GENE_PRODUCT", 23, 28], ["NMDAR", "PROTEIN", 23, 28], ["ZIKV", "SPECIES", 98, 102], ["neurodegeneration", "PROBLEM", 42, 59], ["a pathology", "TEST", 61, 72], ["ZIKV", "PROBLEM", 98, 102]]], ["Upon challenge with memantine, ZIKV replication was unaffected, but antagonism of NMDAR invoked a neuroprotective effect in vivo.", [["memantine", "CHEMICAL", 20, 29], ["memantine", "CHEMICAL", 20, 29], ["memantine", "SIMPLE_CHEMICAL", 20, 29], ["ZIKV", "SIMPLE_CHEMICAL", 31, 35], ["NMDAR", "GENE_OR_GENE_PRODUCT", 82, 87], ["NMDAR", "PROTEIN", 82, 87], ["ZIKV", "SPECIES", 31, 35], ["memantine", "TREATMENT", 20, 29], ["ZIKV replication", "TREATMENT", 31, 47], ["NMDAR", "PROBLEM", 82, 87]]], ["Whilst the exact mechanism(s) of ZIKV neuropathologies are unknown, it is predicted that the virus hyper-stimulates NMDAR to upregulate Ca 2+ signalling to the point of Ca 2+ overload and postsynaptic neuronal death, a process termed \"glutamate excitotoxicity.\"Viral Channelopathies and Ca 2+ ChannelsThe reactivation of herpes simplex virus 1 (HSV-1) can lead to cranial nerve disorders and severe pain.", [["neuronal", "ANATOMY", 201, 209], ["cranial nerve", "ANATOMY", 364, 377], ["Ca", "CHEMICAL", 136, 138], ["Ca", "CHEMICAL", 169, 171], ["neuronal death", "DISEASE", 201, 215], ["glutamate", "CHEMICAL", 235, 244], ["Ca", "CHEMICAL", 287, 289], ["herpes simplex virus", "DISEASE", 321, 341], ["cranial nerve disorders", "DISEASE", 364, 387], ["pain", "DISEASE", 399, 403], ["Ca 2+", "CHEMICAL", 136, 141], ["Ca 2+", "CHEMICAL", 169, 174], ["glutamate", "CHEMICAL", 235, 244], ["Ca 2+", "CHEMICAL", 287, 292], ["ZIKV", "GENE_OR_GENE_PRODUCT", 33, 37], ["NMDAR", "GENE_OR_GENE_PRODUCT", 116, 121], ["Ca 2+", "SIMPLE_CHEMICAL", 136, 141], ["Ca 2+", "SIMPLE_CHEMICAL", 169, 174], ["neuronal", "CELL", 201, 209], ["glutamate", "SIMPLE_CHEMICAL", 235, 244], ["herpes simplex virus 1", "ORGANISM", 321, 343], ["HSV-1", "ORGANISM", 345, 350], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 364, 377], ["NMDAR", "PROTEIN", 116, 121], ["herpes simplex virus 1", "SPECIES", 321, 343], ["HSV-1", "SPECIES", 345, 350], ["ZIKV", "SPECIES", 33, 37], ["herpes simplex virus 1", "SPECIES", 321, 343], ["HSV-1", "SPECIES", 345, 350], ["ZIKV neuropathologies", "PROBLEM", 33, 54], ["the virus hyper", "PROBLEM", 89, 104], ["Ca", "TEST", 136, 138], ["Ca 2+ overload", "PROBLEM", 169, 183], ["postsynaptic neuronal death", "PROBLEM", 188, 215], ["a process termed \"glutamate excitotoxicity", "PROBLEM", 217, 259], ["Viral Channelopathies", "PROBLEM", 261, 282], ["Ca", "TEST", 287, 289], ["herpes simplex virus", "PROBLEM", 321, 341], ["HSV", "TEST", 345, 348], ["cranial nerve disorders", "PROBLEM", 364, 387], ["severe pain", "PROBLEM", 392, 403], ["postsynaptic neuronal death", "OBSERVATION", 188, 215], ["glutamate excitotoxicity", "OBSERVATION", 235, 259], ["Channelopathies", "OBSERVATION", 267, 282], ["herpes simplex", "OBSERVATION", 321, 335], ["cranial nerve", "ANATOMY", 364, 377], ["severe", "OBSERVATION_MODIFIER", 392, 398], ["pain", "OBSERVATION", 399, 403]]], ["Zhang et al. revealed that HSV-1 disrupts the expression of T-type Ca 2+ channels in differentiated sensory-like neurons, as a means to disrupt pain responses [68, 69] .", [["sensory-like neurons", "ANATOMY", 100, 120], ["Ca", "CHEMICAL", 67, 69], ["pain", "DISEASE", 144, 148], ["Ca 2+", "CHEMICAL", 67, 72], ["HSV-1", "ORGANISM", 27, 32], ["T-type Ca 2+", "GENE_OR_GENE_PRODUCT", 60, 72], ["sensory-like neurons", "CELL", 100, 120], ["T-type Ca 2+ channels", "PROTEIN", 60, 81], ["differentiated sensory-like neurons", "CELL_TYPE", 85, 120], ["HSV-1", "SPECIES", 27, 32], ["HSV", "TEST", 27, 30], ["HSV", "OBSERVATION", 27, 30]]], ["Proteomics and transcriptomics showed that HSV-1 decreased the expression of the Ca V 3.2 T-type Ca 2+ channel subunit at the protein level, despite increasing Ca V 3.2 mRNA synthesis.", [["Ca", "CHEMICAL", 81, 83], ["Ca", "CHEMICAL", 97, 99], ["Ca", "CHEMICAL", 160, 162], ["Ca 2+", "CHEMICAL", 97, 102], ["Ca V", "CHEMICAL", 160, 164], ["HSV-1", "ORGANISM", 43, 48], ["Ca 2+ channel subunit", "GENE_OR_GENE_PRODUCT", 97, 118], ["Ca V 3.2", "GENE_OR_GENE_PRODUCT", 160, 168], ["Ca V 3.2 T-type Ca 2+ channel subunit", "PROTEIN", 81, 118], ["Ca V 3.2 mRNA", "RNA", 160, 173], ["HSV-1", "SPECIES", 43, 48], ["Proteomics", "TEST", 0, 10], ["transcriptomics", "TEST", 15, 30], ["HSV", "TEST", 43, 46], ["the Ca V", "TEST", 77, 85], ["T", "TEST", 90, 91], ["the protein level", "TEST", 122, 139], ["increasing Ca V 3.2 mRNA synthesis", "PROBLEM", 149, 183]]], ["This upregulation of Ca V 3.2 mRNA synthesis was postulated to be a compensatory response to decreased expression of the channel subunit.", [["Ca", "CHEMICAL", 21, 23], ["Ca V 3.2", "CHEMICAL", 21, 29], ["Ca V 3.2", "GENE_OR_GENE_PRODUCT", 21, 29], ["Ca V 3.2 mRNA", "RNA", 21, 34], ["channel subunit", "PROTEIN", 121, 136], ["Ca V", "TEST", 21, 25], ["mRNA synthesis", "TEST", 30, 44]]], ["The loss of Ca V 3.2 initially led to reduced pain transmission in infected neurons; however, the release of interleukin-6 (IL-6) in response to viral infection was subsequently shown to restore Ca V 3.2 current density and pain responses.Viral Channelopathies and Ca 2+ ChannelsRotavirus (RV) dysregulates cellular Ca 2+ homeostasis through the depletion of ER stores.", [["neurons", "ANATOMY", 76, 83], ["cellular", "ANATOMY", 307, 315], ["ER", "ANATOMY", 359, 361], ["Ca", "CHEMICAL", 12, 14], ["pain", "DISEASE", 46, 50], ["viral infection", "DISEASE", 145, 160], ["Ca", "CHEMICAL", 195, 197], ["pain", "DISEASE", 224, 228], ["Ca", "CHEMICAL", 265, 267], ["Ca", "CHEMICAL", 316, 318], ["Ca V 3.2", "CHEMICAL", 12, 20], ["Ca V 3.2", "CHEMICAL", 195, 203], ["Ca 2+", "CHEMICAL", 265, 270], ["Ca 2+", "CHEMICAL", 316, 321], ["Ca V 3.2", "GENE_OR_GENE_PRODUCT", 12, 20], ["neurons", "CELL", 76, 83], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 109, 122], ["IL-6", "GENE_OR_GENE_PRODUCT", 124, 128], ["viral", "ORGANISM", 145, 150], ["Ca 2+ ChannelsRotavirus", "SIMPLE_CHEMICAL", 265, 288], ["cellular", "CELL", 307, 315], ["ER", "GENE_OR_GENE_PRODUCT", 359, 361], ["infected neurons", "CELL_TYPE", 67, 83], ["interleukin-6 (IL-6", "PROTEIN", 109, 128], ["ER", "PROTEIN", 359, 361], ["The loss of Ca V", "PROBLEM", 0, 16], ["reduced pain transmission in infected neurons", "PROBLEM", 38, 83], ["interleukin", "TEST", 109, 120], ["viral infection", "PROBLEM", 145, 160], ["Ca V", "TEST", 195, 199], ["pain responses", "PROBLEM", 224, 238], ["Viral Channelopathies", "PROBLEM", 239, 260], ["Ca", "TEST", 265, 267], ["ChannelsRotavirus (RV)", "TREATMENT", 271, 293], ["cellular Ca", "TREATMENT", 307, 318], ["the depletion of ER stores", "TREATMENT", 342, 368], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["infected neurons", "ANATOMY", 67, 83], ["viral infection", "OBSERVATION", 145, 160], ["density", "OBSERVATION", 212, 219], ["Channelopathies", "OBSERVATION", 245, 260], ["RV", "ANATOMY", 290, 292]]], ["Using genetically-encoded Ca 2+ indicators in infected cells, cytosolic Ca 2+ increased in distinct peaks [70] [71] [72] , which was mediated by the non-structural protein NSP4.", [["cells", "ANATOMY", 55, 60], ["cytosolic", "ANATOMY", 62, 71], ["Ca", "CHEMICAL", 26, 28], ["Ca", "CHEMICAL", 72, 74], ["Ca 2+", "CHEMICAL", 26, 31], ["Ca 2+", "CHEMICAL", 72, 77], ["Ca 2+", "SIMPLE_CHEMICAL", 26, 31], ["cells", "CELL", 55, 60], ["Ca 2+", "SIMPLE_CHEMICAL", 72, 77], ["NSP4", "GENE_OR_GENE_PRODUCT", 172, 176], ["Ca 2", "PROTEIN", 26, 30], ["infected cells", "CELL_TYPE", 46, 60], ["non-structural protein", "PROTEIN", 149, 171], ["NSP4", "PROTEIN", 172, 176], ["Ca", "TEST", 26, 28], ["infected cells", "PROBLEM", 46, 60], ["cytosolic Ca", "TEST", 62, 74], ["infected cells", "OBSERVATION", 46, 60], ["protein NSP4", "OBSERVATION", 164, 176]]], ["RV-NSP4 acts as a Ca 2+ -permeable viroporin to release Ca 2+ from the ER, which in turn activates the ER Ca 2+ sensor STIM1, subsequently leading to SOCE activation.", [["ER", "ANATOMY", 71, 73], ["Ca", "CHEMICAL", 18, 20], ["Ca", "CHEMICAL", 56, 58], ["Ca", "CHEMICAL", 106, 108], ["Ca 2+", "CHEMICAL", 18, 23], ["Ca 2+", "CHEMICAL", 56, 61], ["Ca 2+", "CHEMICAL", 106, 111], ["NSP4", "GENE_OR_GENE_PRODUCT", 3, 7], ["Ca 2+", "SIMPLE_CHEMICAL", 18, 23], ["viroporin", "SIMPLE_CHEMICAL", 35, 44], ["Ca 2+", "SIMPLE_CHEMICAL", 56, 61], ["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["ER Ca 2", "GENE_OR_GENE_PRODUCT", 103, 110], ["STIM1", "GENE_OR_GENE_PRODUCT", 119, 124], ["SOCE", "GENE_OR_GENE_PRODUCT", 150, 154], ["NSP4", "PROTEIN", 3, 7], ["Ca 2+ -permeable viroporin", "PROTEIN", 18, 44], ["ER", "PROTEIN", 71, 73], ["ER Ca 2+ sensor", "PROTEIN", 103, 118], ["STIM1", "PROTEIN", 119, 124], ["RV", "TEST", 0, 2], ["a Ca", "TEST", 16, 20], ["permeable viroporin", "TREATMENT", 25, 44], ["Ca", "TEST", 56, 58], ["sensor STIM1", "TEST", 112, 124], ["SOCE activation", "PROBLEM", 150, 165], ["NSP4", "OBSERVATION", 3, 7], ["SOCE activation", "OBSERVATION", 150, 165]]], ["RV-infected cells then secrete a cleavage product of NSP4 (eNSP4), which elicits an inward inositol triphosphate (IP 3 )-dependent Ca 2+ signal, which in turn stimulates Cl \u2212 release through Ca 2+ -activated Cl \u2212 channels (CaCCs) [73] .", [["cells", "ANATOMY", 12, 17], ["inositol triphosphate", "CHEMICAL", 91, 112], ["Ca", "CHEMICAL", 131, 133], ["Cl", "CHEMICAL", 170, 172], ["Ca", "CHEMICAL", 191, 193], ["inositol triphosphate", "CHEMICAL", 91, 112], ["IP 3 )", "CHEMICAL", 114, 120], ["Ca 2+", "CHEMICAL", 131, 136], ["Cl", "CHEMICAL", 170, 172], ["Ca 2+", "CHEMICAL", 191, 196], ["Cl", "CHEMICAL", 208, 210], ["cells", "CELL", 12, 17], ["NSP4", "GENE_OR_GENE_PRODUCT", 53, 57], ["eNSP4", "GENE_OR_GENE_PRODUCT", 59, 64], ["inositol triphosphate", "SIMPLE_CHEMICAL", 91, 112], ["IP 3", "SIMPLE_CHEMICAL", 114, 118], ["Ca 2+", "SIMPLE_CHEMICAL", 131, 136], ["Cl \u2212", "SIMPLE_CHEMICAL", 170, 174], ["Ca 2+", "SIMPLE_CHEMICAL", 191, 196], ["Cl \u2212", "SIMPLE_CHEMICAL", 208, 212], ["RV-infected cells", "CELL_TYPE", 0, 17], ["cleavage product", "PROTEIN", 33, 49], ["NSP4", "PROTEIN", 53, 57], ["eNSP4", "PROTEIN", 59, 64], ["Ca 2+ -activated Cl \u2212 channels", "PROTEIN", 191, 221], ["infected cells", "PROBLEM", 3, 17], ["NSP4", "PROBLEM", 53, 57], ["an inward inositol triphosphate", "TEST", 81, 112], ["dependent Ca", "PROBLEM", 121, 133], ["Ca", "TEST", 191, 193], ["CaCCs", "TEST", 223, 228], ["infected cells", "OBSERVATION", 3, 17]]], ["The efflux of Cl \u2212 from cells is a known causative factor of diarrhoea in vivo, thereby identifying NSP4 as the first viral enterotoxin.", [["cells", "ANATOMY", 24, 29], ["Cl", "CHEMICAL", 14, 16], ["diarrhoea", "DISEASE", 61, 70], ["Cl", "CHEMICAL", 14, 16], ["Cl \u2212", "SIMPLE_CHEMICAL", 14, 18], ["cells", "CELL", 24, 29], ["NSP4", "GENE_OR_GENE_PRODUCT", 100, 104], ["NSP4", "PROTEIN", 100, 104], ["viral enterotoxin", "PROTEIN", 118, 135], ["The efflux", "TEST", 0, 10], ["Cl \u2212 from cells", "PROBLEM", 14, 29], ["diarrhoea", "PROBLEM", 61, 70], ["NSP4", "PROBLEM", 100, 104], ["the first viral enterotoxin", "PROBLEM", 108, 135], ["efflux", "OBSERVATION_MODIFIER", 4, 10], ["diarrhoea", "OBSERVATION", 61, 70]]], ["This multi-faceted control of Ca 2+ signalling suggests a crucial role for Ca 2+ channels in the pathophysiology of RV.", [["RV", "ANATOMY", 116, 118], ["Ca", "CHEMICAL", 30, 32], ["Ca", "CHEMICAL", 75, 77], ["Ca 2+", "CHEMICAL", 30, 35], ["Ca 2+", "CHEMICAL", 75, 80], ["Ca 2+", "SIMPLE_CHEMICAL", 30, 35], ["Ca 2+", "SIMPLE_CHEMICAL", 75, 80], ["RV", "PATHOLOGICAL_FORMATION", 116, 118], ["Ca 2+ channels", "PROTEIN", 75, 89], ["RV", "ANATOMY", 116, 118]]], ["In this regard, it was shown that the blockade of CaCCs, including TMEM16A, reduces intestinal motility and fluid loss in vivo with no direct effects on the levels of virus infection [74] .Viral Channelopathies Associated with K + ChannelsCoxsackie virus B3 (CVB3), amongst other enteroviruses, is associated with cardiomyopathies and sudden cardiac death [76] .", [["intestinal", "ANATOMY", 84, 94], ["fluid", "ANATOMY", 108, 113], ["cardiac", "ANATOMY", 342, 349], ["fluid loss", "DISEASE", 108, 118], ["infection", "DISEASE", 173, 182], ["Viral Channelopathies", "DISEASE", 189, 210], ["K", "CHEMICAL", 227, 228], ["enteroviruses", "DISEASE", 280, 293], ["cardiomyopathies", "DISEASE", 314, 330], ["sudden cardiac death", "DISEASE", 335, 355], ["CaCCs", "GENE_OR_GENE_PRODUCT", 50, 55], ["TMEM16A", "GENE_OR_GENE_PRODUCT", 67, 74], ["intestinal", "ORGAN", 84, 94], ["fluid", "ORGANISM_SUBSTANCE", 108, 113], ["K + ChannelsCoxsackie virus B3", "ORGANISM", 227, 257], ["CVB3", "ORGANISM", 259, 263], ["cardiac", "ORGAN", 342, 349], ["CaCCs", "PROTEIN", 50, 55], ["TMEM16A", "PROTEIN", 67, 74], ["ChannelsCoxsackie virus B3", "SPECIES", 231, 257], ["K + ChannelsCoxsackie virus B3", "SPECIES", 227, 257], ["CVB3", "SPECIES", 259, 263], ["the blockade of CaCCs", "TREATMENT", 34, 55], ["TMEM16A", "TREATMENT", 67, 74], ["intestinal motility", "PROBLEM", 84, 103], ["fluid loss in vivo", "PROBLEM", 108, 126], ["direct effects", "PROBLEM", 135, 149], ["virus infection", "PROBLEM", 167, 182], ["Viral Channelopathies", "PROBLEM", 189, 210], ["K", "TEST", 227, 228], ["ChannelsCoxsackie virus B3 (CVB3", "PROBLEM", 231, 263], ["amongst other enteroviruses", "PROBLEM", 266, 293], ["cardiomyopathies", "PROBLEM", 314, 330], ["sudden cardiac death", "PROBLEM", 335, 355], ["intestinal motility", "OBSERVATION", 84, 103], ["fluid loss", "OBSERVATION", 108, 118], ["Channelopathies", "OBSERVATION", 195, 210], ["enteroviruses", "OBSERVATION", 280, 293], ["associated with", "UNCERTAINTY", 298, 313], ["cardiomyopathies", "OBSERVATION", 314, 330], ["cardiac", "ANATOMY", 342, 349], ["death", "OBSERVATION", 350, 355]]], ["KCNQ1 is a K V channel (K V 7.1) that mediates a delayed, slow rectifying K + current in ventricular tissue to regulate contractility.", [["ventricular tissue", "ANATOMY", 89, 107], ["K", "CHEMICAL", 74, 75], ["K +", "CHEMICAL", 74, 77], ["KCNQ1", "GENE_OR_GENE_PRODUCT", 0, 5], ["K V", "GENE_OR_GENE_PRODUCT", 11, 14], ["K V 7.1", "GENE_OR_GENE_PRODUCT", 24, 31], ["K +", "SIMPLE_CHEMICAL", 74, 77], ["ventricular tissue", "TISSUE", 89, 107], ["KCNQ1", "PROTEIN", 0, 5], ["K V channel", "PROTEIN", 11, 22], ["K V 7.1", "PROTEIN", 24, 31], ["a K V channel", "TEST", 9, 22], ["K V", "TEST", 24, 27], ["slow rectifying K", "PROBLEM", 58, 75], ["ventricular tissue", "ANATOMY", 89, 107], ["contractility", "OBSERVATION_MODIFIER", 120, 133]]], ["Kv7.1 trafficking and activity are regulated by the serine/threonine kinase SGK1 [80] , which is upregulated by CVB3.", [["serine", "CHEMICAL", 52, 58], ["threonine", "CHEMICAL", 59, 68], ["Kv7.1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SGK1 [80", "GENE_OR_GENE_PRODUCT", 76, 84], ["CVB3", "ORGANISM", 112, 116], ["Kv7.1", "PROTEIN", 0, 5], ["serine/threonine kinase", "PROTEIN", 52, 75], ["SGK1", "PROTEIN", 76, 80], ["CVB3", "SPECIES", 112, 116], ["the serine/threonine kinase SGK1", "TEST", 48, 80]]], ["As such, KCNQ1 currents are elevated to 125% in CVB infected cells, whilst hERG1 (K V 11.1) and Ca V 1.2 activity decrease by 59% and 83% respectively.", [["CVB", "ANATOMY", 48, 51], ["cells", "ANATOMY", 61, 66], ["Ca", "CHEMICAL", 96, 98], ["Ca V 1.2", "CHEMICAL", 96, 104], ["KCNQ1", "GENE_OR_GENE_PRODUCT", 9, 14], ["cells", "CELL", 61, 66], ["Ca V 1.2", "GENE_OR_GENE_PRODUCT", 96, 104], ["KCNQ1", "PROTEIN", 9, 14], ["CVB infected cells", "CELL_TYPE", 48, 66], ["hERG1", "PROTEIN", 75, 80], ["KCNQ1 currents", "TEST", 9, 23], ["elevated", "PROBLEM", 28, 36], ["CVB infected cells", "PROBLEM", 48, 66], ["hERG1", "TEST", 75, 80], ["K V", "TEST", 82, 85], ["Ca V", "TEST", 96, 100], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["infected cells", "OBSERVATION", 52, 66]]], ["These results corroborated with localisation studies of each channel and demonstrated that the surface expression of KCNQ1 increased, whilst hERG1 and Ca V 1.2 expression decreased in infected cells.", [["surface", "ANATOMY", 95, 102], ["cells", "ANATOMY", 193, 198], ["Ca", "CHEMICAL", 151, 153], ["Ca V 1.2", "CHEMICAL", 151, 159], ["surface", "CELLULAR_COMPONENT", 95, 102], ["KCNQ1", "GENE_OR_GENE_PRODUCT", 117, 122], ["hERG1", "GENE_OR_GENE_PRODUCT", 141, 146], ["Ca V 1.2", "GENE_OR_GENE_PRODUCT", 151, 159], ["cells", "CELL", 193, 198], ["KCNQ1", "PROTEIN", 117, 122], ["hERG1", "PROTEIN", 141, 146], ["infected cells", "CELL_TYPE", 184, 198], ["localisation studies", "TEST", 32, 52], ["KCNQ1", "PROBLEM", 117, 122], ["hERG1", "TEST", 141, 146], ["Ca V", "TEST", 151, 155], ["infected cells", "PROBLEM", 184, 198], ["decreased", "OBSERVATION_MODIFIER", 171, 180], ["infected cells", "OBSERVATION", 184, 198]]], ["Inherited mutations in each of these three ion channels are associated with heart rhythm disorders.", [["heart", "ANATOMY", 76, 81], ["heart rhythm disorders", "DISEASE", 76, 98], ["heart", "ORGAN", 76, 81], ["ion channels", "PROTEIN", 43, 55], ["Inherited mutations", "PROBLEM", 0, 19], ["heart rhythm disorders", "PROBLEM", 76, 98], ["mutations", "OBSERVATION", 10, 19], ["heart", "ANATOMY", 76, 81], ["rhythm", "OBSERVATION", 82, 88]]], ["Importantly, decreased hERG1 expression increases the risk of drug-induced arrhythmias; the additional inhibition or reduced trafficking of this channel in cells targeted by small therapeutic molecules reduces the number of redundant repolarisation currents, in turn depleting the overall repolarisation reserve.", [["cells", "ANATOMY", 156, 161], ["arrhythmias", "DISEASE", 75, 86], ["hERG1", "GENE_OR_GENE_PRODUCT", 23, 28], ["cells", "CELL", 156, 161], ["hERG1", "PROTEIN", 23, 28], ["decreased hERG1 expression", "PROBLEM", 13, 39], ["drug-induced arrhythmias", "PROBLEM", 62, 86], ["the additional inhibition", "TREATMENT", 88, 113], ["this channel in cells", "TREATMENT", 140, 161], ["small therapeutic molecules", "PROBLEM", 174, 201], ["redundant repolarisation currents", "PROBLEM", 224, 257], ["decreased", "OBSERVATION_MODIFIER", 13, 22], ["hERG1 expression", "OBSERVATION", 23, 39], ["arrhythmias", "OBSERVATION", 75, 86], ["small", "OBSERVATION_MODIFIER", 174, 179], ["therapeutic molecules", "OBSERVATION", 180, 201], ["redundant", "OBSERVATION_MODIFIER", 224, 233], ["repolarisation currents", "OBSERVATION", 234, 257], ["overall", "OBSERVATION_MODIFIER", 281, 288], ["repolarisation reserve", "OBSERVATION", 289, 311]]], ["Together, these data suggest that CVB3 re-programmes ion channel expression in cardiac tissue, leading to an increased risk of arrhythmia.", [["cardiac tissue", "ANATOMY", 79, 93], ["arrhythmia", "DISEASE", 127, 137], ["CVB3", "ORGANISM", 34, 38], ["cardiac tissue", "TISSUE", 79, 93], ["CVB3", "SPECIES", 34, 38], ["these data", "TEST", 10, 20], ["CVB3", "PROBLEM", 34, 38], ["cardiac tissue", "PROBLEM", 79, 93], ["arrhythmia", "PROBLEM", 127, 137], ["cardiac tissue", "ANATOMY", 79, 93], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["arrhythmia", "OBSERVATION", 127, 137]]], ["This highlights these channels as therapeutic targets to prevent the sudden cardiac death that results from CVB3 infection.Viral Channelopathies Associated with Na + ChannelsA number of viruses that primarily infect the airway system have been shown to dysregulate airway epithelial Na + transport.", [["cardiac", "ANATOMY", 76, 83], ["airway system", "ANATOMY", 220, 233], ["airway epithelial", "ANATOMY", 265, 282], ["sudden cardiac death", "DISEASE", 69, 89], ["CVB3 infection", "DISEASE", 108, 122], ["Na", "CHEMICAL", 161, 163], ["Na", "CHEMICAL", 283, 285], ["Na", "CHEMICAL", 161, 163], ["Na +", "CHEMICAL", 283, 287], ["cardiac", "ORGAN", 76, 83], ["CVB3", "ORGANISM", 108, 112], ["Na + ChannelsA", "GENE_OR_GENE_PRODUCT", 161, 175], ["airway", "ORGAN", 220, 226], ["airway epithelial", "TISSUE", 265, 282], ["Na +", "SIMPLE_CHEMICAL", 283, 287], ["CVB3", "SPECIES", 108, 112], ["therapeutic targets", "TREATMENT", 34, 53], ["the sudden cardiac death", "PROBLEM", 65, 89], ["CVB3 infection", "PROBLEM", 108, 122], ["Viral Channelopathies", "PROBLEM", 123, 144], ["Na", "TEST", 161, 163], ["viruses", "PROBLEM", 186, 193], ["cardiac", "ANATOMY", 76, 83], ["death", "OBSERVATION", 84, 89], ["CVB3 infection", "OBSERVATION", 108, 122], ["Channelopathies", "OBSERVATION", 129, 144], ["Na +", "OBSERVATION_MODIFIER", 161, 165], ["viruses", "OBSERVATION", 186, 193], ["airway", "ANATOMY", 220, 226]]], ["Human respiratory syncytial virus (HRSV) primarily infects airway epithelial cells, and dysregulates epithelial Na + channels (ENaC) to disrupt Na + flux in the airways [81] .", [["airway epithelial cells", "ANATOMY", 59, 82], ["epithelial", "ANATOMY", 101, 111], ["airways", "ANATOMY", 161, 168], ["respiratory syncytial virus", "DISEASE", 6, 33], ["Na", "CHEMICAL", 112, 114], ["Na", "CHEMICAL", 144, 146], ["Na +", "CHEMICAL", 112, 116], ["Na +", "CHEMICAL", 144, 148], ["Human respiratory syncytial virus", "ORGANISM", 0, 33], ["HRSV", "ORGANISM", 35, 39], ["airway epithelial cells", "CELL", 59, 82], ["epithelial", "CELL", 101, 111], ["Na + channels", "GENE_OR_GENE_PRODUCT", 112, 125], ["ENaC", "GENE_OR_GENE_PRODUCT", 127, 131], ["Na +", "SIMPLE_CHEMICAL", 144, 148], ["airway epithelial cells", "CELL_TYPE", 59, 82], ["epithelial Na + channels", "PROTEIN", 101, 125], ["ENaC", "PROTEIN", 127, 131], ["Na", "PROTEIN", 144, 146], ["Human", "SPECIES", 0, 5], ["respiratory syncytial virus", "SPECIES", 6, 33], ["HRSV", "SPECIES", 35, 39], ["Human respiratory syncytial virus", "SPECIES", 0, 33], ["HRSV", "SPECIES", 35, 39], ["Human respiratory syncytial virus", "PROBLEM", 0, 33], ["HRSV", "PROBLEM", 35, 39], ["infects airway epithelial cells", "PROBLEM", 51, 82], ["syncytial virus", "OBSERVATION", 18, 33], ["airway epithelial cells", "OBSERVATION", 59, 82], ["airways", "ANATOMY", 161, 168]]], ["ENaCs are a critical mediator of osmotic fluid absorption across airway epithelia, through the selective transport of Na + .", [["airway epithelia", "ANATOMY", 65, 81], ["Na", "CHEMICAL", 118, 120], ["Na +", "CHEMICAL", 118, 122], ["ENaCs", "SIMPLE_CHEMICAL", 0, 5], ["airway epithelia", "TISSUE", 65, 81], ["Na +", "SIMPLE_CHEMICAL", 118, 122], ["osmotic fluid absorption across airway epithelia", "PROBLEM", 33, 81], ["osmotic", "OBSERVATION_MODIFIER", 33, 40], ["fluid absorption", "OBSERVATION", 41, 57], ["airway epithelia", "OBSERVATION", 65, 81]]], ["Electrochemical balance is maintained through apical Cl \u2212 channels, which include CFTR.", [["Cl", "CHEMICAL", 53, 55], ["Cl", "CHEMICAL", 53, 55], ["CFTR", "GENE_OR_GENE_PRODUCT", 82, 86], ["apical Cl \u2212 channels", "PROTEIN", 46, 66], ["CFTR", "PROTEIN", 82, 86], ["Electrochemical balance", "TEST", 0, 23], ["apical", "ANATOMY_MODIFIER", 46, 52], ["Cl", "OBSERVATION", 53, 55]]], ["Clinical studies of infants diagnosed with HRSV showed a negative correlation between ENaC mRNA expression and the severity of HRSV bronchiolitis [82] .", [["bronchiolitis", "DISEASE", 132, 145], ["infants", "ORGANISM", 20, 27], ["ENaC", "GENE_OR_GENE_PRODUCT", 86, 90], ["ENaC mRNA", "RNA", 86, 95], ["infants", "SPECIES", 20, 27], ["HRSV", "SPECIES", 43, 47], ["Clinical studies", "TEST", 0, 16], ["HRSV", "PROBLEM", 43, 47], ["ENaC mRNA expression", "PROBLEM", 86, 106], ["HRSV bronchiolitis", "PROBLEM", 127, 145], ["HRSV bronchiolitis", "OBSERVATION", 127, 145]]], ["HRSV has been shown to manipulate airway ion flux through upregulation of channels involved in the cough reflex, namely, transient receptor cation channel, subfamily A, member 1 (TRPA1), and the acid sensing ion channel receptor 3 (ASIC3), a member of the ENaC family of Na + channels [77] .", [["airway", "ANATOMY", 34, 40], ["cough", "DISEASE", 99, 104], ["Na", "CHEMICAL", 271, 273], ["Na +", "CHEMICAL", 271, 275], ["HRSV", "ORGANISM", 0, 4], ["airway", "MULTI-TISSUE_STRUCTURE", 34, 40], ["subfamily A, member 1", "GENE_OR_GENE_PRODUCT", 156, 177], ["TRPA1", "GENE_OR_GENE_PRODUCT", 179, 184], ["acid sensing ion channel receptor 3", "GENE_OR_GENE_PRODUCT", 195, 230], ["ASIC3", "GENE_OR_GENE_PRODUCT", 232, 237], ["ENaC", "GENE_OR_GENE_PRODUCT", 256, 260], ["Na +", "SIMPLE_CHEMICAL", 271, 275], ["transient receptor cation channel", "PROTEIN", 121, 154], ["subfamily A", "PROTEIN", 156, 167], ["member 1", "PROTEIN", 169, 177], ["TRPA1", "PROTEIN", 179, 184], ["acid sensing ion channel receptor 3", "PROTEIN", 195, 230], ["ASIC3", "PROTEIN", 232, 237], ["ENaC family", "PROTEIN", 256, 267], ["Na + channels", "PROTEIN", 271, 284], ["HRSV", "SPECIES", 0, 4], ["HRSV", "PROBLEM", 0, 4], ["the cough reflex", "TEST", 95, 111], ["the acid sensing ion channel receptor", "TREATMENT", 191, 228]]], ["HRSV induced a 30-fold increase in ASIC3 mRNA in normal bronchial epithelial cells, compared to the 3-fold increase observed in cells challenged with measles virus (MeV).", [["bronchial epithelial cells", "ANATOMY", 56, 82], ["cells", "ANATOMY", 128, 133], ["HRSV", "ORGANISM", 0, 4], ["ASIC3", "GENE_OR_GENE_PRODUCT", 35, 40], ["bronchial epithelial cells", "CELL", 56, 82], ["cells", "CELL", 128, 133], ["measles virus", "ORGANISM", 150, 163], ["ASIC3 mRNA", "RNA", 35, 45], ["normal bronchial epithelial cells", "CELL_TYPE", 49, 82], ["HRSV", "SPECIES", 0, 4], ["measles virus", "SPECIES", 150, 163], ["HRSV", "PROBLEM", 0, 4], ["a 30-fold increase", "PROBLEM", 13, 31], ["ASIC3 mRNA", "PROBLEM", 35, 45], ["measles virus", "PROBLEM", 150, 163], ["30-fold", "OBSERVATION_MODIFIER", 15, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["ASIC3 mRNA", "OBSERVATION", 35, 45], ["normal", "OBSERVATION_MODIFIER", 49, 55], ["bronchial epithelial cells", "OBSERVATION", 56, 82]]], ["Interestingly, UV-inactivated HRSV and MeV maintained their ability to upregulate ASIC3, suggesting these effects were independent of genome replication.", [["UV", "CHEMICAL", 15, 17], ["HRSV", "ORGANISM", 30, 34], ["ASIC3", "GENE_OR_GENE_PRODUCT", 82, 87], ["genome", "CELLULAR_COMPONENT", 134, 140], ["ASIC3", "PROTEIN", 82, 87], ["HRSV", "SPECIES", 30, 34], ["UV", "TEST", 15, 17], ["HRSV", "PROBLEM", 30, 34], ["ASIC3", "TEST", 82, 87], ["genome replication", "TREATMENT", 134, 152]]], ["The virion-induced upregulation of IL-6 and IL-8 was subsequently shown to inhibit TRP receptor activity, identifying these receptors as potential targets for virus-induced cough symptoms.Viral Channelopathies Associated with Na + ChannelsENaC and CFTR channel expression are also modulated by IAV.", [["cough symptoms", "DISEASE", 173, 187], ["Na", "CHEMICAL", 226, 228], ["Na", "CHEMICAL", 226, 228], ["IL-6", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-8", "GENE_OR_GENE_PRODUCT", 44, 48], ["TRP receptor", "GENE_OR_GENE_PRODUCT", 83, 95], ["Na + ChannelsENaC", "GENE_OR_GENE_PRODUCT", 226, 243], ["CFTR", "GENE_OR_GENE_PRODUCT", 248, 252], ["IAV", "ORGANISM", 294, 297], ["IL-6", "PROTEIN", 35, 39], ["IL-8", "PROTEIN", 44, 48], ["TRP receptor", "PROTEIN", 83, 95], ["CFTR", "PROTEIN", 248, 252], ["The virion-induced upregulation of IL", "TREATMENT", 0, 37], ["these receptors", "TREATMENT", 118, 133], ["virus", "PROBLEM", 159, 164], ["induced cough symptoms", "PROBLEM", 165, 187], ["Viral Channelopathies", "PROBLEM", 188, 209], ["Na + ChannelsENaC", "TREATMENT", 226, 243], ["CFTR channel expression", "TREATMENT", 248, 271], ["Channelopathies", "OBSERVATION", 194, 209], ["IAV", "OBSERVATION_MODIFIER", 294, 297]]], ["From single-cell recordings in intact lung epithelial cells, Brand et al. described a reduction in ENaC and CFTR activity upon IAV-infection, through reduced surface expression.", [["cell", "ANATOMY", 12, 16], ["lung epithelial cells", "ANATOMY", 38, 59], ["surface", "ANATOMY", 158, 165], ["infection", "DISEASE", 131, 140], ["lung epithelial cells", "CELL", 38, 59], ["ENaC", "GENE_OR_GENE_PRODUCT", 99, 103], ["CFTR", "GENE_OR_GENE_PRODUCT", 108, 112], ["IAV", "ORGANISM", 127, 130], ["lung epithelial cells", "CELL_TYPE", 38, 59], ["ENaC", "PROTEIN", 99, 103], ["CFTR", "PROTEIN", 108, 112], ["single-cell recordings", "TEST", 5, 27], ["a reduction in ENaC and CFTR activity", "PROBLEM", 84, 121], ["IAV", "PROBLEM", 127, 130], ["infection", "PROBLEM", 131, 140], ["intact", "ANATOMY_MODIFIER", 31, 37], ["lung", "ANATOMY", 38, 42], ["epithelial cells", "OBSERVATION", 43, 59], ["reduction", "OBSERVATION_MODIFIER", 86, 95], ["ENaC", "OBSERVATION", 99, 103], ["CFTR activity", "OBSERVATION", 108, 121], ["IAV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140]]], ["The mechanisms governing this downregulation were not characterised, but it is thought that IAV promote ER stress, known to cause deficits in ENaC abundance [83] .", [["IAV", "ORGANISM", 92, 95], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["ENaC", "GENE_OR_GENE_PRODUCT", 142, 146], ["ER", "PROTEIN", 104, 106], ["ENaC", "PROTEIN", 142, 146], ["deficits", "PROBLEM", 130, 138]]], ["The loss of ENaC and CFTR surface expression was accompanied by a reduction in airway surface liquid (ASL), a known contributor to cystic fibrosis.", [["surface", "ANATOMY", 26, 33], ["airway surface", "ANATOMY", 79, 93], ["cystic", "ANATOMY", 131, 137], ["fibrosis", "DISEASE", 138, 146], ["ENaC", "GENE_OR_GENE_PRODUCT", 12, 16], ["CFTR", "GENE_OR_GENE_PRODUCT", 21, 25], ["ENaC", "PROTEIN", 12, 16], ["CFTR", "PROTEIN", 21, 25], ["The loss of ENaC and CFTR surface expression", "PROBLEM", 0, 44], ["a reduction in airway surface liquid", "PROBLEM", 64, 100], ["cystic fibrosis", "PROBLEM", 131, 146], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["ENaC", "OBSERVATION_MODIFIER", 12, 16], ["surface", "OBSERVATION_MODIFIER", 26, 33], ["reduction", "OBSERVATION_MODIFIER", 66, 75], ["airway", "ANATOMY", 79, 85], ["surface liquid", "OBSERVATION", 86, 100], ["cystic", "OBSERVATION_MODIFIER", 131, 137], ["fibrosis", "OBSERVATION", 138, 146]]], ["Importantly, treatment with the FDA-approved CFTR corrector lumacaftor could restore IAV-mediated ASL perturbations, highlighting how virus-induced pathologies can be treated by therapies targeting host ion channels [78] .Viral Channelopathies Associated with Na + ChannelsThe altered activity of Na + channels was observed in cells latently infected HSV-1 dorsal root ganglion neurones.", [["cells", "ANATOMY", 327, 332], ["dorsal root ganglion neurones", "ANATOMY", 357, 386], ["lumacaftor", "CHEMICAL", 60, 70], ["Na", "CHEMICAL", 260, 262], ["Na", "CHEMICAL", 297, 299], ["lumacaftor", "CHEMICAL", 60, 70], ["Na +", "CHEMICAL", 260, 264], ["Na +", "CHEMICAL", 297, 301], ["CFTR", "GENE_OR_GENE_PRODUCT", 45, 49], ["lumacaftor", "SIMPLE_CHEMICAL", 60, 70], ["IAV", "ORGANISM", 85, 88], ["ASL", "MULTI-TISSUE_STRUCTURE", 98, 101], ["Na +", "SIMPLE_CHEMICAL", 260, 264], ["Na +", "SIMPLE_CHEMICAL", 297, 301], ["cells", "CELL", 327, 332], ["HSV-1", "ORGANISM", 351, 356], ["dorsal root ganglion neurones", "CELL", 357, 386], ["Na + channels", "PROTEIN", 297, 310], ["HSV-1", "SPECIES", 351, 356], ["HSV-1", "SPECIES", 351, 356], ["the FDA", "TREATMENT", 28, 35], ["CFTR corrector lumacaftor", "TREATMENT", 45, 70], ["IAV-mediated ASL perturbations", "TREATMENT", 85, 115], ["Viral Channelopathies", "PROBLEM", 222, 243], ["The altered activity of Na + channels", "PROBLEM", 273, 310], ["Channelopathies", "OBSERVATION", 228, 243], ["altered", "OBSERVATION_MODIFIER", 277, 284], ["activity", "OBSERVATION_MODIFIER", 285, 293], ["infected HSV", "OBSERVATION", 342, 354], ["dorsal", "ANATOMY_MODIFIER", 357, 363], ["root ganglion", "ANATOMY", 364, 377]]], ["Upon acute lytic infection, HSV-1 was found to reduce functional voltage-gated sodium channel (VGSC) expression within 24 h and abolish VGSC activity within 3 days, whilst latent HSV-1 infection led to a recovery of these currents and increased Na V 1.7 channel expression.", [["infection", "DISEASE", 17, 26], ["sodium", "CHEMICAL", 79, 85], ["infection", "DISEASE", 185, 194], ["Na", "CHEMICAL", 245, 247], ["sodium", "CHEMICAL", 79, 85], ["Na V 1.7", "CHEMICAL", 245, 253], ["HSV-1", "ORGANISM", 28, 33], ["voltage-gated sodium channel", "GENE_OR_GENE_PRODUCT", 65, 93], ["VGSC", "GENE_OR_GENE_PRODUCT", 95, 99], ["VGSC", "GENE_OR_GENE_PRODUCT", 136, 140], ["HSV-1", "ORGANISM", 179, 184], ["Na V 1.7 channel", "GENE_OR_GENE_PRODUCT", 245, 261], ["voltage-gated sodium channel", "PROTEIN", 65, 93], ["VGSC", "PROTEIN", 95, 99], ["VGSC", "PROTEIN", 136, 140], ["Na V 1.7 channel", "PROTEIN", 245, 261], ["HSV-1", "SPECIES", 28, 33], ["HSV-1", "SPECIES", 28, 33], ["HSV-1", "SPECIES", 179, 184], ["acute lytic infection", "PROBLEM", 5, 26], ["HSV", "TEST", 28, 31], ["functional voltage", "TEST", 54, 72], ["gated sodium channel", "TEST", 73, 93], ["abolish VGSC activity", "PROBLEM", 128, 149], ["latent HSV-1 infection", "PROBLEM", 172, 194], ["these currents", "PROBLEM", 216, 230], ["increased Na V", "PROBLEM", 235, 249], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["lytic", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26], ["infection", "OBSERVATION", 185, 194]]], ["Furthermore, HSV-1 reactivation from a dormant state decreased VGSC activity.", [["HSV-1", "ORGANISM", 13, 18], ["VGSC", "GENE_OR_GENE_PRODUCT", 63, 67], ["VGSC", "PROTEIN", 63, 67], ["HSV-1", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["decreased", "OBSERVATION_MODIFIER", 53, 62], ["VGSC activity", "OBSERVATION", 63, 76]]], ["It is known that VGSCs play a role in the transmission of pain signals [75] .", [["VGSCs", "ANATOMY", 17, 22], ["pain", "DISEASE", 58, 62], ["VGSCs", "GENE_OR_GENE_PRODUCT", 17, 22], ["VGSCs", "CELL_TYPE", 17, 22], ["pain signals", "PROBLEM", 58, 70]]], ["Similarly, post-herpetic neuralgia associated with varicella-zoster virus is associated with an increase in Na + current amplitude through the activity of Na V 1.6 and Na V 1.7 [84] .", [["post-herpetic neuralgia", "DISEASE", 11, 34], ["varicella-zoster virus", "DISEASE", 51, 73], ["Na", "CHEMICAL", 108, 110], ["Na", "CHEMICAL", 155, 157], ["Na", "CHEMICAL", 168, 170], ["Na +", "CHEMICAL", 108, 112], ["Na V", "CHEMICAL", 155, 159], ["Na V 1.7", "CHEMICAL", 168, 176], ["varicella-zoster virus", "ORGANISM", 51, 73], ["Na +", "SIMPLE_CHEMICAL", 108, 112], ["Na V 1.6", "GENE_OR_GENE_PRODUCT", 155, 163], ["Na V", "GENE_OR_GENE_PRODUCT", 168, 172], ["varicella-zoster virus", "SPECIES", 51, 73], ["varicella-zoster virus", "SPECIES", 51, 73], ["post-herpetic neuralgia", "PROBLEM", 11, 34], ["varicella-zoster virus", "PROBLEM", 51, 73], ["an increase in Na", "PROBLEM", 93, 110], ["Na V", "TEST", 155, 159], ["Na V", "TEST", 168, 172], ["post-herpetic", "OBSERVATION_MODIFIER", 11, 24], ["neuralgia", "OBSERVATION", 25, 34], ["varicella", "OBSERVATION", 51, 60], ["zoster virus", "OBSERVATION", 61, 73], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["Na + current amplitude", "OBSERVATION_MODIFIER", 108, 130]]], ["Na V 1.7 dysregulation has also been associated with hereditary pain disorders.", [["Na", "CHEMICAL", 0, 2], ["hereditary pain", "DISEASE", 53, 68], ["disorders", "DISEASE", 69, 78], ["Na V 1.7", "CHEMICAL", 0, 8], ["Na V 1.7", "GENE_OR_GENE_PRODUCT", 0, 8], ["Na V 1.7 dysregulation", "PROBLEM", 0, 22], ["hereditary pain disorders", "PROBLEM", 53, 78], ["associated with", "UNCERTAINTY", 37, 52], ["hereditary", "OBSERVATION_MODIFIER", 53, 63], ["pain", "OBSERVATION", 64, 68]]], ["Gain-of-function mutations in SCN9A, the gene encoding Na V 1.7, are causative of primary erythromelalgia (PE), a rare neuropathy characterised by recurring pain, warmth, and redness of the extremities.", [["primary erythromelalgia", "ANATOMY", 82, 105], ["extremities", "ANATOMY", 190, 201], ["Na", "CHEMICAL", 55, 57], ["primary erythromelalgia", "DISEASE", 82, 105], ["PE", "DISEASE", 107, 109], ["neuropathy", "DISEASE", 119, 129], ["pain", "DISEASE", 157, 161], ["redness of the extremities", "DISEASE", 175, 201], ["SCN9A", "GENE_OR_GENE_PRODUCT", 30, 35], ["Na V 1.7", "GENE_OR_GENE_PRODUCT", 55, 63], ["erythromelalgia", "CANCER", 90, 105], ["extremities", "ORGANISM_SUBDIVISION", 190, 201], ["SCN9A", "DNA", 30, 35], ["Na V 1.7", "PROTEIN", 55, 63], ["Gain", "TEST", 0, 4], ["Na V", "TEST", 55, 59], ["primary erythromelalgia (PE", "PROBLEM", 82, 109], ["a rare neuropathy", "PROBLEM", 112, 129], ["recurring pain", "PROBLEM", 147, 161], ["warmth", "PROBLEM", 163, 169], ["redness of the extremities", "PROBLEM", 175, 201], ["primary", "OBSERVATION_MODIFIER", 82, 89], ["erythromelalgia", "OBSERVATION", 90, 105], ["PE", "OBSERVATION", 107, 109], ["rare", "OBSERVATION_MODIFIER", 114, 118], ["neuropathy", "OBSERVATION", 119, 129], ["recurring", "OBSERVATION_MODIFIER", 147, 156], ["pain", "OBSERVATION", 157, 161], ["warmth", "OBSERVATION_MODIFIER", 163, 169], ["redness", "OBSERVATION", 175, 182], ["extremities", "ANATOMY", 190, 201]]], ["Research into the management of PE identified two novel selective Na V 1.7 blockers, PF-05089771 and TV-45070, which may hold promise in ameliorating pain symptoms associated with PE [85] and viral-induced neuropathies.Viral Channelopathies Associated with Cl \u2212 ChannelsStakaityt\u0117 et al., used a proteomics approach to identify changes in the host channelome in response to the overexpression of MCPyV small tumour antigen (ST).", [["PE", "DISEASE", 32, 34], ["Na", "CHEMICAL", 66, 68], ["PF-05089771", "CHEMICAL", 85, 96], ["TV-45070", "CHEMICAL", 101, 109], ["pain", "DISEASE", 150, 154], ["PE", "CHEMICAL", 180, 182], ["neuropathies", "DISEASE", 206, 218], ["Viral Channelopathies", "DISEASE", 219, 240], ["Cl", "CHEMICAL", 257, 259], ["Na V 1.7", "CHEMICAL", 66, 74], ["PF-05089771", "CHEMICAL", 85, 96], ["TV-45070", "CHEMICAL", 101, 109], ["Na V 1.7 blockers", "SIMPLE_CHEMICAL", 66, 83], ["PF-05089771", "SIMPLE_CHEMICAL", 85, 96], ["TV-45070", "SIMPLE_CHEMICAL", 101, 109], ["MCPyV small tumour antigen", "GENE_OR_GENE_PRODUCT", 396, 422], ["MCPyV small tumour antigen", "PROTEIN", 396, 422], ["ST", "PROTEIN", 424, 426], ["PE", "PROBLEM", 32, 34], ["novel selective Na V 1.7 blockers", "TREATMENT", 50, 83], ["PF", "TEST", 85, 87], ["TV", "TEST", 101, 103], ["ameliorating pain symptoms", "PROBLEM", 137, 163], ["PE", "PROBLEM", 180, 182], ["viral-induced neuropathies", "PROBLEM", 192, 218], ["Viral Channelopathies", "PROBLEM", 219, 240], ["a proteomics approach", "TREATMENT", 294, 315], ["MCPyV small tumour antigen", "PROBLEM", 396, 422], ["PE", "OBSERVATION", 32, 34], ["PE", "OBSERVATION", 180, 182], ["neuropathies", "OBSERVATION", 206, 218], ["Channelopathies", "OBSERVATION", 225, 240], ["small", "OBSERVATION_MODIFIER", 402, 407], ["tumour", "OBSERVATION", 408, 414]]], ["The analysis revealed a role for two CLIC proteins [79] , CLIC1 and CLIC4 (4-fold and 5-fold up regulation in cells overexpressing ST vs. control cells, respectively).", [["cells", "ANATOMY", 110, 115], ["cells", "ANATOMY", 146, 151], ["CLIC", "GENE_OR_GENE_PRODUCT", 37, 41], ["CLIC1", "GENE_OR_GENE_PRODUCT", 58, 63], ["CLIC4", "GENE_OR_GENE_PRODUCT", 68, 73], ["cells", "CELL", 110, 115], ["cells", "CELL", 146, 151], ["CLIC proteins", "PROTEIN", 37, 50], ["CLIC1", "PROTEIN", 58, 63], ["CLIC4", "PROTEIN", 68, 73], ["ST", "PROTEIN", 131, 133], ["The analysis", "TEST", 0, 12], ["two CLIC proteins", "TEST", 33, 50], ["CLIC1", "TEST", 58, 63], ["CLIC4", "TEST", 68, 73], ["fold", "TEST", 77, 81]]], ["Pharmacological and genetic inhibition of these channels reduced ST-induced motility and migration, implicating their function in MCPyV, ST-induced metastatic processes [86] .", [["MCPyV", "ORGANISM", 130, 135], ["Pharmacological", "TREATMENT", 0, 15], ["these channels", "PROBLEM", 42, 56], ["ST-induced motility", "PROBLEM", 65, 84], ["ST-induced metastatic processes", "PROBLEM", 137, 168], ["metastatic", "OBSERVATION", 148, 158]]], ["These data were reinforced by the finding that MCPyV-positive MCC tumours showed enhanced CLIC1 and CLIC4 expression (2.5-fold and 3.5-fold increase respectively), implicating their involvement in MCC tumorigenesis.", [["MCC tumours", "ANATOMY", 62, 73], ["MCC", "ANATOMY", 197, 200], ["MCPyV", "GENE_OR_GENE_PRODUCT", 47, 52], ["MCC tumours", "CANCER", 62, 73], ["CLIC1", "GENE_OR_GENE_PRODUCT", 90, 95], ["CLIC4", "GENE_OR_GENE_PRODUCT", 100, 105], ["MCC", "CANCER", 197, 200], ["CLIC1", "PROTEIN", 90, 95], ["CLIC4", "PROTEIN", 100, 105], ["MCPyV", "TEST", 47, 52], ["enhanced CLIC1", "PROBLEM", 81, 95], ["CLIC4 expression", "TEST", 100, 116], ["MCC tumorigenesis", "PROBLEM", 197, 214], ["enhanced CLIC1", "OBSERVATION", 81, 95], ["MCC tumorigenesis", "OBSERVATION", 197, 214]]], ["These findings align with earlier evidence that CLIC1 and CLIC4 are involved in the metastatic progression of specific tumour types, through switching of cellular localisation and function to integral transmembrane proteins as active anion channels and signal transducers [87] .Conclusions and Further PerspectivesIt is now clear that host cell ion channels play an important role during viral infection at the cellular level, and as causative factors of disease states in infected tissues.", [["tumour", "ANATOMY", 119, 125], ["cellular", "ANATOMY", 154, 162], ["transmembrane", "ANATOMY", 201, 214], ["cell", "ANATOMY", 340, 344], ["cellular", "ANATOMY", 411, 419], ["tissues", "ANATOMY", 482, 489], ["tumour", "DISEASE", 119, 125], ["infection", "DISEASE", 394, 403], ["CLIC1", "GENE_OR_GENE_PRODUCT", 48, 53], ["CLIC4", "GENE_OR_GENE_PRODUCT", 58, 63], ["tumour", "CANCER", 119, 125], ["cellular", "CELL", 154, 162], ["transmembrane", "CELLULAR_COMPONENT", 201, 214], ["anion", "SIMPLE_CHEMICAL", 234, 239], ["host cell", "CELL", 335, 344], ["cellular", "CELL", 411, 419], ["tissues", "TISSUE", 482, 489], ["CLIC1", "PROTEIN", 48, 53], ["CLIC4", "PROTEIN", 58, 63], ["integral transmembrane proteins", "PROTEIN", 192, 223], ["anion channels", "PROTEIN", 234, 248], ["CLIC1 and CLIC4", "PROBLEM", 48, 63], ["the metastatic progression of specific tumour types", "PROBLEM", 80, 131], ["integral transmembrane proteins", "TEST", 192, 223], ["signal transducers", "TEST", 253, 271], ["host cell ion channels", "TREATMENT", 335, 357], ["viral infection", "PROBLEM", 388, 403], ["disease", "PROBLEM", 455, 462], ["infected tissues", "PROBLEM", 473, 489], ["CLIC1", "OBSERVATION", 48, 53], ["metastatic", "OBSERVATION_MODIFIER", 84, 94], ["specific", "OBSERVATION_MODIFIER", 110, 118], ["tumour types", "OBSERVATION", 119, 131], ["cellular localisation", "OBSERVATION", 154, 175], ["active", "OBSERVATION_MODIFIER", 227, 233], ["anion channels", "OBSERVATION", 234, 248], ["viral", "OBSERVATION_MODIFIER", 388, 393], ["infection", "OBSERVATION", 394, 403], ["infected tissues", "OBSERVATION", 473, 489]]], ["Ion channels have been linked to multiple stages of viral lifecycles, in which viruses are either passively dependent upon or actively modulate channel functionality.", [["viral lifecycles", "PROBLEM", 52, 68], ["viral lifecycles", "OBSERVATION", 52, 68], ["viruses", "OBSERVATION", 79, 86]]], ["Given this knowledge, evidence is emerging that ion channel inhibitors represent a new antiviral strategy.", [["ion channel inhibitors", "TREATMENT", 48, 70], ["a new antiviral strategy", "TREATMENT", 81, 105], ["new", "OBSERVATION_MODIFIER", 83, 86], ["antiviral strategy", "OBSERVATION", 87, 105]]], ["Whilst toxicity profiles for ion channel inhibitors are only available in the context of those used to treat hereditary channelopathies, in vivo evidence is emerging that these drugs can be efficacious against viruses.", [["toxicity", "DISEASE", 7, 15], ["hereditary channelopathies", "DISEASE", 109, 135], ["Whilst toxicity profiles", "PROBLEM", 0, 24], ["ion channel inhibitors", "TREATMENT", 29, 51], ["hereditary channelopathies", "PROBLEM", 109, 135], ["these drugs", "TREATMENT", 171, 182], ["viruses", "PROBLEM", 210, 217]]], ["Moreover, overlapping mechanisms of acquired and hereditary channelopathies may underpin the efficacy of ion channel modulators in treating virally-induced pathophysiologies.", [["hereditary channelopathies", "DISEASE", 49, 75], ["hereditary channelopathies", "PROBLEM", 49, 75], ["ion channel modulators", "TREATMENT", 105, 127], ["virally-induced pathophysiologies", "PROBLEM", 140, 173]]], ["The manipulation of host ion homeostasis presents an attractive target for the treatment of many clinically important viruses and their associated pathologies, whilst circumventing the risks of resistance associated with direct-acting antiviral drugs.", [["host ion homeostasis", "TREATMENT", 20, 40], ["the treatment", "TREATMENT", 75, 88], ["many clinically important viruses", "PROBLEM", 92, 125], ["their associated pathologies", "PROBLEM", 130, 158], ["resistance", "PROBLEM", 194, 204], ["direct-acting antiviral drugs", "TREATMENT", 221, 250]]], ["As such, continued studies of host-virus interactions may guide future antiviral approaches.Conclusions and Further PerspectivesFunding: J.M. and J.F. are supported by the Academic Fellow scheme at the University of Leeds.Conflicts of Interest:The authors declare no conflict of interest.", [["host-virus", "ORGANISM", 30, 40], ["continued studies", "TEST", 9, 26], ["host-virus interactions", "TREATMENT", 30, 53], ["antiviral approaches", "TREATMENT", 71, 91]]]], "640d9b2f25137702138492204082fca73df51df2": [["The recent appearance of clusters of a new coronaviral infection in Wuhan, China has made headlines, as more and more people have become infected in China and in a number of other countries.", [["coronaviral infection", "DISEASE", 43, 64], ["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["a new coronaviral infection", "PROBLEM", 37, 64], ["clusters", "OBSERVATION_MODIFIER", 25, 33], ["new", "OBSERVATION_MODIFIER", 39, 42], ["coronaviral", "OBSERVATION_MODIFIER", 43, 54], ["infection", "OBSERVATION", 55, 64], ["infected", "OBSERVATION", 137, 145]]], ["Already more than 100 deaths have been ascribed to this virus, and there are fears of additional outbreaks.", [["deaths", "DISEASE", 22, 28], ["this virus", "PROBLEM", 51, 61]]], ["The virus has been isolated from the lower respiratory tracts of patients with pneumonia, sequenced and visualized by electron microscopy (Zhu et al 2020) .", [["lower respiratory tracts", "ANATOMY", 37, 61], ["pneumonia", "DISEASE", 79, 88], ["lower respiratory", "ORGANISM_SUBDIVISION", 37, 54], ["tracts", "ORGANISM_SUBDIVISION", 55, 61], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["The virus", "PROBLEM", 0, 9], ["pneumonia", "PROBLEM", 79, 88], ["electron microscopy", "TEST", 118, 137], ["virus", "OBSERVATION", 4, 9], ["lower", "ANATOMY_MODIFIER", 37, 42], ["respiratory tracts", "ANATOMY", 43, 61], ["pneumonia", "OBSERVATION", 79, 88]]], ["The virus, which has received the placeholder name 2019-nCoV, turns out to be a new member of the subgenus sarbecovirus, in the Orthocoronavirinae subfamily, but is distinct from MERS CoV and SARS CoV (Zhu et al 2020) .", [["SARS", "DISEASE", 192, 196], ["sarbecovirus", "GENE_OR_GENE_PRODUCT", 107, 119], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 128, 146], ["MERS CoV", "ORGANISM", 179, 187], ["SARS CoV", "ORGANISM", 192, 200], ["Orthocoronavirinae subfamily", "PROTEIN", 128, 156], ["MERS CoV", "SPECIES", 179, 187], ["SARS CoV", "SPECIES", 192, 200], ["The virus", "PROBLEM", 0, 9], ["nCoV", "TREATMENT", 56, 60], ["the subgenus sarbecovirus", "PROBLEM", 94, 119], ["virus", "OBSERVATION", 4, 9]]], ["The coronaviruses are positive-sense, single strand RNA viruses, and thus share properties with other single-stranded RNA viruses such as hepatitis C virus, West Nile virus, Marburg virus, HIV virus, Ebola virus, dengue virus, and rhinoviruses.", [["hepatitis C", "DISEASE", 138, 149], ["HIV virus", "DISEASE", 189, 198], ["Ebola virus", "DISEASE", 200, 211], ["dengue", "DISEASE", 213, 219], ["rhinoviruses", "DISEASE", 231, 243], ["coronaviruses", "ORGANISM", 4, 17], ["hepatitis C virus", "ORGANISM", 138, 155], ["West Nile virus", "ORGANISM", 157, 172], ["Marburg virus", "ORGANISM", 174, 187], ["HIV virus", "ORGANISM", 189, 198], ["Ebola virus", "ORGANISM", 200, 211], ["dengue virus", "ORGANISM", 213, 225], ["rhinoviruses", "ORGANISM", 231, 243], ["hepatitis C virus", "SPECIES", 138, 155], ["West Nile virus", "SPECIES", 157, 172], ["Marburg virus", "SPECIES", 174, 187], ["HIV virus", "SPECIES", 189, 198], ["Ebola virus", "SPECIES", 200, 211], ["dengue virus", "SPECIES", 213, 225], ["hepatitis C virus", "SPECIES", 138, 155], ["West Nile virus", "SPECIES", 157, 172], ["Marburg virus", "SPECIES", 174, 187], ["HIV virus", "SPECIES", 189, 198], ["Ebola virus", "SPECIES", 200, 211], ["dengue virus", "SPECIES", 213, 225], ["single strand RNA viruses", "PROBLEM", 38, 63], ["other single-stranded RNA viruses", "PROBLEM", 96, 129], ["hepatitis C virus", "PROBLEM", 138, 155], ["West Nile virus", "PROBLEM", 157, 172], ["Marburg virus", "PROBLEM", 174, 187], ["HIV virus", "PROBLEM", 189, 198], ["Ebola virus", "PROBLEM", 200, 211], ["dengue virus", "PROBLEM", 213, 225], ["rhinoviruses", "PROBLEM", 231, 243], ["coronaviruses", "OBSERVATION", 4, 17], ["positive", "OBSERVATION", 22, 30], ["RNA viruses", "OBSERVATION", 52, 63], ["stranded RNA viruses", "OBSERVATION", 109, 129]]]], "PMC7340084": [["IntroductionThe onset of the COVID-19 pandemic has resulted in many variants of international response across social, epidemiological and economic frontiers.", [["the COVID", "TEST", 25, 34]]], ["The same variation was similarly observed in the response of both financial markets and investors when attempting to evaluate the scale of the issue to which they were confronted.", [["variation", "OBSERVATION_MODIFIER", 9, 18]]], ["Chinese financial markets acted as the initial epicentre of the shock (Corbet et al., 2020b), however, international contagion effects quickly escalated.", [["shock", "DISEASE", 64, 69]]], ["In the midst of this confusion, traditional flight-to-safety channels within energy markets dissipated with the escalation of geopolitical tensions largely instigated by the US, Russia and Saudi Arabia, with investors struggling to identify credible safe-havens (Goodell, 2020, Corbet et al., 2020a).", [["confusion", "DISEASE", 21, 30], ["this confusion", "PROBLEM", 16, 30], ["geopolitical tensions", "PROBLEM", 126, 147]]], ["Within this environment, we test the hypotheses as to whether cryptocurrencies acted in this capacity.Introduction", [["cryptocurrencies", "PROBLEM", 62, 78]]]], "0092ef431ef0ae30c62c793f6ca49858f1f6ce3b": [["2Dear Editor, Primary care providers (PCP) play an essential role in preventing transmission of COVID-19 by determining when patients should discontinue home isolation and return to work.", [["PCP", "DISEASE", 38, 41], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["COVID", "TREATMENT", 96, 101], ["home isolation", "TREATMENT", 153, 167]]], ["Current CDC guidelines addressing such decisions include (1) non-test-based strategy, which advises that patients may discontinue home isolation after at least 72 hours have passed since recovery (defined as resolution of fever without use of fever-reducing medications) and improvement in respiratory symptoms and at least 7 days have passed since symptom onset or (2) test-based strategy, which advises resolution of fever and improvement in respiratory symptoms and negative results of an FDA Emergency Use Authorized molecular assay for COVID-19 from at least 2 consecutive nasopharyngeal swab specimens collected \u226524 hours apart.", [["respiratory", "ANATOMY", 290, 301], ["respiratory", "ANATOMY", 444, 455], ["nasopharyngeal swab specimens", "ANATOMY", 578, 607], ["fever", "DISEASE", 222, 227], ["fever", "DISEASE", 243, 248], ["fever", "DISEASE", 419, 424], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["home isolation", "TREATMENT", 130, 144], ["fever", "PROBLEM", 222, 227], ["fever", "PROBLEM", 243, 248], ["reducing medications", "TREATMENT", 249, 269], ["respiratory symptoms", "PROBLEM", 290, 310], ["symptom onset", "PROBLEM", 349, 362], ["test", "TEST", 370, 374], ["fever", "PROBLEM", 419, 424], ["respiratory symptoms", "PROBLEM", 444, 464], ["COVID", "TEST", 541, 546], ["nasopharyngeal swab specimens", "TEST", 578, 607], ["respiratory", "ANATOMY", 290, 301], ["fever", "OBSERVATION", 419, 424], ["respiratory", "ANATOMY", 444, 455], ["nasopharyngeal", "ANATOMY", 578, 592]]], ["1 In some instances, more stringent criteria are warranted to reduce the risk of transmission in settings where a patient may be returning to work at a transportation hub or healthcare setting.", [["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121]]], ["Repeat testing in the convalescent period is typically advised in patients entering a congregate setting after hospitalization.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Repeat testing", "TEST", 0, 14]]], ["For example, we recently encountered a case of SARS-CoV-2 prolonged viral shedding in an ambulatory patient.", [["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "ORGANISM", 47, 57], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["CoV", "PROBLEM", 52, 55], ["2 prolonged viral shedding", "PROBLEM", 56, 82]]], ["This 34 year old man without chronic medical problems or prescribed medications presented to his PCP with a dry cough, fever, anosmia, ageusia and diarrhea of 4 days duration and tested positive by molecular assay for COVID-19 from nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 232, 251], ["PCP", "DISEASE", 97, 100], ["dry cough", "DISEASE", 108, 117], ["fever", "DISEASE", 119, 124], ["anosmia", "DISEASE", 126, 133], ["ageusia", "DISEASE", 135, 142], ["diarrhea", "DISEASE", 147, 155], ["man", "ORGANISM", 17, 20], ["COVID-19", "GENE_OR_GENE_PRODUCT", 218, 226], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 232, 251], ["man", "SPECIES", 17, 20], ["chronic medical problems", "PROBLEM", 29, 53], ["prescribed medications", "TREATMENT", 57, 79], ["a dry cough", "PROBLEM", 106, 117], ["fever", "PROBLEM", 119, 124], ["anosmia", "PROBLEM", 126, 133], ["ageusia", "PROBLEM", 135, 142], ["diarrhea", "PROBLEM", 147, 155], ["COVID", "TEST", 218, 223], ["nasopharyngeal swab", "TEST", 232, 251], ["without", "UNCERTAINTY", 21, 28], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["cough", "OBSERVATION", 112, 117], ["fever", "OBSERVATION", 119, 124], ["diarrhea", "OBSERVATION", 147, 155], ["nasopharyngeal", "ANATOMY", 232, 246], ["swab", "OBSERVATION", 247, 251]]], ["After 3 weeks, the patient reported resolution of all symptoms except cough, which was diagnosed as post-viral cough.", [["cough", "DISEASE", 70, 75], ["cough", "DISEASE", 111, 116], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["all symptoms", "PROBLEM", 50, 62], ["cough", "PROBLEM", 70, 75], ["post-viral cough", "PROBLEM", 100, 116], ["cough", "OBSERVATION", 70, 75], ["cough", "OBSERVATION", 111, 116]]], ["Because the patient worked at the airport, he sought medical advice before returning to work.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["Due to ongoing cough, repeat molecular assay for COVID-19 from nasopharyngeal swab was performed and was found to be positive.2This case poses many challenges to the PCP.", [["nasopharyngeal swab", "ANATOMY", 63, 82], ["cough", "DISEASE", 15, 20], ["COVID-19", "CHEMICAL", 49, 57], ["PCP", "DISEASE", 166, 169], ["PCP", "CHEMICAL", 166, 169], ["COVID-19", "GENE_OR_GENE_PRODUCT", 49, 57], ["nasopharyngeal swab", "CANCER", 63, 82], ["COVID-19", "DNA", 49, 57], ["ongoing cough", "PROBLEM", 7, 20], ["repeat molecular assay", "TEST", 22, 44], ["COVID", "TEST", 49, 54], ["nasopharyngeal swab", "TEST", 63, 82], ["cough", "OBSERVATION", 15, 20], ["positive", "OBSERVATION", 117, 125]]], ["What does a positive COVID-19 test tell us at this stage?2Can the patient return to work or remain on home isolation?", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["home isolation", "TREATMENT", 102, 116]]], ["When should the test be repeated?2Although a positive molecular test result may not correlate with viral load or infectivity, it seems reasonable to assume that patients with prolonged cough may aerosolize virus and transmit infection even if viral loads in the upper airways are low.", [["upper airways", "ANATOMY", 262, 275], ["cough", "DISEASE", 185, 190], ["infection", "DISEASE", 225, 234], ["patients", "ORGANISM", 161, 169], ["upper airways", "MULTI-TISSUE_STRUCTURE", 262, 275], ["patients", "SPECIES", 161, 169], ["the test", "TEST", 12, 20], ["a positive molecular test result", "PROBLEM", 43, 75], ["viral load", "PROBLEM", 99, 109], ["infectivity", "PROBLEM", 113, 124], ["prolonged cough", "PROBLEM", 175, 190], ["aerosolize virus", "PROBLEM", 195, 211], ["transmit infection", "PROBLEM", 216, 234], ["viral loads in the upper airways", "PROBLEM", 243, 275], ["upper", "ANATOMY_MODIFIER", 262, 267], ["airways", "ANATOMY", 268, 275], ["low", "OBSERVATION", 280, 283]]], ["This is supported by emerging data demonstrating that viral clearance can be delayed in samples collected from lower airway, stool, and nasopharyngeal swabs.", [["samples", "ANATOMY", 88, 95], ["lower airway", "ANATOMY", 111, 123], ["stool", "ANATOMY", 125, 130], ["nasopharyngeal swabs", "ANATOMY", 136, 156], ["lower airway", "MULTI-TISSUE_STRUCTURE", 111, 123], ["stool", "ORGANISM_SUBSTANCE", 125, 130], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 136, 156], ["viral clearance", "PROBLEM", 54, 69], ["stool, and nasopharyngeal swabs", "TEST", 125, 156], ["lower", "ANATOMY_MODIFIER", 111, 116], ["airway", "ANATOMY", 117, 123], ["stool", "OBSERVATION", 125, 130], ["nasopharyngeal", "ANATOMY", 136, 150]]], ["3 Indeed, certain populations, such as those immunocompromised, pregnant and advanced age individuals, are known to be at risk for prolonged viral shedding.", [["prolonged viral shedding", "PROBLEM", 131, 155], ["viral", "OBSERVATION", 141, 146]]], ["4 Reports have shown that some patients shed virus for weeks or even months.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["5 Further, PCPs must evaluate the risk of transmission when considering retesting in patients with ongoing symptoms since current guidelines do not indicate this is necessary.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["ongoing symptoms", "PROBLEM", 99, 115]]], ["And, guidance will be needed on whether retesting should be performed in asymptomatic individuals at high risk for prolonged viral shedding.", [["prolonged viral shedding", "PROBLEM", 115, 139]]], ["To date, testing guidance has prioritized hospitalized patients and health care workers in order to allocate and conserve limited test kits and personal protective equipment.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["limited test kits", "TEST", 122, 139], ["personal protective equipment", "TREATMENT", 144, 173]]], ["As more resources become available, we anticipate liberalization of testing to include retesting in (a) those with symptoms suggestive of prolonged viral shedding and (b) those asymptomatic yet at increased risk for prolonged viral shedding.", [["testing", "TEST", 68, 75], ["symptoms", "PROBLEM", 115, 123], ["prolonged viral shedding and (b) those asymptomatic", "PROBLEM", 138, 189], ["prolonged viral shedding", "PROBLEM", 216, 240]]], ["We note that there are individual differences in rate of recovery, viral clearance, as well as the risk of forward transmission.", [["viral clearance", "TEST", 67, 82], ["individual", "OBSERVATION_MODIFIER", 23, 33], ["differences", "OBSERVATION_MODIFIER", 34, 45]]], ["Given the absence of guidelines, for our patient who worked in the public transit industry, we recommended continued home isolation and repeat molecular testing in one week, with negative results permitting a return to work.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["home isolation", "TREATMENT", 117, 131], ["repeat molecular testing", "TEST", 136, 160]]]], "f22d654d94c461ffd15f46bf1d827f6cd0362bdf": [["IntroductionCoronavirus disease 2019 has had unplanned consequences for non-COVID-19 health services.", [["Coronavirus disease", "DISEASE", 12, 31], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["Coronavirus disease", "OBSERVATION", 12, 31]]], ["We described reductions in urgent cancer referrals and chemotherapy compared to pre-COVID-19 levels 1 .", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["cancer", "CANCER", 34, 40], ["urgent cancer referrals", "TREATMENT", 27, 50], ["chemotherapy", "TREATMENT", 55, 67], ["pre-COVID", "TEST", 80, 89], ["reductions", "OBSERVATION_MODIFIER", 13, 23], ["urgent", "OBSERVATION_MODIFIER", 27, 33], ["cancer", "OBSERVATION", 34, 40]]], ["Decreases in presentation and treatment of myocardial infarction(MI) [2] [3] [4] in Italy and the USA suggest effects on care, but services have not been studied across specific CVDs, countries or different phases of the pandemic.IntroductionEarly reports from Wuhan, China, demonstrated high prevalence of and mortality from COVID-19 in individuals with CVD; confirmed across countries, particularly with coronary heart disease(CHD) and heart failure(HF) 5-8 .", [["myocardial", "ANATOMY", 43, 53], ["coronary", "ANATOMY", 406, 414], ["heart", "ANATOMY", 415, 420], ["heart", "ANATOMY", 438, 443], ["myocardial infarction", "DISEASE", 43, 64], ["MI", "DISEASE", 65, 67], ["CVDs", "DISEASE", 178, 182], ["CVD", "DISEASE", 355, 358], ["coronary heart disease", "DISEASE", 406, 428], ["CHD", "DISEASE", 429, 432], ["heart failure", "DISEASE", 438, 451], ["HF", "DISEASE", 452, 454], ["myocardial", "MULTI-TISSUE_STRUCTURE", 43, 53], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 406, 420], ["heart", "ORGAN", 438, 443], ["myocardial infarction", "PROBLEM", 43, 64], ["MI", "PROBLEM", 65, 67], ["the pandemic", "PROBLEM", 217, 229], ["COVID", "TEST", 326, 331], ["CVD", "PROBLEM", 355, 358], ["coronary heart disease(CHD)", "PROBLEM", 406, 433], ["heart failure(HF", "PROBLEM", 438, 454], ["myocardial", "ANATOMY", 43, 53], ["infarction", "OBSERVATION", 54, 64], ["coronary heart", "ANATOMY", 406, 420], ["disease", "OBSERVATION", 421, 428], ["heart", "ANATOMY", 438, 443], ["failure", "OBSERVATION", 444, 451]]], ["UK government policy for \"physical distancing\" in high-risk subgroups for COVID-19, announced on 16 March 2020, included CVD, especially HF 9 .", [["CVD", "DISEASE", 121, 124], ["COVID", "TEST", 74, 79], ["CVD", "PROBLEM", 121, 124], ["HF", "PROBLEM", 137, 139]]], ["On 22 March 2020, a further 1.5 million people in England(with 'extremely vulnerable' conditions) were recommended at least 12 weeks of 'shielding' 10 , excluding those with CVD, prior to UK lockdown on 23 March 11 .", [["CVD", "DISEASE", 174, 177], ["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46], ["'shielding'", "TREATMENT", 136, 147]]], ["Better understanding of pre-and post-COVID-19 mortality risk across specific CVDs may help decisions and policies regarding physical isolation.IntroductionTherefore, effects of COVID-19 on individuals and health systems are: (i)direct due to infection, and (ii)indirect due to unprecedented system strain and associated behaviour changes 12 .", [["CVDs", "DISEASE", 77, 81], ["COVID-19", "CHEMICAL", 177, 185], ["infection", "DISEASE", 242, 251], ["COVID-19", "CHEMICAL", 177, 185], ["physical isolation", "TREATMENT", 124, 142], ["COVID", "TEST", 177, 182], ["infection", "PROBLEM", 242, 251], ["unprecedented system strain", "PROBLEM", 277, 304], ["associated behaviour changes", "PROBLEM", 309, 337], ["infection", "OBSERVATION", 242, 251]]], ["Those with CVD, carrying the greatest burden of global morbidity and mortality 13 , are likely to be particularly affected.", [["CVD", "DISEASE", 11, 14], ["CVD", "PROBLEM", 11, 14], ["global morbidity", "PROBLEM", 48, 64], ["greatest", "OBSERVATION_MODIFIER", 29, 37], ["burden", "OBSERVATION_MODIFIER", 38, 44], ["global", "OBSERVATION_MODIFIER", 48, 54], ["morbidity", "OBSERVATION", 55, 64], ["likely to be", "UNCERTAINTY", 88, 100]]], ["Beyond direct effects, systematic examination of recent and longer-term trends for CVD services may help in planning the timing and nature of exit from lockdown and strategies for any subsequent infection peaks.", [["CVD", "DISEASE", 83, 86], ["infection", "DISEASE", 195, 204], ["systematic examination", "TEST", 23, 45], ["CVD services", "TREATMENT", 83, 95], ["lockdown", "TREATMENT", 152, 160], ["strategies", "TREATMENT", 165, 175], ["any subsequent infection peaks", "PROBLEM", 180, 210], ["infection", "OBSERVATION", 195, 204]]], ["Moreover, reductions in rates of referral, diagnosis, and treatment, may have fatal long-term consequences, caused by \"supply\"(e.g. lower healthcare availability) and/or \"demand\"(e.g. delayed presentation), but have not been investigated.", [["treatment", "TREATMENT", 58, 67], ["fatal long-term consequences", "PROBLEM", 78, 106], ["reductions", "OBSERVATION_MODIFIER", 10, 20]]], ["Electronic health records(EHR) have been used in studies across different specific CVDs 14 , and enable novel insights regarding direct and indirect COVID-19-related excess deaths, across incident and prevalent CVD, and the spectrum of care.IntroductionObjective: We used: (i)national mortality data for England and Wales to investigate trends in non-COVID-19 and CVD excess deaths; (ii)routine data from hospitals in England, Italy and China to assess indirect effects on services for referral, diagnosis and treatment of CVD during the pandemic; and (iii)population-based EHR in England to investigate pre-COVID-19 mortality by underlying risk factors and excess mortality during the COVID-19 pandemic.", [["CVDs", "DISEASE", 83, 87], ["deaths", "DISEASE", 173, 179], ["CVD", "DISEASE", 211, 214], ["CVD", "DISEASE", 364, 367], ["deaths", "DISEASE", 375, 381], ["CVD", "DISEASE", 523, 526], ["indirect COVID", "TEST", 140, 154], ["excess deaths", "PROBLEM", 166, 179], ["CVD excess deaths", "PROBLEM", 364, 381], ["treatment", "TREATMENT", 510, 519], ["CVD", "PROBLEM", 523, 526], ["pre-COVID", "TEST", 604, 613], ["underlying risk factors", "PROBLEM", 630, 653], ["excess mortality", "PROBLEM", 658, 674], ["the COVID", "TEST", 682, 691], ["pandemic", "PROBLEM", 695, 703]]], ["No reuse allowed without permission.Introduction(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IntroductionThe copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprintData sources and study populationTo estimate pre-COVID-19 incidence and mortality in individuals with CVD and comorbidities, we used EHR across primary care(Clinical Practice Research Datalink, CPRD-GOLD), hospital care(Hospital Episodes Statistics, HES), and death registry(Office of National Statistics, ONS) with prospective recording and follow-up; linked by CPRD and NHS Digital using unique healthcare identifiers 15 .", [["CVD", "DISEASE", 438, 441], ["death", "DISEASE", 596, 601], ["The copyright holder", "TREATMENT", 195, 215], ["study populationTo", "TEST", 353, 371], ["pre-COVID", "TEST", 381, 390], ["CVD", "PROBLEM", 438, 441], ["comorbidities", "PROBLEM", 446, 459], ["prospective recording", "TEST", 652, 673], ["med", "ANATOMY", 127, 130]]], ["CPRD is representative by socio-demography, ethnicity and overall mortality 16 Weekly/monthly information on CVD care and mortalityData sources and study populationWe obtained: (i)weekly cause-specific mortality data for England and Wales from ONS 19 and cardiac-related attendance data from the Emergency Department(ED) SyndromicData sources and study populationSurveillance System for England 20 ; (ii)monthly referral, diagnosis and treatment data for All rights reserved.", [["cardiac", "ANATOMY", 255, 262], ["CVD", "DISEASE", 109, 112], ["CVD care", "TREATMENT", 109, 117], ["treatment data", "TEST", 436, 450], ["All rights", "TREATMENT", 455, 465]]], ["No reuse allowed without permission.Data sources and study population(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Methods.Estimating incidence rates and 1-year mortality We estimated incidence rates per 100,000 person-years and pre-COVID- 19 1-year mortality risk for incident and prevalent CVD using Kaplan-Meier analyses stratified by specific CVD and number of (non-CVD) comorbidities(0, 1, 2 and 3+), scaling up from CALIBER Given service changes in CVD observed across countries 2-4 , to capture direct and indirect excess deaths, we modelled in addition to the 10% infected, 40% and 80% affected rates, where 30% and 70% of the population respectively would be un-infected but affected at corresponding RRs.", [["CVD", "DISEASE", 381, 384], ["CVD", "DISEASE", 436, 439], ["CVD", "DISEASE", 459, 462], ["CVD", "DISEASE", 544, 547], ["deaths", "DISEASE", 618, 624], ["person", "SPECIES", 301, 307], ["study population", "TEST", 53, 69], ["Estimating incidence rates", "PROBLEM", 212, 238], ["Meier analyses", "TEST", 398, 412], ["non-CVD) comorbidities", "PROBLEM", 455, 477], ["CVD", "PROBLEM", 544, 547], ["indirect excess deaths", "PROBLEM", 602, 624], ["med", "ANATOMY", 148, 151], ["CALIBER", "OBSERVATION_MODIFIER", 511, 518], ["infected", "OBSERVATION", 760, 768]]], ["Based on RRs from ONS data(peak RR 1.14 for excess CVD deaths and 1.29 for excess non-COVID-19 deaths; Figure 2 ) and likely longer-term effects on CVD mortality, we estimated direct and indirect excess deaths together by applying RR 1. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Methods.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprintMonthly hospital data across countriesIn China (both Wuhan and other hospitals) and Italy, activity(referral, diagnosis and treatment) was significantly reduced compared with pre-COVID levels.", [["CVD", "DISEASE", 51, 54], ["deaths", "DISEASE", 55, 61], ["deaths", "DISEASE", 95, 101], ["CVD", "DISEASE", 148, 151], ["deaths", "DISEASE", 203, 209], ["RRs", "TEST", 9, 12], ["ONS data", "TEST", 18, 26], ["peak RR", "TEST", 27, 34], ["excess CVD deaths", "PROBLEM", 44, 61], ["excess non-COVID-19 deaths", "PROBLEM", 75, 101], ["CVD mortality", "PROBLEM", 148, 161], ["RR", "TEST", 231, 233], ["The copyright holder", "TREATMENT", 380, 400], ["treatment", "TREATMENT", 645, 654], ["pre-COVID levels", "TEST", 696, 712], ["likely", "UNCERTAINTY", 118, 124], ["longer", "OBSERVATION_MODIFIER", 125, 131], ["med", "ANATOMY", 316, 319]]], ["In Wuhan, there was 83.4% reduction in referral, 92% in diagnosis and 99% in treatment levels of MI by the 1 February, a month after the outbreak started.", [["MI", "DISEASE", 97, 99], ["MI", "PROBLEM", 97, 99]]], ["Corresponding decreases were 92%, 97% and 87% for stroke, 83%, 93% and 98% for HF, and 83%, 95% and 94% for AF.", [["stroke", "DISEASE", 50, 56], ["HF", "DISEASE", 79, 81], ["AF", "DISEASE", 108, 110], ["stroke", "TEST", 50, 56], ["HF", "PROBLEM", 79, 81], ["AF", "PROBLEM", 108, 110], ["decreases", "OBSERVATION_MODIFIER", 14, 23]]], ["Tianmen and Xiantao demonstrated equivalent decreases across all four disease services.", [["Xiantao", "TREATMENT", 12, 19], ["equivalent", "OBSERVATION_MODIFIER", 33, 43], ["decreases", "OBSERVATION_MODIFIER", 44, 53]]], ["Although decreases were relatively less in Zaoyang and Xiangtang, there were 40-80% reductions across services, except for diagnosis of MI which increased in Zaoyang between January and March.Monthly hospital data across countriesEven after easing and stopping of lockdown, Wuhan reported 50-100% decreases in services for MI, stroke, HF and AF.", [["MI", "DISEASE", 136, 138], ["MI", "DISEASE", 323, 325], ["stroke", "DISEASE", 327, 333], ["HF", "DISEASE", 335, 337], ["AF", "DISEASE", 342, 344], ["MI", "PROBLEM", 136, 138], ["MI", "PROBLEM", 323, 325], ["stroke", "PROBLEM", 327, 333], ["HF", "PROBLEM", 335, 337], ["AF", "PROBLEM", 342, 344], ["decreases", "OBSERVATION_MODIFIER", 9, 18], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["less", "OBSERVATION_MODIFIER", 35, 39], ["MI", "OBSERVATION", 136, 138], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["stroke", "OBSERVATION", 327, 333], ["AF", "OBSERVATION", 342, 344]]], ["Recovery of activity began to occur during the lockdown period and differed across Chinese hospitals, suggesting possible differences in infection rates, patient presentation and behaviour, clinician behaviour and COVID-19-related system strain.", [["infection", "DISEASE", 137, 146], ["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["differences in infection rates", "PROBLEM", 122, 152], ["COVID", "TEST", 214, 219], ["related system strain", "PROBLEM", 223, 244], ["activity", "OBSERVATION_MODIFIER", 12, 20], ["suggesting possible", "UNCERTAINTY", 102, 121], ["infection", "OBSERVATION", 137, 146]]], ["In Italy, decreases ranged from 45% for stroke treatment to 94% for HF treatment and 100% for AF diagnosis.", [["stroke", "DISEASE", 40, 46], ["HF", "DISEASE", 68, 70], ["AF", "DISEASE", 94, 96], ["stroke treatment", "TREATMENT", 40, 56], ["HF treatment", "TREATMENT", 68, 80], ["decreases", "OBSERVATION_MODIFIER", 10, 19]]], ["In England, there was reduced activity across CVDs during the pandemic.", [["CVDs", "DISEASE", 46, 50], ["reduced activity across CVDs", "PROBLEM", 22, 50], ["the pandemic", "PROBLEM", 58, 70], ["reduced", "OBSERVATION_MODIFIER", 22, 29], ["activity", "OBSERVATION_MODIFIER", 30, 38]]], ["Across countries, referral rates for all diseases and treatment of MI were particularly affected and declines in activity occurred before the peak of cases or deaths (Figure 1 ).Weekly national mortality data and emergency attendance dataNon-COVID-19 and CVD-related deaths in England and Wales increased in the same chronology as total(including COVID-19) deaths until mid-May 2020(compared with the same week over the last 5 years).", [["MI", "DISEASE", 67, 69], ["deaths", "DISEASE", 159, 165], ["CVD", "DISEASE", 255, 258], ["deaths", "DISEASE", 267, 273], ["deaths", "DISEASE", 357, 363], ["all diseases", "PROBLEM", 37, 49], ["treatment", "TREATMENT", 54, 63], ["MI", "PROBLEM", 67, 69], ["CVD", "PROBLEM", 255, 258]]], ["The peak observed RR for CVD deaths was in the week ending 24 April(1850 vs 1626 deaths, RR 1.14) and the lowest in the week ending 8 May 2020(1318 vs 1487 deaths, RR 0.89).", [["CVD", "DISEASE", 25, 28], ["deaths", "DISEASE", 29, 35], ["deaths", "DISEASE", 81, 87], ["deaths", "DISEASE", 156, 162], ["CVD deaths", "PROBLEM", 25, 35], ["RR", "TEST", 89, 91], ["RR", "TEST", 164, 166]]], ["The same trend was present regardless of whether the RR was calculated compared to the average of previous years, or pre-COVID-19(3 January 2020).", [["the RR", "TEST", 49, 55]]], ["Between 6 and 27 March, cardiac ED attendances decreased in England(minimum RR 0.57) and were had not fully recovered on 15 May, which was after easing of lockdown (Figure 2 ).Weekly national mortality data and emergency attendance dataIncidence, prevalence and pre-COVID-19 mortality for CVD All rights reserved.", [["cardiac", "ANATOMY", 24, 31], ["CVD", "DISEASE", 289, 292], ["RR", "TEST", 76, 78], ["pre-COVID", "TEST", 262, 271], ["CVD", "PROBLEM", 289, 292], ["cardiac", "ANATOMY", 24, 31]]], ["No reuse allowed without permission.Weekly national mortality data and emergency attendance data(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Weekly national mortality data and emergency attendance dataThe copyright holder for this preprint this version posted June 11, 2020. and stroke(63,276).", [["stroke", "DISEASE", 369, 375], ["emergency attendance data", "TEST", 266, 291], ["The copyright holder", "TREATMENT", 291, 311], ["stroke", "PROBLEM", 369, 375], ["med", "ANATOMY", 175, 178], ["stroke", "OBSERVATION", 369, 375]]], ["Mortality rates were relatively lower for prevalent CVDs (Figure S2) .Comorbidities in individuals with CVDAcross incident and prevalent CVDs, prevalence of 0, 1, 2 and 3+ co-morbidities was 26 Figure S3 ).", [["CVDs", "DISEASE", 52, 56], ["CVDAcross", "DISEASE", 104, 113], ["CVDs", "DISEASE", 137, 141], ["Mortality rates", "TEST", 0, 15], ["Comorbidities in individuals", "PROBLEM", 70, 98], ["prevalent CVDs", "PROBLEM", 127, 141]]], ["Comorbidity profiles were similar in those with prevalent CVD (Figure S4) .", [["CVD", "DISEASE", 58, 61], ["Comorbidity profiles", "TEST", 0, 20]]], ["Multimorbidity was associated with increased 1-year mortality, e.g. in incident AF, 1-year mortality was 31% vs 9% in men and 34% vs 16% in women for \u2265 3 vs 0 conditions.", [["Multimorbidity", "DISEASE", 0, 14], ["AF", "DISEASE", 80, 82], ["men", "ORGANISM", 118, 121], ["women", "ORGANISM", 140, 145], ["men", "SPECIES", 118, 121], ["women", "SPECIES", 140, 145], ["AF", "PROBLEM", 80, 82]]], ["One-year mortality risks were >50% in those with incident cardiac arrest or intracerebral haemorrhage and and at 80% COVID-19 rate, we estimated 8026 vs 3417 excess deaths in multimorbidity All rights reserved.", [["cardiac", "ANATOMY", 58, 65], ["intracerebral", "ANATOMY", 76, 89], ["cardiac arrest", "DISEASE", 58, 72], ["intracerebral haemorrhage", "DISEASE", 76, 101], ["deaths", "DISEASE", 165, 171], ["cardiac", "ORGAN", 58, 65], ["One-year mortality risks", "PROBLEM", 0, 24], ["incident cardiac arrest", "PROBLEM", 49, 72], ["intracerebral haemorrhage", "PROBLEM", 76, 101], ["COVID", "TEST", 117, 122], ["excess deaths", "PROBLEM", 158, 171], ["cardiac", "ANATOMY", 58, 65], ["arrest", "OBSERVATION", 66, 72], ["intracerebral", "ANATOMY", 76, 89], ["haemorrhage", "OBSERVATION", 90, 101]]], ["No reuse allowed without permission.Comorbidities in individuals with CVD(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Comorbidities in individuals with CVDThe copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint compared with no comorbidities at corresponding RRs( Figure 4B ).", [["CVD", "DISEASE", 70, 73], ["CVD", "PROBLEM", 70, 73], ["Comorbidities", "PROBLEM", 208, 221], ["CVDThe copyright holder", "TREATMENT", 242, 265], ["medRxiv", "TREATMENT", 370, 377], ["comorbidities", "PROBLEM", 404, 417], ["RRs", "TEST", 435, 438], ["med", "ANATOMY", 152, 155]]], ["Among those with prevalent CVDs, we estimated higher excess deaths at 1 year than for incident CVDs with similar associations with number of comorbidities( Figure 5B ).", [["CVDs", "DISEASE", 27, 31], ["deaths", "DISEASE", 60, 66], ["CVDs", "DISEASE", 95, 99], ["CVDs", "PROBLEM", 95, 99]]], ["There is debate about which conditions should be on \"high-risk\" and \"extremely vulnerable\" lists of conditions for physical isolation policies, which should include some CVDs and combinations of comorbidities, based on our risk estimates and COVID-death data todate 6,12 .", [["CVDs", "DISEASE", 170, 174], ["death", "DISEASE", 248, 253], ["physical isolation policies", "TREATMENT", 115, 142], ["some CVDs", "PROBLEM", 165, 174], ["comorbidities", "PROBLEM", 195, 208]]], ["CVD is known to have high prevalence, incidence and mortality, varying by arterial territory.", [["arterial", "ANATOMY", 74, 82], ["CVD", "DISEASE", 0, 3], ["arterial territory", "MULTI-TISSUE_STRUCTURE", 74, 92], ["CVD", "PROBLEM", 0, 3], ["high", "OBSERVATION_MODIFIER", 21, 25], ["prevalence", "OBSERVATION", 26, 36], ["mortality", "OBSERVATION", 52, 61], ["varying", "OBSERVATION_MODIFIER", 63, 70], ["arterial", "ANATOMY", 74, 82], ["territory", "ANATOMY_MODIFIER", 83, 92]]], ["We now show that AF, CHD, HF, stable angina, and DVT have the highest pre-COVID-19 incidence rates.", [["AF", "DISEASE", 17, 19], ["CHD", "DISEASE", 21, 24], ["HF", "DISEASE", 26, 28], ["stable angina", "DISEASE", 30, 43], ["DVT", "DISEASE", 49, 52], ["AF", "PROBLEM", 17, 19], ["CHD", "PROBLEM", 21, 24], ["HF", "PROBLEM", 26, 28], ["stable angina", "PROBLEM", 30, 43], ["DVT", "PROBLEM", 49, 52], ["AF", "OBSERVATION", 17, 19], ["stable", "OBSERVATION_MODIFIER", 30, 36], ["angina", "OBSERVATION", 37, 43], ["DVT", "OBSERVATION", 49, 52]]], ["Prognosis varies by incident versus prevalent disease, specific CVD and number and combination of comorbidities, highlighting need for individualised risk All rights reserved.", [["CVD", "DISEASE", 64, 67], ["prevalent disease", "PROBLEM", 36, 53], ["comorbidities", "PROBLEM", 98, 111]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint prediction across CVD.", [["CVD", "DISEASE", 351, 354], ["medRxiv", "TREATMENT", 316, 323], ["med", "ANATOMY", 125, 128]]], ["On a different note, our findings also bring into question the rationale for looking at composite endpoints such as \"MACE\"(major adverse cardiovascular events) in trials and other studies due to highly variable risk across specific CVD 28 .DiscussionIn individuals with CVD at 10% population infection rate, there would be 50,937 excess deaths at RR 1.5, with higher rates at higher infection rates.", [["cardiovascular", "ANATOMY", 137, 151], ["adverse cardiovascular events", "DISEASE", 129, 158], ["CVD", "DISEASE", 232, 235], ["CVD", "DISEASE", 270, 273], ["infection", "DISEASE", 292, 301], ["deaths", "DISEASE", 337, 343], ["infection", "DISEASE", 383, 392], ["major adverse cardiovascular events", "PROBLEM", 123, 158], ["other studies", "TEST", 174, 187], ["CVD", "PROBLEM", 270, 273], ["infection rate", "TEST", 292, 306], ["excess deaths", "PROBLEM", 330, 343], ["RR", "TEST", 347, 349], ["higher infection rates", "PROBLEM", 376, 398], ["infection", "OBSERVATION", 383, 392]]], ["An earlier lockdown, as in New Our findings may have implications for which aspects of health services(acute vs chronic, treatment vs prevention, across specific CVDs) require attention at different pandemic phases.", [["CVDs", "DISEASE", 162, 166], ["treatment", "TREATMENT", 121, 130], ["prevention", "TREATMENT", 134, 144]]], ["Demand for NCD care is documented in humanitarian emergencies 29 , but NCD surveillance is absent in pandemic preparedness, planning and responses, particularly in low-middle income countries 13 , where our findings will be magnified.", [["NCD care", "TREATMENT", 11, 19], ["NCD surveillance", "TEST", 71, 87]]], ["The learning health system concept 30 , where near real-time data inform science, evidence and care, has not been used optimally during the COVID-19 pandemic, but our CVD referral, diagnosis and treatment data show that data need not be complex.Strengths and limitationsOur study uses large-scale, nationally representative EHR with validated definitions across a comprehensive list of specific CVDs and comorbidities.", [["CVD", "DISEASE", 167, 170], ["CVDs", "DISEASE", 395, 399], ["treatment data", "TEST", 195, 209], ["Our study", "TEST", 270, 279], ["comorbidities", "PROBLEM", 404, 417], ["large", "OBSERVATION_MODIFIER", 285, 290]]], ["There are several limitations.", [["several", "OBSERVATION_MODIFIER", 10, 17], ["limitations", "OBSERVATION_MODIFIER", 18, 29]]], ["In the UK, our study population was 5% of the overall population.", [["our study population", "TEST", 11, 31]]], ["Our analyses of risk and excess deaths use retrospective EHR data.", [["deaths", "DISEASE", 32, 38], ["retrospective EHR data", "TEST", 43, 65]]], ["Our model assumes static infection rate and RR and do not include changes over time.", [["infection", "DISEASE", 25, 34], ["static infection rate", "PROBLEM", 18, 39], ["RR", "TEST", 44, 46], ["static", "OBSERVATION_MODIFIER", 18, 24], ["infection", "OBSERVATION", 25, 34]]], ["We used service data from limited hospitals and only UK(ONS) administrative data was available.", [["administrative data", "TEST", 61, 80]]], ["We do not report primary care or community level data regarding CVD services.", [["CVD", "DISEASE", 64, 67], ["CVD services", "TREATMENT", 64, 76]]], ["We modelled using limited comorbidities and simple multimorbidity counts, and did not study impact of ethnicity.", [["limited comorbidities", "PROBLEM", 18, 39], ["simple multimorbidity counts", "TEST", 44, 72]]], ["We assumed the same effect across all specific CVDs.", [["CVDs", "DISEASE", 47, 51]]], ["No reuse allowed without permission.Strengths and limitations(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Strengths and limitationsThe copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprintConclusionThere is a substantial avoidable burden of excess mortality in people with CVD during the COVID-19 pandemic.", [["CVD", "DISEASE", 447, 450], ["people", "ORGANISM", 435, 441], ["people", "SPECIES", 435, 441], ["The copyright holder", "TREATMENT", 221, 241], ["medRxiv", "TREATMENT", 346, 353], ["excess mortality", "PROBLEM", 415, 431], ["CVD", "PROBLEM", 447, 450], ["the COVID", "TEST", 458, 467], ["pandemic", "PROBLEM", 471, 479], ["med", "ANATOMY", 140, 143], ["substantial", "OBSERVATION_MODIFIER", 383, 394], ["avoidable", "OBSERVATION_MODIFIER", 395, 404], ["burden", "OBSERVATION_MODIFIER", 405, 411], ["excess", "OBSERVATION_MODIFIER", 415, 421], ["mortality", "OBSERVATION", 422, 431]]], ["Excess CVD deaths can be reduced in more integrated approaches, focused on reducing COVID-19 infection rates, as well as managing CVD and comorbidities.Contributor and guarantor information:Research question: AB, GYHL, HH (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Contributor and guarantor information:The copyright holder for this preprint this version posted June 11, 2020. .", [["CVD deaths", "DISEASE", 7, 17], ["infection", "DISEASE", 93, 102], ["CVD", "DISEASE", 130, 133], ["Excess CVD deaths", "PROBLEM", 0, 17], ["reducing COVID", "TREATMENT", 75, 89], ["infection rates", "PROBLEM", 93, 108], ["comorbidities", "PROBLEM", 138, 151], ["reduced", "OBSERVATION_MODIFIER", 25, 32], ["infection", "OBSERVATION", 93, 102], ["med", "ANATOMY", 301, 304]]], ["No reuse allowed without permission.Contributor and guarantor information:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Contributor and guarantor information:The copyright holder for this preprint this version posted June 11, 2020.", [["med", "ANATOMY", 153, 156]]], ["No reuse allowed without permission.Contributor and guarantor information:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Contributor and guarantor information:The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint All rights reserved.", [["medRxiv", "TREATMENT", 372, 379], ["med", "ANATOMY", 153, 156]]], ["No reuse allowed without permission.Figures and Tables(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figures and TablesThe copyright holder for this preprint this version posted June 11, 2020. .", [["med", "ANATOMY", 133, 136]]], ["No reuse allowed without permission.Figures and Tables(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 133, 136]]], ["Weekly national data for excess total, non-COVID and cardiovascular deaths in England and Wales, and emergency department cardiac attendances for England: relative risks.Figures and TablesAll rights reserved.", [["cardiovascular", "ANATOMY", 53, 67], ["cardiac", "ANATOMY", 122, 129], ["cardiovascular deaths", "DISEASE", 53, 74], ["cardiovascular", "ANATOMY", 53, 67]]], ["No reuse allowed without permission.Figures and Tables(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figures and TablesThe copyright holder for this preprint A.B.All rights reserved.", [["The copyright holder", "TREATMENT", 207, 227], ["this preprint A.B.", "TREATMENT", 232, 250], ["med", "ANATOMY", 133, 136]]], ["No reuse allowed without permission.B.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.B.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint Figure 4 : Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) incident cases; and (B) number of comorbidities for incident cases.B.A.B.All rights reserved.", [["deaths", "DISEASE", 352, 358], ["CVD", "DISEASE", 397, 400], ["B", "GENE_OR_GENE_PRODUCT", 173, 174], ["The copyright holder", "TREATMENT", 175, 195], ["med", "ANATOMY", 117, 120]]], ["No reuse allowed without permission.B.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.B.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20127175 doi: medRxiv preprint", [["B", "GENE_OR_GENE_PRODUCT", 173, 174], ["The copyright holder", "TREATMENT", 175, 195], ["medRxiv", "TREATMENT", 300, 307], ["med", "ANATOMY", 117, 120]]]], "79d2c5d3f7524b1070616145f910651d23603f22": [["Alternative medicines for AIDS in resource-poor settings: insights from exploratory anthropological studies in Asia and AfricaA large number of new treatments offered to people living with HIV/AIDS (PLWA) have appeared over the last fifteen years in the therapeutic domain of AIDS.", [["AIDS", "DISEASE", 26, 30], ["HIV/AIDS", "DISEASE", 189, 197], ["PLWA", "DISEASE", 199, 203], ["AIDS", "DISEASE", 276, 280], ["people", "ORGANISM", 170, 176], ["PLWA", "CANCER", 199, 203], ["people", "SPECIES", 170, 176], ["HIV", "SPECIES", 189, 192], ["Alternative medicines", "TREATMENT", 0, 21], ["AIDS", "PROBLEM", 26, 30], ["exploratory anthropological studies", "TEST", 72, 107], ["new treatments", "TREATMENT", 144, 158], ["HIV/AIDS", "PROBLEM", 189, 197]]], ["These med-icines are particularly heterogeneous, both in their presentation and in their geographic and cultural origin.", [["med-icines", "GENE_OR_GENE_PRODUCT", 6, 16], ["heterogeneous", "OBSERVATION_MODIFIER", 34, 47], ["cultural origin", "OBSERVATION", 104, 119]]], ["They constitute a group of products with a therapeutic aim that occupies a space between the customary traditional, popular and biomedical sectors of health care [1] .", [["a group of products", "TREATMENT", 16, 35]]], ["These products often mix reference to biomedicine and science with notions of traditional health culture and nature in a syncretic way.", [["traditional health culture", "TEST", 78, 104]]], ["They consist mainly of herbs and nutritional substances and are packaged as 'modern' pharmaceuticals: capsules, tablets, and solutions.", [["capsules", "SIMPLE_CHEMICAL", 102, 110], ["nutritional substances", "TREATMENT", 33, 55], ["tablets", "TREATMENT", 112, 119]]], ["The names of these alternative treatments reflect their reference to biomedicine: Immunocomplex, Viralgic, Virjint, etc. Their accompanying leaflets provide detailed information on substance, as well as dosage, indications, and biomedical efficacy claims.", [["Viralgic", "SIMPLE_CHEMICAL", 97, 105], ["Virjint", "SIMPLE_CHEMICAL", 107, 114], ["leaflets", "MULTI-TISSUE_STRUCTURE", 140, 148], ["these alternative treatments", "TREATMENT", 13, 41], ["leaflets", "OBSERVATION", 140, 148]]], ["Their diffusion follows contemporary paths in the global economy and makes use of new information technologies.", [["global", "OBSERVATION_MODIFIER", 50, 56], ["economy", "OBSERVATION", 57, 64]]], ["In this paper, we will use the term \"alternative\" to consider a generic category including medicines that recently appeared for AIDS which have not been authorised by drug regulatory authorities, nor recommended by WHO.", [["AIDS", "DISEASE", 128, 132], ["medicines", "TREATMENT", 91, 100], ["AIDS", "PROBLEM", 128, 132]]], ["Other terms, such as neo-traditional or neo-phytotherapeutic, may be discussed for the characterization of some of these treatments, related to their local meanings or their social status.Alternative medicines for AIDS in resource-poor settings: insights from exploratory anthropological studies in Asia and AfricaThe emergence of alternative medicines for AIDS in Asia and Africa was discussed at a satellite symposium and the parallel session on alternative and traditional treatments of the AIDSImpact meeting, held in Marseille, in July 2007.", [["AIDS", "DISEASE", 214, 218], ["AIDS", "DISEASE", 357, 361], ["these treatments", "TREATMENT", 115, 131], ["Alternative medicines", "TREATMENT", 188, 209], ["AIDS", "PROBLEM", 214, 218], ["exploratory anthropological studies", "TEST", 260, 295], ["alternative medicines", "TREATMENT", 331, 352], ["AIDS", "PROBLEM", 357, 361]]], ["We were especially interested in the role of these medications since the introduction and rapid scale-up of highly active anti-retroviral therapy (HAART) in resource poor settings.Alternative medicines for AIDS in resource-poor settings: insights from exploratory anthropological studies in Asia and AfricaTwenty anthropologists and health researchers attended the satellite session and presented exploratory findings from Asia and Africa (Uganda, Senegal, Benin, Burkina Faso, China and Indonesia).", [["AIDS", "DISEASE", 206, 210], ["these medications", "TREATMENT", 45, 62], ["the introduction", "TREATMENT", 69, 85], ["rapid scale", "TEST", 90, 101], ["highly active anti-retroviral therapy", "TREATMENT", 108, 145], ["HAART", "TREATMENT", 147, 152], ["Alternative medicines", "TREATMENT", 180, 201], ["AIDS", "PROBLEM", 206, 210], ["exploratory anthropological studies", "TEST", 252, 287], ["active", "OBSERVATION_MODIFIER", 115, 121], ["anti-retroviral therapy", "OBSERVATION", 122, 145]]], ["The aims of the satellite, the results of which were presented at the parallel session [2] , were to (1) identify the actors involved in the diffusion of these alternative medicines for HIV/AIDS, (2) explore uses and forms of these medicines, and the way they are given legitimacy, (3) reflect on underlying processes of globalisation and cultural differentiation, and (4) define priority questions for future research in this area.", [["HIV/AIDS", "DISEASE", 186, 194], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 186, 189], ["these alternative medicines", "TREATMENT", 154, 181], ["HIV/AIDS", "PROBLEM", 186, 194], ["these medicines", "TREATMENT", 226, 241]]], ["We present here the insights generated at the meeting, illustrated with some findings from the studies that were discussed.Modernization of traditional medicineThere has been an increased professionalisation and commercialisation of traditional medicine in response to the development of biomedicine.", [["the studies", "TEST", 91, 102], ["traditional medicine", "TREATMENT", 140, 160], ["an increased professionalisation", "PROBLEM", 175, 207], ["traditional medicine", "TREATMENT", 233, 253], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["professionalisation", "OBSERVATION", 188, 207]]], ["This trend is not specific to AIDS and not necessarily a recent development.", [["AIDS", "DISEASE", 30, 34], ["AIDS", "PROBLEM", 30, 34]]], ["Social scientists first noted this trend in the late 1980s: Charles Leslie [3] for example has shown how, in India, in response to an increased authority of biomedicine and the globalisation of health markets, Unani and Ayurvedic medicine production changed; and Afdhal and Welsch [4] described the rise of 'modern' jamu in Indonesia.", [["Unani", "CHEMICAL", 210, 215]]], ["Jamu is the traditional term for Indonesian indigenous medicines usually prepared from herbal medicines such as leaves, bark, roots and flowers.", [["leaves", "ANATOMY", 112, 118], ["bark", "ANATOMY", 120, 124], ["roots", "ANATOMY", 126, 131], ["flowers", "ANATOMY", 136, 143], ["leaves", "ORGANISM_SUBDIVISION", 112, 118], ["bark", "TISSUE", 120, 124], ["roots", "TISSUE", 126, 131], ["flowers", "ORGANISM_SUBDIVISION", 136, 143], ["Indonesian indigenous medicines", "TREATMENT", 33, 64], ["herbal medicines", "TREATMENT", 87, 103]]], ["Nowadays a multimillion dollar industry is involved in the production of Ayurvedic and Unani medicines in India, and of jamu in Indonesia.", [["Unani medicines", "TREATMENT", 87, 102]]], ["A rapidly expanding assortment of powders, creams, pills, capsules and cosmetics has been manufactured both in small cottage industries as in large factories with increasingly sophisticated technologies [3, 4] .", [["A rapidly expanding assortment of powders", "TREATMENT", 0, 41], ["creams", "TREATMENT", 43, 49], ["pills", "TREATMENT", 51, 56], ["capsules", "TREATMENT", 58, 66], ["cosmetics", "TREATMENT", 71, 80], ["rapidly", "OBSERVATION_MODIFIER", 2, 9], ["small", "OBSERVATION_MODIFIER", 111, 116], ["large", "OBSERVATION_MODIFIER", 142, 147]]], ["The modernization of the manufacturing of these drugs has been accompanied with more modern biomedical modes of presenting their efficacy [5] .", [["these drugs", "TREATMENT", 42, 53]]], ["Under globalization, similar trends occurred in other regions and these products diffused more rapidly.Modernization of traditional medicineAt the seminars in Marseille, we discussed the ways in which such alternative remedies operate in the therapeutic domain of AIDS care.", [["AIDS", "DISEASE", 264, 268], ["traditional medicine", "TREATMENT", 120, 140], ["alternative remedies", "TREATMENT", 206, 226], ["AIDS care", "TREATMENT", 264, 273], ["globalization", "OBSERVATION", 6, 19], ["similar", "OBSERVATION_MODIFIER", 21, 28], ["trends", "OBSERVATION_MODIFIER", 29, 35], ["products", "OBSERVATION_MODIFIER", 72, 80], ["diffused", "OBSERVATION_MODIFIER", 81, 89], ["more", "OBSERVATION_MODIFIER", 90, 94], ["rapidly", "OBSERVATION_MODIFIER", 95, 102]]], ["In the first decade of the AIDS epidemic there was no effective treatment for HIV/AIDS and patients were faced with nearly certain premature death.", [["AIDS", "DISEASE", 27, 31], ["HIV/AIDS", "DISEASE", 78, 86], ["premature death", "DISEASE", 131, 146], ["patients", "ORGANISM", 91, 99], ["HIV", "SPECIES", 78, 81], ["patients", "SPECIES", 91, 99], ["HIV", "SPECIES", 78, 81], ["the AIDS epidemic", "PROBLEM", 23, 40], ["effective treatment", "TREATMENT", 54, 73], ["HIV", "PROBLEM", 78, 81], ["AIDS", "PROBLEM", 82, 86], ["premature death", "PROBLEM", 131, 146], ["no effective", "UNCERTAINTY", 51, 63]]], ["But with the introduction of ART, alternative treatments are now marketed for many additional purposes too: to prevent AIDS, to kill viruses, to delay the need for ART, to restore and enhance health while on ART, to treat opportunistic infections, and to alleviate adverse side effects of other treatments.", [["AIDS", "DISEASE", 119, 123], ["opportunistic infections", "DISEASE", 222, 246], ["ART", "TREATMENT", 29, 32], ["alternative treatments", "TREATMENT", 34, 56], ["AIDS", "PROBLEM", 119, 123], ["ART", "TREATMENT", 164, 167], ["ART", "TREATMENT", 208, 211], ["opportunistic infections", "PROBLEM", 222, 246], ["other treatments", "TREATMENT", 289, 305], ["opportunistic", "OBSERVATION_MODIFIER", 222, 235], ["infections", "OBSERVATION", 236, 246]]], ["Biomedical practitioners generally discourage the use of alternative medicines, fearing interactions with ART and also through the concern that patients may stop using ART.Supplying alternative medicines for HIV/AIDSAt the AIDSImpact sessions Egrot and colleagues [6] presented findings on the supply of what they label \"neo-traditional medicines\" to refer to the boundary-crossing nature of these treatments in West Africa.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["HIV", "SPECIES", 208, 211], ["HIV", "SPECIES", 208, 211], ["alternative medicines", "TREATMENT", 57, 78], ["ART", "TREATMENT", 106, 109], ["alternative medicines", "TREATMENT", 182, 203], ["HIV", "PROBLEM", 208, 211], ["neo-traditional medicines", "TREATMENT", 321, 346], ["these treatments", "TREATMENT", 392, 408]]], ["The \"designers\" of the inventoried products are extremely heterogeneous.", [["extremely", "OBSERVATION_MODIFIER", 48, 57], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71]]], ["In some cases these people are nationals of African countries who present themselves as healers.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["Some say they have undertaken \"research\" on the basis of therapeutic products that were already known locally.", [["therapeutic products", "TREATMENT", 57, 77]]], ["Others refer to a dream revelation (classic in the universe of healers in Africa) of a plant composition that is \"efficacious\" against AIDS, while yet others speak of a divine revelation.", [["AIDS", "DISEASE", 135, 139]]], ["Physicians, scientists and academics are solicitated, brought into involvement or spontaneously engage themselves in the exploitation of neo-traditional products.", [["neo-traditional products", "TREATMENT", 137, 161]]], ["The case studies in West Africa show that other treatments, such as Immunicomplex or Aloe Vera, originate in Europe and the USA.", [["The case studies", "TEST", 0, 16], ["other treatments", "TREATMENT", 42, 58], ["Aloe Vera", "PROBLEM", 85, 94]]], ["Alternative medicines from Europe and the USA occupy the same shelves in ordinary pharmacies as those originating from Africa and China, often along with a few 'immune-boosting' food products (honey, olive oil).", [["olive oil", "ANATOMY", 200, 209], ["honey", "ORGANISM_SUBDIVISION", 193, 198], ["olive", "ORGANISM_SUBDIVISION", 200, 205], ["oil", "ORGANISM_SUBSTANCE", 206, 209], ["Alternative medicines", "TREATMENT", 0, 21], ["a few 'immune-boosting' food products", "TREATMENT", 154, 191]]], ["The distributors and marketing men of these products also target health workers and clinics directly.", [["men", "ORGANISM", 31, 34], ["men", "SPECIES", 31, 34]]], ["The West Africa case studies noted that health workers also have started to prescribe alternative products such as Immuboost (NHi2T) or Viralgic (Pharma Concept) (see Figure 1) .Supplying alternative medicines for HIV/AIDSA case study from Uganda showed how health workers operating an anti-retroviral treatment program adopted a locally available traditional ointment as an alternative medication for skins problems of people living with HIV and AIDS.", [["skins", "ANATOMY", 402, 407], ["Immuboost", "CHEMICAL", 115, 124], ["NHi2T", "CHEMICAL", 126, 131], ["HIV", "DISEASE", 439, 442], ["AIDS", "DISEASE", 447, 451], ["Immuboost", "SIMPLE_CHEMICAL", 115, 124], ["skins", "ORGANISM_SUBDIVISION", 402, 407], ["people", "ORGANISM", 420, 426], ["people", "SPECIES", 420, 426], ["HIV", "SPECIES", 439, 442], ["HIV", "SPECIES", 214, 217], ["HIV", "SPECIES", 439, 442], ["alternative products", "TREATMENT", 86, 106], ["Immuboost (NHi2T)", "TREATMENT", 115, 132], ["Viralgic (Pharma Concept", "TREATMENT", 136, 160], ["alternative medicines", "TREATMENT", 188, 209], ["HIV", "PROBLEM", 214, 217], ["an anti-retroviral treatment program", "TREATMENT", 283, 319], ["traditional ointment", "TREATMENT", 348, 368], ["an alternative medication", "TREATMENT", 372, 397], ["skins problems", "PROBLEM", 402, 416]]], ["The skin problems result from adverse effects of ART or symptoms of opportunistic infections.", [["skin", "ANATOMY", 4, 8], ["opportunistic infections", "DISEASE", 68, 92], ["skin", "ORGAN", 4, 8], ["The skin problems", "PROBLEM", 0, 17], ["symptoms", "PROBLEM", 56, 64], ["opportunistic infections", "PROBLEM", 68, 92], ["skin", "ANATOMY", 4, 8], ["opportunistic", "OBSERVATION_MODIFIER", 68, 81], ["infections", "OBSERVATION", 82, 92]]], ["The health workers obtained the recipe from local traditional healers (patients had told them that the cream works well), and the patients help collect the ingredients.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 130, 138], ["the cream", "TREATMENT", 99, 108]]], ["One of the nurses reports:Supplying alternative medicines for HIV/AIDS\"The mobile cream, which we ourselves prepare either at our chief nurse's home or here at the office depending on how busy we are at the office, is very efficacious for many kinds of skin related conditions.", [["skin", "ANATOMY", 253, 257], ["HIV/AIDS", "DISEASE", 62, 70], ["skin", "ORGAN", 253, 257], ["HIV", "SPECIES", 62, 65], ["alternative medicines", "TREATMENT", 36, 57], ["HIV/AIDS", "PROBLEM", 62, 70], ["The mobile cream", "TREATMENT", 71, 87], ["skin related conditions", "PROBLEM", 253, 276], ["skin", "ANATOMY", 253, 257]]], ["We are quick to prescribe it to the patients because we know it works and it is popular among patients too because it works for them [7] .\"", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 94, 102]]], ["Most commonly cited (biomedical) properties are immune-stimulation and antioxidant.", [["immune-stimulation", "TREATMENT", 48, 66], ["antioxidant", "TREATMENT", 71, 82]]], ["Some manufacturers suggest that the products have antiviral properties as well.", [["antiviral properties", "TREATMENT", 50, 70], ["antiviral properties", "OBSERVATION", 50, 70]]], ["The antiviral dimension refers either to the opportunistic infections such as herpes (mentioned for example in the product information for Immuboost) or eventually to the immunodeficiency syndrome itself.Supplying alternative medicines for HIV/AIDSIndeed, some products boldly claim anti-HIV activity as well, and are marketed as natural ART (see Figure 2 ).", [["infections", "DISEASE", 59, 69], ["herpes", "DISEASE", 78, 84], ["immunodeficiency syndrome", "DISEASE", 171, 196], ["herpes", "ORGANISM", 78, 84], ["HIV", "SPECIES", 240, 243], ["The antiviral dimension", "TREATMENT", 0, 23], ["the opportunistic infections", "PROBLEM", 41, 69], ["herpes", "PROBLEM", 78, 84], ["the immunodeficiency syndrome", "PROBLEM", 167, 196], ["alternative medicines", "TREATMENT", 214, 235], ["HIV/AIDSIndeed", "TREATMENT", 240, 254], ["some products", "TREATMENT", 256, 269], ["antiviral dimension", "OBSERVATION_MODIFIER", 4, 23], ["opportunistic", "OBSERVATION_MODIFIER", 45, 58], ["infections", "OBSERVATION", 59, 69], ["immunodeficiency syndrome", "OBSERVATION", 171, 196], ["anti-HIV activity", "OBSERVATION", 283, 300]]], ["The producer of Virusinest (Nesto-Pharma) recently withdrew the antiviral claim, stating in its information leaflet: \"the analyses carried out among patients do not allow the anti-HIV assertion to be upheld\".", [["Virusinest", "CHEMICAL", 16, 26], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Virusinest (Nesto-Pharma)", "TREATMENT", 16, 41]]], ["The brochure for Viralgic (Pharma Concept) says that this is a product which renders the virus undetectable, but the website of the manufacturer presents the drug as immunostimulant (result of trials published on the web site), and present the product as treatment for opportunistic infections: \"antiherpes...for healthy persons\".The demand for alternative medicinesA case study on Indonesia [9] dealt with the demand for alternative medicines among PLWA.", [["opportunistic infections", "DISEASE", 269, 293], ["PLWA", "CHEMICAL", 450, 454], ["persons", "ORGANISM", 321, 328], ["PLWA", "SIMPLE_CHEMICAL", 450, 454], ["persons", "SPECIES", 321, 328], ["the virus", "PROBLEM", 85, 94], ["opportunistic infections", "PROBLEM", 269, 293], ["alternative medicines", "TREATMENT", 422, 443]]], ["Jamu are sold for a wide range of indications: common colds, influenza, headaches, aches and pains, high blood pressure, beauty, improvements in sexual performance, and recently to treat and prevent HIVrelated health problems.", [["blood", "ANATOMY", 105, 110], ["colds", "DISEASE", 54, 59], ["influenza", "DISEASE", 61, 70], ["headaches", "DISEASE", 72, 81], ["aches", "DISEASE", 83, 88], ["pains", "DISEASE", 93, 98], ["aches", "ORGANISM_SUBDIVISION", 83, 88], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["common colds", "PROBLEM", 47, 59], ["influenza", "PROBLEM", 61, 70], ["headaches", "PROBLEM", 72, 81], ["aches", "PROBLEM", 83, 88], ["pains", "PROBLEM", 93, 98], ["high blood pressure", "PROBLEM", 100, 119], ["HIVrelated health problems", "PROBLEM", 199, 225], ["influenza", "OBSERVATION", 61, 70]]], ["AIDS prevalence is below 1% (i.e. this is a low prevalence area), but the disease is stigmatised, because of its association with intravenous drug use and prostitution.", [["intravenous", "ANATOMY", 130, 141], ["AIDS", "DISEASE", 0, 4], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 130, 141], ["the disease", "PROBLEM", 70, 81], ["intravenous drug use", "TREATMENT", 130, 150], ["low prevalence", "OBSERVATION_MODIFIER", 44, 58], ["disease", "OBSERVATION", 74, 81]]], ["Hardon and her colleagues conducted interviews with women and men who live with HIV and use anti-retroviral therapy, mainly intravenous drug users and their partners.", [["intravenous", "ANATOMY", 124, 135], ["women", "ORGANISM", 52, 57], ["men", "ORGANISM", 62, 65], ["HIV", "ORGANISM", 80, 83], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 135], ["women", "SPECIES", 52, 57], ["men", "SPECIES", 62, 65], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 80, 83], ["HIV", "PROBLEM", 80, 83], ["anti-retroviral therapy", "TREATMENT", 92, 115]]], ["All of them had better health since taking these modern drugs.", [["these modern drugs", "TREATMENT", 43, 61]]], ["The respondents do not make distinctions between modern medicines and jamu in these health maintenance and restoring practices.", [["modern medicines", "TREATMENT", 49, 65], ["restoring practices", "TREATMENT", 107, 126]]], ["They use popular jamu to treat side effects of HAART, such as itchiness.", [["popular jamu", "TREATMENT", 9, 21], ["HAART", "TREATMENT", 47, 52], ["itchiness", "PROBLEM", 62, 71], ["HAART", "OBSERVATION", 47, 52]]], ["These jamus are not specifically promoted for HIV and AIDS in Indonesia, perhaps partly because the disease is so stigmatised.The demand for alternative medicinesHowever one neo-traditional preparation stood out in the narratives of our respondents as a product which can treat HIV/AIDS: virgin coconut oil.", [["jamus", "ANATOMY", 6, 11], ["coconut oil", "ANATOMY", 295, 306], ["HIV and", "DISEASE", 46, 53], ["AIDS", "DISEASE", 54, 58], ["HIV/AIDS", "DISEASE", 278, 286], ["jamus", "CANCER", 6, 11], ["HIV", "ORGANISM", 278, 281], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 278, 281], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 278, 281], ["HIV", "PROBLEM", 46, 49], ["AIDS", "PROBLEM", 54, 58], ["the disease", "PROBLEM", 96, 107], ["alternative medicines", "TREATMENT", 141, 162], ["one neo-traditional preparation", "TREATMENT", 170, 201], ["virgin coconut oil", "TREATMENT", 288, 306], ["disease", "OBSERVATION", 100, 107]]], ["Ceri, for example, started using coconut oil shortly after she found out she was HIVpositive.", [["coconut oil", "ANATOMY", 33, 44], ["Ceri", "SIMPLE_CHEMICAL", 0, 4], ["coconut oil", "TREATMENT", 33, 44], ["HIVpositive", "PROBLEM", 81, 92]]], ["She says:The demand for alternative medicinesActually, the effect is not only for your immune system.", [["alternative medicines", "TREATMENT", 24, 45], ["your immune system", "PROBLEM", 82, 100]]], ["It's self-suggestion that matters...She stopped taking the oil because it is very expensive.Mia (a 28 year old woman from Jakarta) was given virgin coconut oil by a friend from Yogjakarta: I got 70 boxes.", [["oil", "ANATOMY", 59, 62], ["coconut oil", "ANATOMY", 148, 159], ["oil", "ORGANISM_SUBSTANCE", 59, 62], ["woman", "ORGANISM", 111, 116], ["oil", "ORGANISM_SUBSTANCE", 156, 159], ["woman", "SPECIES", 111, 116], ["the oil", "TREATMENT", 55, 62]]], ["A box contains 60 capsules.", [["A box contains 60 capsules", "TREATMENT", 0, 26], ["60 capsules", "OBSERVATION_MODIFIER", 15, 26]]], ["It took it every day until I felt sick, but there was no effect.", [["sick", "PROBLEM", 34, 38]]], ["My CD4 level did not increase.", [["CD4", "GENE_OR_GENE_PRODUCT", 3, 6], ["CD4", "PROTEIN", 3, 6], ["My CD4 level", "TEST", 0, 12], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["The good effect when you take VCO is that your skin is silk smooth, your face is fairer and if you take a shower, you don't need any lotion, because your skin is naturally oily.", [["skin", "ANATOMY", 47, 51], ["skin", "ANATOMY", 154, 158], ["VCO", "CANCER", 30, 33], ["skin", "ORGAN", 47, 51], ["skin", "ORGAN", 154, 158], ["any lotion", "TREATMENT", 129, 139], ["good effect", "OBSERVATION", 4, 15], ["skin", "ANATOMY", 47, 51], ["skin", "ANATOMY", 154, 158]]], ["That is the positive effect.", [["positive effect", "OBSERVATION", 12, 27]]], ["Your hair is also stronger.She stopped taking the oil because it is very expensive.But Buli, a 29-year-old ex-drug user from Karawang, one of the most active members of the support group in Karawang says:The coconut oil, I was also suggested it, but I don't dare to try it, because I thought I'm taking ARV now, so it's better if I just continue.In Indonesia, the drug sellers were not very willing to discuss the effects of VCO.", [["hair", "ANATOMY", 5, 9], ["oil", "ANATOMY", 50, 53], ["coconut oil", "ANATOMY", 208, 219], ["VCO", "CHEMICAL", 425, 428], ["VCO", "CHEMICAL", 425, 428], ["hair", "ORGAN", 5, 9], ["oil", "ORGANISM_SUBSTANCE", 50, 53], ["oil", "ORGANISM_SUBSTANCE", 216, 219], ["VCO", "SIMPLE_CHEMICAL", 425, 428], ["the oil", "TREATMENT", 46, 53], ["stronger", "OBSERVATION_MODIFIER", 18, 26]]], ["They would acknowledge that indeed these drugs are used by PLWA, or they would deny knowing anything about the drugs.", [["PLWA", "SIMPLE_CHEMICAL", 59, 63]]], ["But their pharmacies are full of advertisements for the products and they have prominent positions on their shelves (see Figure 3 ).The coconut oil, I was also suggested it, but I don't dare to try it, because I thought I'm taking ARV now, so it's better if I just continue.Content analysis of the package information for VCO in Indonesia revealed that they are marketed as real 'curealls', i.e. to kill viruses and bacteria and/or strengthen the immune system, efficacy claims that we also found in West Africa.", [["coconut oil", "ANATOMY", 136, 147], ["oil", "ORGANISM_SUBSTANCE", 144, 147], ["the products", "TREATMENT", 52, 64], ["kill viruses", "PROBLEM", 399, 411], ["bacteria", "PROBLEM", 416, 424], ["prominent", "OBSERVATION_MODIFIER", 79, 88], ["positions", "OBSERVATION_MODIFIER", 89, 98]]], ["For example the package leaflet for Vicofit (manufactured by Sumber Dinamis in Bogor) states that the drug has \"a high content of lauric acid which has antivirus, anti-bacterials and anti-protozoa properties.\"", [["Vicofit", "CHEMICAL", 36, 43], ["lauric acid", "CHEMICAL", 130, 141], ["lauric acid", "CHEMICAL", 130, 141], ["lauric acid", "SIMPLE_CHEMICAL", 130, 141], ["antivirus", "SIMPLE_CHEMICAL", 152, 161], ["anti-bacterials", "SIMPLE_CHEMICAL", 163, 178], ["Vicofit", "TREATMENT", 36, 43], ["lauric acid", "TREATMENT", 130, 141], ["antivirus", "TREATMENT", 152, 161], ["anti-bacterials", "TREATMENT", 163, 178], ["anti-protozoa properties", "TREATMENT", 183, 207], ["package leaflet", "OBSERVATION", 16, 31]]], ["And that it is \"believed to help improve the health condition of those with cholesterol, diabetes, coronary heart disease, hepatitis C, HIV positive, cancer, prostate, uric acid, osteoporosis, influenza and weight problems\".", [["coronary", "ANATOMY", 99, 107], ["heart", "ANATOMY", 108, 113], ["cancer", "ANATOMY", 150, 156], ["prostate", "ANATOMY", 158, 166], ["cholesterol", "CHEMICAL", 76, 87], ["diabetes", "DISEASE", 89, 97], ["coronary heart disease", "DISEASE", 99, 121], ["hepatitis C", "DISEASE", 123, 134], ["HIV positive", "DISEASE", 136, 148], ["cancer", "DISEASE", 150, 156], ["uric acid", "CHEMICAL", 168, 177], ["osteoporosis", "DISEASE", 179, 191], ["influenza", "DISEASE", 193, 202], ["weight problems", "DISEASE", 207, 222], ["cholesterol", "CHEMICAL", 76, 87], ["uric acid", "CHEMICAL", 168, 177], ["cholesterol", "SIMPLE_CHEMICAL", 76, 87], ["heart", "ORGAN", 108, 113], ["cancer", "CANCER", 150, 156], ["prostate", "CANCER", 158, 166], ["uric acid", "SIMPLE_CHEMICAL", 168, 177], ["HIV", "SPECIES", 136, 139], ["diabetes", "PROBLEM", 89, 97], ["coronary heart disease", "PROBLEM", 99, 121], ["hepatitis C", "PROBLEM", 123, 134], ["HIV positive", "PROBLEM", 136, 148], ["cancer", "PROBLEM", 150, 156], ["prostate, uric acid", "PROBLEM", 158, 177], ["osteoporosis", "PROBLEM", 179, 191], ["influenza", "PROBLEM", 193, 202], ["weight problems\"", "PROBLEM", 207, 223], ["coronary heart", "ANATOMY", 99, 113], ["disease", "OBSERVATION", 114, 121], ["hepatitis", "OBSERVATION", 123, 132], ["prostate", "ANATOMY", 158, 166]]], ["The package for Virjint (produced by PT Vermindo International) states that the medicine is safe for daily use and without side effects.", [["Virjint", "CHEMICAL", 16, 23], ["Virjint", "SIMPLE_CHEMICAL", 16, 23], ["side effects", "PROBLEM", 123, 135]]], ["It lists two dosages: one for prevention (2 \u00d7 2 capsules per day) and another for treatment (2 \u00d7 3 capsules per day).", [["treatment", "TREATMENT", 82, 91]]], ["The leaflet stipulates that the indications are:The coconut oil, I was also suggested it, but I don't dare to try it, because I thought I'm taking ARV now, so it's better if I just continue.-\"to increase energy and body stamina -to increase body resistance (Meningkatkan daya tahan tubuh) against bacterial, viral and fungal pathogens -to reduce weight -anti-oxidant, anticancer, and anti-HIV -to overcome uric acid, hypertension, stroke, heart disease, atherosclerosis, osteoporosis, influenza, hepatitis, chickenpox, herpes, TB, diabetes, epilepsy, eczema, liver, haemorrhoids, kidney, peradangan (burning sensation), infection, degenerative disease.\"The coconut oil, I was also suggested it, but I don't dare to try it, because I thought I'm taking ARV now, so it's better if I just continue.The packages cite clinical research conducted elsewhere (Philippines, USA) to give legitimacy to the products.", [["coconut oil", "ANATOMY", 52, 63], ["body", "ANATOMY", 215, 219], ["body", "ANATOMY", 241, 245], ["anticancer", "ANATOMY", 368, 378], ["heart", "ANATOMY", 439, 444], ["liver", "ANATOMY", 559, 564], ["kidney", "ANATOMY", 580, 586], ["coconut oil", "ANATOMY", 657, 668], ["uric acid", "CHEMICAL", 406, 415], ["hypertension", "DISEASE", 417, 429], ["stroke", "DISEASE", 431, 437], ["heart disease", "DISEASE", 439, 452], ["atherosclerosis", "DISEASE", 454, 469], ["osteoporosis", "DISEASE", 471, 483], ["influenza", "DISEASE", 485, 494], ["hepatitis", "DISEASE", 496, 505], ["chickenpox", "DISEASE", 507, 517], ["herpes, TB", "DISEASE", 519, 529], ["diabetes", "DISEASE", 531, 539], ["epilepsy", "DISEASE", 541, 549], ["eczema", "DISEASE", 551, 557], ["liver, haemorrhoids", "DISEASE", 559, 578], ["kidney, peradangan (burning sensation", "DISEASE", 580, 617], ["infection", "DISEASE", 620, 629], ["degenerative disease", "DISEASE", 631, 651], ["uric acid", "CHEMICAL", 406, 415], ["body", "ORGANISM_SUBDIVISION", 215, 219], ["body", "ORGANISM_SUBDIVISION", 241, 245], ["daya tahan tubuh", "ORGANISM", 271, 287], ["anticancer", "CANCER", 368, 378], ["uric acid", "SIMPLE_CHEMICAL", 406, 415], ["heart", "ORGAN", 439, 444], ["herpes", "ORGANISM", 519, 525], ["liver", "ORGAN", 559, 564], ["kidney", "ORGAN", 580, 586], ["oil", "ORGANISM_SUBSTANCE", 665, 668], ["Meningkatkan daya tahan tubuh", "SPECIES", 258, 287], ["body resistance (Meningkatkan daya tahan tubuh", "TREATMENT", 241, 287], ["bacterial, viral and fungal pathogens", "PROBLEM", 297, 334], ["weight", "TEST", 346, 352], ["anti-oxidant", "TREATMENT", 354, 366], ["anticancer", "TREATMENT", 368, 378], ["anti-HIV", "TREATMENT", 384, 392], ["uric acid", "PROBLEM", 406, 415], ["hypertension", "PROBLEM", 417, 429], ["stroke", "PROBLEM", 431, 437], ["heart disease", "PROBLEM", 439, 452], ["atherosclerosis", "PROBLEM", 454, 469], ["osteoporosis", "PROBLEM", 471, 483], ["influenza", "PROBLEM", 485, 494], ["hepatitis", "PROBLEM", 496, 505], ["chickenpox", "PROBLEM", 507, 517], ["herpes", "PROBLEM", 519, 525], ["TB", "PROBLEM", 527, 529], ["diabetes", "PROBLEM", 531, 539], ["epilepsy", "PROBLEM", 541, 549], ["eczema", "PROBLEM", 551, 557], ["liver", "PROBLEM", 559, 564], ["haemorrhoids", "PROBLEM", 566, 578], ["kidney, peradangan (burning sensation", "PROBLEM", 580, 617], ["infection", "PROBLEM", 620, 629], ["degenerative disease", "PROBLEM", 631, 651], ["legitimacy to the products", "TREATMENT", 878, 904], ["leaflet", "ANATOMY_MODIFIER", 4, 11], ["fungal pathogens", "OBSERVATION", 318, 334], ["hypertension", "OBSERVATION", 417, 429], ["stroke", "OBSERVATION", 431, 437], ["heart", "ANATOMY", 439, 444], ["disease", "OBSERVATION", 445, 452], ["atherosclerosis", "OBSERVATION", 454, 469], ["osteoporosis", "OBSERVATION", 471, 483], ["influenza", "OBSERVATION", 485, 494], ["hepatitis", "OBSERVATION", 496, 505], ["chickenpox", "OBSERVATION", 507, 517], ["herpes", "OBSERVATION", 519, 525], ["diabetes", "OBSERVATION", 531, 539], ["epilepsy", "OBSERVATION", 541, 549], ["eczema", "OBSERVATION", 551, 557], ["liver", "ANATOMY", 559, 564], ["haemorrhoids", "OBSERVATION", 566, 578], ["kidney", "ANATOMY", 580, 586], ["infection", "OBSERVATION", 620, 629], ["degenerative", "OBSERVATION_MODIFIER", 631, 643], ["disease", "OBSERVATION", 644, 651]]], ["For example the leaflet of Holistic Virgin Coconut Oil states: \"Based on research conducted in the Philippines, Holistic Virgin Coconut Oil is very effective to fight against SARS and AIDS\".ConclusionOne of the key characteristics of alternative medicines in Asia and Africa is that they move from one cultural and geographic space to another, apparently without being constrained by trade-barriers, or regulatory mechanisms.", [["SARS", "DISEASE", 175, 179], ["AIDS", "DISEASE", 184, 188], ["Holistic Virgin Coconut Oil", "TREATMENT", 112, 139], ["SARS", "PROBLEM", 175, 179], ["alternative medicines", "TREATMENT", 234, 255], ["leaflet", "OBSERVATION_MODIFIER", 16, 23], ["Holistic Virgin", "OBSERVATION", 27, 42], ["Coconut Oil", "OBSERVATION", 43, 54]]], ["Some governments promote the production and diffusion of neo-traditional medicines.", [["neo-traditional medicines", "TREATMENT", 57, 82]]], ["They do so for economic reasons: alternative medicines are big business, but they also do so for ideological reasons: neo-traditional medicines reflect an attractive hybrid of modernity and national heritage, providing a sense of national identity in the globalized health economy [10] .", [["alternative medicines", "TREATMENT", 33, 54], ["neo-traditional medicines", "TREATMENT", 118, 143]]], ["The governments of India, China, Indonesia, and some African countries support research programs to further advance these neo-traditional products, and facilitate market diffusion.", [["Indonesia", "TREATMENT", 33, 42], ["research programs", "TREATMENT", 79, 96], ["these neo-traditional products", "TREATMENT", 116, 146]]], ["While registered pharmaceuticals are regulated heavily upon market entry (proof of efficacy is assessed by national drug regulatory authorities), this is not the case for alternative medicines.", [["alternative medicines", "TREATMENT", 171, 192]]], ["ART programs, which are sponsored by the same governments, usually discourage the use of alternative medicines, fearing the toxicity of the drugs, or that these medicines will interact with anti-retroviral medication and lead to discontinuation of ART therapy [11] .", [["toxicity", "DISEASE", 124, 132], ["ART programs", "TREATMENT", 0, 12], ["alternative medicines", "TREATMENT", 89, 110], ["the drugs", "TREATMENT", 136, 145], ["these medicines", "TREATMENT", 155, 170], ["anti-retroviral medication", "TREATMENT", 190, 216], ["ART therapy", "TREATMENT", 248, 259]]], ["Governmental agencies may have contradictory attitudes towards the use of alternative medicines for AIDS, discouraging it within ART programs and supporting it within divisions of traditional medicine.", [["AIDS", "DISEASE", 100, 104], ["alternative medicines", "TREATMENT", 74, 95], ["AIDS", "PROBLEM", 100, 104], ["traditional medicine", "TREATMENT", 180, 200]]], ["An exception is the Chinese government, which officially supports a complementary medicine program for AIDS care and research [12] .ConclusionMass-produced alternative medicines meet an increasing demand for health products, a trend which has been labelled the \"commodification of health\" [13, 14] : from the slums of Djakarta to rural settings in Burkina Faso, people believe more and more that they need pharmaceutical 'things' to protect their health and to treat illness symptoms.", [["AIDS", "DISEASE", 103, 107], ["illness", "DISEASE", 467, 474], ["people", "ORGANISM", 362, 368], ["people", "SPECIES", 362, 368], ["AIDS care", "TREATMENT", 103, 112], ["ConclusionMass", "PROBLEM", 132, 146], ["alternative medicines", "TREATMENT", 156, 177], ["health products", "TREATMENT", 208, 223], ["illness symptoms", "PROBLEM", 467, 483], ["Mass", "OBSERVATION", 142, 146]]], ["People living with HIV and AIDS are particularly uncertain about their health and their future: ART may be accessible and improve health now, but they wonder if this will be the case in the future.", [["HIV and", "DISEASE", 19, 26], ["AIDS", "DISEASE", 27, 31], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["HIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 19, 22]]], ["This uncertainty makes them an attractive market for the 'best of both worlds', alternative medicines, which come with assertions of 'natural' safety and 'biomedical' efficacy [15] .", [["alternative medicines", "TREATMENT", 80, 101]]], ["However the case studies presented in Marseille suggest that people especially want to use alternative medicines to delay onset of ART, treat opportunistic infections, restore health and alleviate adverse effects once on ART.", [["opportunistic infections", "DISEASE", 142, 166], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["the case studies", "TEST", 8, 24], ["alternative medicines", "TREATMENT", 91, 112], ["ART", "TREATMENT", 131, 134], ["opportunistic infections", "PROBLEM", 142, 166]]], ["Immuneboosters are popular, though our case studies suggest that PLWA are often ambivalent about alternative medicines that claim anti-HIV efficacy.ConclusionThe case studies make clear that the market of alternative medicines for HIV/AIDS is dynamic.", [["HIV/", "DISEASE", 231, 235], ["AIDS", "DISEASE", 235, 239], ["PLWA", "SIMPLE_CHEMICAL", 65, 69], ["anti-HIV", "CANCER", 130, 138], ["HIV", "ORGANISM", 231, 234], ["HIV", "SPECIES", 231, 234], ["our case studies", "TEST", 35, 51], ["alternative medicines", "TREATMENT", 97, 118], ["The case studies", "TEST", 158, 174], ["alternative medicines", "TREATMENT", 205, 226], ["HIV/AIDS", "PROBLEM", 231, 239]]], ["It adapts to progress in biomedicine, which has produced potent anti-retrovi-ral medications.", [["potent anti-retrovi-ral medications", "TREATMENT", 57, 92]]], ["In some cases, the efficacy claims for alternative medicines reinforce a biomedical paradigm for HIV/AIDS, and fit with a healthy living ideology promoted by AIDS care programs and support groups.", [["HIV/AIDS", "DISEASE", 97, 105], ["AIDS", "DISEASE", 158, 162], ["HIV", "ORGANISM", 97, 100], ["HIV", "SPECIES", 97, 100], ["alternative medicines", "TREATMENT", 39, 60], ["HIV/AIDS", "PROBLEM", 97, 105], ["support groups", "TREATMENT", 181, 195]]], ["More interdisciplinary research is needed on the experience of people living with HIV/AIDS with these alternative medicines, the ways in which the products and their representations move from one cultural setting to another, and on the ways in which these products interact (or not) with anti-retroviral therapy at pharmacological as well as psychosocial levels.", [["HIV/AIDS", "DISEASE", 82, 90], ["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["HIV", "SPECIES", 82, 85], ["these alternative medicines", "TREATMENT", 96, 123], ["anti-retroviral therapy", "TREATMENT", 288, 311], ["psychosocial levels", "TEST", 342, 361]]], ["More research is also needed to assess the economic impact of these therapies, since people seem to be spending much on these 'other' medicines while ART is provided for free.", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["these therapies", "TREATMENT", 62, 77], ["these 'other' medicines", "TREATMENT", 120, 143], ["ART", "TREATMENT", 150, 153]]], ["A blanket denial of the relevance of these products for the quality of life of PLWA does not make sense for patients, who need precise information that make clear which products are likely to have negative interactions with ART, and which ones could be beneficial.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["A blanket denial", "TREATMENT", 0, 16], ["these products", "TREATMENT", 37, 51]]], ["Unfortunately research on the interactions between alternative medicine and antiretroviral drugs is sparse [11] .", [["alternative medicine", "TREATMENT", 51, 71], ["antiretroviral drugs", "TREATMENT", 76, 96]]], ["To be able to inform patients better, more clinical research is needed on the benefits and risks of those alternative medicines that are perceived to be beneficial by people living with HIV and AIDS.", [["HIV", "DISEASE", 186, 189], ["AIDS", "DISEASE", 194, 198], ["patients", "ORGANISM", 21, 29], ["people", "ORGANISM", 167, 173], ["patients", "SPECIES", 21, 29], ["people", "SPECIES", 167, 173], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 186, 189], ["those alternative medicines", "TREATMENT", 100, 127]]]], "PMC7299029": [["IntroductionAs of 17 April 2020, over 2 million cases of COVID-19 had been reported in over 200 countries and territories with a death toll approaching 150,000 globally.1 Economists have been quick to highlight the macroeconomic impacts and global repercussions of the COVID-19 outbreak on economies.", [["COVID-19", "CHEMICAL", 57, 65], ["death", "DISEASE", 129, 134], ["COVID", "TEST", 57, 62], ["a death", "PROBLEM", 127, 134], ["the macroeconomic impacts", "PROBLEM", 211, 236], ["the COVID", "TEST", 265, 274]]], ["This article aims to highlight the microeconomic impacts through an account of the myriad stressors that are being experienced by individuals and households.IntroductionVietnam\u2019s proximity to China increased the early risk assessment for COVID-19 spread and the resulting response has posed a heavy impact on the country\u2019s economy and supply chain.", [["the microeconomic impacts", "PROBLEM", 31, 56], ["the myriad stressors", "PROBLEM", 79, 99], ["the early risk assessment", "TEST", 208, 233], ["COVID", "TEST", 238, 243], ["myriad", "OBSERVATION_MODIFIER", 83, 89], ["stressors", "OBSERVATION", 90, 99]]], ["As the fourth most visited country in the world by Chinese tourists, Vietnam typically welcomes one-third of all its tourists from China.2 Moreover, up to 30% of Vietnam\u2019s imports are dependent on China and the suspension of seafood and agriculture exports to China has caused a massive crisis for Vietnamese farmers.34 In the last 20 years, Vietnam has undergone various transnational health threats including Severe Acute Respiratory Syndrome (SARS) and avian influenza A (H5N1, H5N6 and H1N1).5 Since then, the Vietnamese government has pooled its resources to develop a more resilient health system that builds on the experiences and learnt lessons in disease surveillance, training and outbreak response.", [["Acute Respiratory Syndrome", "DISEASE", 418, 444], ["SARS", "DISEASE", 446, 450], ["avian influenza A (H5N1, H5N6 and H1N1", "DISEASE", 456, 494], ["avian influenza A", "ORGANISM", 456, 473], ["avian influenza A", "SPECIES", 456, 473], ["H5N6", "SPECIES", 481, 485], ["a massive crisis", "PROBLEM", 277, 293], ["Severe Acute Respiratory Syndrome", "PROBLEM", 411, 444], ["SARS", "PROBLEM", 446, 450], ["avian influenza A", "PROBLEM", 456, 473], ["H5N1", "PROBLEM", 475, 479], ["learnt lessons in disease surveillance", "PROBLEM", 638, 676], ["massive", "OBSERVATION_MODIFIER", 279, 286], ["crisis", "OBSERVATION", 287, 293], ["Severe", "OBSERVATION_MODIFIER", 411, 417], ["Acute", "OBSERVATION_MODIFIER", 418, 423], ["Respiratory Syndrome", "OBSERVATION", 424, 444]]], ["Given its location and characteristics, we use Vietnam and COVID-19 as a case study to help highlight social inequality and describe the major issues that need to be addressed to mitigate the socioeconomic impacts of disease outbreaks for individuals and households.COVID-19 situation in VietnamThe Vietnamese government declared COVID-19 an epidemic on 1 February.", [["a case study", "TEST", 71, 83], ["disease outbreaks", "PROBLEM", 217, 234]]], ["Since then, the border with China has been closed, flights to and from China have ceased, and a 14-day quarantine has been instituted for people coming from severely affected areas.", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["severely affected areas", "PROBLEM", 157, 180], ["closed", "OBSERVATION", 43, 49], ["severely", "OBSERVATION_MODIFIER", 157, 165], ["affected", "OBSERVATION", 166, 174]]], ["Many public events have been cancelled and schools have been closed for almost three months.COVID-19 situation in VietnamDuring the second wave of COVID-19 starting 6 March, all returning and entering citizens and non-citizens were quarantined at military camps and repurposed facilities for at least 14 days.6 In the first wave, a village of 10,600 residents in Vinh Phuc, where 10 out of 16 cases were identified, was quarantined for 18 days6 and more hotbed villages/residential areas were quarantined subsequently.", [["COVID", "TEST", 92, 97], ["COVID", "TREATMENT", 147, 152], ["non-citizens", "TREATMENT", 214, 226]]], ["As of 17 April, there have been 268 confirmed cases of COVID-19 in Vietnam, of which 177 have been discharged from hospital after recovery.7Changing pattern in out-of-pocket expenditureIn Vietnam, individuals have felt the impact of COVID-19 first and foremost through day-to-day consumption.", [["COVID", "DISEASE", 55, 60], ["COVID", "TREATMENT", 233, 238]]], ["A sudden surge of demand for preventative goods, including hand sanitisers and face masks\u2014as illustrated in figure 1, has led to the price increase of these consumables three- to ten-fold.", [["hand", "ANATOMY", 59, 63], ["hand", "ORGANISM_SUBDIVISION", 59, 63], ["A sudden surge of demand", "PROBLEM", 0, 24], ["preventative goods", "TREATMENT", 29, 47], ["hand sanitisers", "TREATMENT", 59, 74]]], ["If a household of four people uses on average eight masks a day with each mask costing 6,000 VND (US$0.25) apiece, the family is required to spend a minimum of 1.5 million VND (US$60) a month\u2014roughly 20% of their monthly income on masks alone.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["each mask costing", "TREATMENT", 69, 86]]], ["National television has estimated that with the purchasing pattern during the initial period of the outbreak, in major cities alone: over 50 billion VND (US$2 million) could have been spent out-of-pocket (OOP) per day on masks.8Changing pattern in out-of-pocket expenditureWhile preventive recommendations such as wearing face masks and using hand sanitisers when going out may have helped in raising self-prevention and public health awareness, the need for preventative resources has greatly driven up OOP expenditure for individuals and families.Changing pattern in out-of-pocket expenditureDue to closure of schools, families have been struggling to find childcare alternatives while they are at work.", [["hand", "ANATOMY", 343, 347], ["VND", "DISEASE", 149, 152], ["face masks", "TREATMENT", 322, 332], ["hand sanitisers", "TREATMENT", 343, 358], ["preventative resources", "TREATMENT", 459, 481], ["closure", "OBSERVATION", 601, 608]]], ["Working class families who cannot perform their jobs remotely are most likely to be impacted.", [["most likely", "UNCERTAINTY", 66, 77], ["impacted", "OBSERVATION", 84, 92]]], ["After three days of taking leave to look after her son, she resorted to sending him to a neighbour\u2019s house, costing 120,000 VND (US$5.10) per day with a meal.9 An additional three months of school closure would have cost Mrs Cuc around 12 million VND (US$516)\u2014roughly half of her monthly wage would have been spent on babysitting each month.Income and productivity lossThe disruption to the nation\u2019s economic activities has resulted in a shortage of work, loss of income and financial uncertainties, particularly for informal, low-skilled and blue-collar workers.Income and productivity lossAs an attempt from the government to mitigate the economic impact of the outbreak on individuals, quarantined cases being held outside of the home are entitled to a daily food allowance of 60,000 VND (US$2.59), while those remaining at home as part of the quarantine measure receive 40,000 VND (US$1.72).10 Given that the average monthly wage in Vietnam is US$150,11 this would slash an individual\u2019s income by 2\u20133 times while remaining in quarantine and unable to work.", [["VND", "DISEASE", 124, 127], ["VND", "DISEASE", 247, 250], ["school closure", "TREATMENT", 190, 204], ["quarantined cases", "TREATMENT", 689, 706], ["productivity loss", "OBSERVATION", 352, 369], ["disruption", "OBSERVATION", 373, 383], ["productivity loss", "OBSERVATION", 574, 591]]], ["Assuming they are released after 14 days and could resume work again, social stigma directed toward people who have returned from an epidemic area could hinder their chance of returning to work promptly.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106]]], ["In such cases, the loss of income could be felt over the course of weeks or months.Income and productivity lossOther noteworthy cases of affected groups are farmers.", [["productivity loss", "OBSERVATION", 94, 111]]], ["Hundreds of hectares of land with massive unsold stocks are the results of closed borders.", [["massive unsold stocks", "TREATMENT", 34, 55], ["hectares", "OBSERVATION_MODIFIER", 12, 20], ["massive", "OBSERVATION_MODIFIER", 34, 41], ["unsold stocks", "OBSERVATION", 42, 55], ["closed", "OBSERVATION", 75, 81]]], ["This is not enough to break even, let alone to make ends meet.", [["not enough to", "UNCERTAINTY", 8, 21]]], ["The staff were given an initial four months off work and a monthly stipend of 1.5 million VND (US$65).13 This is a massive cut from their usual 8-15 million VND (US$259\u2013US$650) monthly salary.", [["VND", "DISEASE", 90, 93], ["VND", "DISEASE", 157, 160], ["massive", "OBSERVATION_MODIFIER", 115, 122], ["cut", "OBSERVATION_MODIFIER", 123, 126]]], ["According to the General Statistics Office, as of 2018, the average monthly expenditure per capita in urban setting is approximately 3.3 million VND (US$142).14 In reality, this figure is likely to be much higher for an expensive metropolitan city like Hanoi.Income and productivity lossAs a preliminary estimate, the whole country has seen 19% of businesses suspending or downsizing their operations, 98% of tourism and service workers out of work, 78% of transport and textile workers with reduced job hours or laid off, 98% of aviation workers furloughed.", [["their operations", "TREATMENT", 384, 400], ["likely to be", "UNCERTAINTY", 188, 200], ["productivity loss", "OBSERVATION", 270, 287]]], ["Overall, the conservative estimate is of 2 million out-of-work people.15Balancing public health priorities with socioeconomic stabilityIn Vietnam, what the richest person can make in an hour from their existing wealth is around 5,000 times greater than what the poorest 10 percent of the population spend on bare necessities for a whole day.16 An account of individual experiences reveals how the COVID-19 outbreak exacerbates pre-existing inequalities.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["person", "SPECIES", 164, 170], ["the COVID", "TEST", 393, 402]]], ["From the increase of OOP expenditure to the loss of income from trading restrictions and mass quarantines, Vietnam\u2019s most economically disadvantaged groups are being hit the hardest on dual fronts\u2014the disease burden itself and the respective countermeasure burden.Balancing public health priorities with socioeconomic stabilityWith the sudden competition for protective commodities, those with the access and means fare better.", [["OOP expenditure", "PROBLEM", 21, 36], ["mass quarantines", "PROBLEM", 89, 105], ["the disease burden", "PROBLEM", 197, 215], ["the respective countermeasure burden", "PROBLEM", 227, 263], ["protective commodities", "TREATMENT", 359, 381], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["disease", "OBSERVATION", 201, 208]]], ["When government provision is scarce, some people resort to purchasing overpriced consumables, adding a financial strain to their already unstable income.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48]]], ["Furthermore, many are not compensated for the lost wages during their time spent in confinement.", [["compensated", "OBSERVATION", 26, 37]]], ["Stigmatisation further impedes people\u2019s ability to work after quarantines, with employers fearing that workers could be carrying a latent form of the virus.", [["Stigmatisation", "DISEASE", 0, 14], ["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["the virus", "PROBLEM", 146, 155]]], ["These outcomes were observed during the SARS epidemic in 2003, when several individuals in Toronto, Canada lost their jobs due to their period in quarantine.17Balancing public health priorities with socioeconomic stabilityEconomic inequality is also aggravated by poverty of voice and opportunities.", [["SARS", "DISEASE", 40, 44], ["socioeconomic stability", "PROBLEM", 199, 222]]], ["Particularly, ethnic minorities, small-scale farmers, migrant workers, low-skilled labourers and women are prone to financial hardship and likely face access barriers to health services and discrimination.14 In Vietnam, health insurance is provided free to those categorised \u2018poor\u2019 based on stringent criteria, while many who are considered near-poor do not receive the same treatment.", [["women", "ORGANISM", 97, 102], ["women", "SPECIES", 97, 102], ["the same treatment", "TREATMENT", 366, 384], ["small", "OBSERVATION_MODIFIER", 33, 38]]], ["Despite being social policy beneficiaries, nearly 600,000 households were still plunged into poverty or extreme poverty due to catastrophic health expenditures in 2012.18 \u2018Medical poverty trap\u2019 is a term used to describe this phenomenon.18 With multitudes of socioeconomic and environmental factors contributing to the association, those most susceptible to diseases are typically the poorest.", [["poverty", "DISEASE", 112, 119], ["catastrophic health expenditures", "PROBLEM", 127, 159], ["Medical poverty trap", "TREATMENT", 172, 192], ["this phenomenon", "PROBLEM", 221, 236], ["socioeconomic and environmental factors", "PROBLEM", 259, 298], ["diseases", "PROBLEM", 358, 366]]], ["They suffer the most when attempting to access healthcare and are often pushed deeper into poverty and ill health.19 The COVID-19 poverty trap is shaped by access barriers to prevention, vulnerability in the face of economic disruption and financial uncertainties, and incurrence of catastrophic costs as people try to cope with the outbreak.", [["ill", "DISEASE", 103, 106], ["people", "ORGANISM", 305, 311], ["people", "SPECIES", 305, 311], ["The COVID-19 poverty trap", "TREATMENT", 117, 142], ["economic disruption", "PROBLEM", 216, 235], ["catastrophic costs", "PROBLEM", 283, 301], ["economic disruption", "OBSERVATION", 216, 235], ["catastrophic", "OBSERVATION_MODIFIER", 283, 295]]], ["Coupled with this is the mental strain instigated by loss of work, reduced income, increased costs and changes in daily routines; not to mention the anxiety associated with the outbreak itself.", [["anxiety", "DISEASE", 149, 156], ["the mental strain", "PROBLEM", 21, 38], ["increased costs", "PROBLEM", 83, 98], ["the anxiety", "PROBLEM", 145, 156]]], ["It is well known that mental stress affects the poorest part of the population hardest and contributes to the drivers of inequalities.20ConclusionWherever a new epidemic occurs, a strain on public services is inevitable.", [["mental stress", "PROBLEM", 22, 35], ["a new epidemic", "PROBLEM", 155, 169], ["public services", "TREATMENT", 190, 205], ["new", "OBSERVATION_MODIFIER", 157, 160], ["epidemic", "OBSERVATION", 161, 169]]], ["To ensure socioeconomic stability during such crises, social protection schemes (e.g. social insurance, microfinancing) must be in place to help people cope with economic uncertainties and the loss of income security.21 An interim relief package of 62 trillion VND (US$2.6 billion) has recently been rolled out by the government in the form of a three-month cash transfer scheme to people affected by the pandemic including: social policy beneficiaries, people who rendered services to the state during the revolution, the poor and near-poor, furloughed workers or those on unpaid leave during the pandemic and freelancers.13 This may go some way to mitigating the economic impact on the most vulnerable people in Vietnam.ConclusionHowever, in the case of COVID-19, the direct and indirect costs for individuals are likely to be staggering and temporary relief measures may help to some extent but are unlikely to be either socially inclusive or alleviate poverty long term.", [["pandemic", "DISEASE", 598, 606], ["people", "ORGANISM", 145, 151], ["people", "ORGANISM", 382, 388], ["people", "ORGANISM", 454, 460], ["people", "ORGANISM", 704, 710], ["people", "SPECIES", 145, 151], ["people", "SPECIES", 382, 388], ["people", "SPECIES", 454, 460], ["people", "SPECIES", 704, 710], ["socioeconomic stability", "PROBLEM", 10, 33], ["such crises", "PROBLEM", 41, 52], ["social protection schemes", "TREATMENT", 54, 79], ["An interim relief package", "TREATMENT", 220, 245], ["the pandemic and freelancers", "PROBLEM", 594, 622], ["COVID", "TEST", 756, 761], ["temporary relief measures", "TREATMENT", 844, 869], ["socioeconomic stability", "OBSERVATION_MODIFIER", 10, 33]]], ["Indeed, having in place a basic universal social protection floor at all times\u2014not just during crises\u2014is the ideal we should all strive for.22 Further quantification of the true extent of these costs may spark greater attention toward more sustainable and scalable social protection policies both within and outwith periods of public health crisis.", [["these costs", "PROBLEM", 188, 199]]]], "6df9b6f97b1f886b16d2a2304346d0dd790b3225": [["INTRODUCTIONIn an 8-year serologic study of coronavirus 229E and OC 43 in working adults, Hendley et al. (1) found that 3 per cent of all colds were serologically related to 229E infection.", [["OC", "CHEMICAL", 65, 67], ["colds", "DISEASE", 138, 143], ["infection", "DISEASE", 179, 188], ["coronavirus 229E", "ORGANISM", 44, 60], ["coronavirus", "SPECIES", 44, 55], ["serologic study", "TEST", 25, 40], ["coronavirus", "PROBLEM", 44, 55], ["all colds", "PROBLEM", 134, 143], ["229E infection", "PROBLEM", 174, 188]]], ["In a 6-year surveillance of 229E infections in young adults, Hamre and Beem (2) found 15 to 35 per cent of infections occurred during three seasons of \"high\" prevalence and 1 to 5 per cent in intervening seasons of \"low\" prevalence.", [["infections", "DISEASE", 33, 43], ["infections", "DISEASE", 107, 117], ["229E infections", "PROBLEM", 28, 43], ["infections", "PROBLEM", 107, 117], ["infections", "OBSERVATION", 107, 117]]], ["Infection also occurred in a winter and spring seasonal pattern.", [["Infection", "PROBLEM", 0, 9], ["seasonal pattern", "OBSERVATION", 47, 63]]], ["Similar infection rates and seasonal distributions have been demonstrated in other adult populations (3) (4) (5) .", [["infection", "DISEASE", 8, 17], ["Similar infection rates", "PROBLEM", 0, 23], ["seasonal distributions", "PROBLEM", 28, 50], ["infection", "OBSERVATION", 8, 17], ["seasonal distributions", "OBSERVATION", 28, 50], ["adult", "OBSERVATION_MODIFIER", 83, 88], ["populations", "OBSERVATION_MODIFIER", 89, 100]]], ["Confirmation and extension of these studies to include groups of children have been limited (4, 5) .INTRODUCTIONAssay procedures for 229E antibodies have not been entirely satisfactory.", [["children", "ORGANISM", 65, 73], ["229E antibodies", "GENE_OR_GENE_PRODUCT", 133, 148], ["229E antibodies", "PROTEIN", 133, 148], ["children", "SPECIES", 65, 73], ["these studies", "TEST", 30, 43], ["INTRODUCTIONAssay procedures", "TREATMENT", 100, 128], ["229E antibodies", "TEST", 133, 148]]], ["The complement fixation (CF) test has been used for serodiagnosis, but it is not recommended for serosurveys since 229E CF antibodies are relatively short-lived (4) .", [["229E CF antibodies", "PROTEIN", 115, 133], ["The complement fixation (CF) test", "TEST", 0, 33], ["serodiagnosis", "TEST", 52, 65], ["serosurveys", "TEST", 97, 108], ["229E CF antibodies", "TEST", 115, 133], ["fixation", "OBSERVATION", 15, 23]]], ["Neutralizing antibodies persist longer, but the examination of large numbers of sera by neutralization (NT) test in cell cultures is tedious (6) .", [["sera", "ANATOMY", 80, 84], ["cell cultures", "ANATOMY", 116, 129], ["sera", "ORGANISM_SUBSTANCE", 80, 84], ["cell cultures", "CELL", 116, 129], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["cell cultures", "CELL_LINE", 116, 129], ["Neutralizing antibodies", "TEST", 0, 23], ["the examination", "TEST", 44, 59], ["neutralization (NT) test in cell cultures", "TEST", 88, 129], ["large", "OBSERVATION_MODIFIER", 63, 68]]], ["In an earlier report (7) we described the development of an indirect hemagglutination (IHA) test for 229E antibodies.", [["229E antibodies", "GENE_OR_GENE_PRODUCT", 101, 116], ["229E antibodies", "PROTEIN", 101, 116], ["an indirect hemagglutination (IHA) test", "PROBLEM", 57, 96], ["229E antibodies", "TEST", 101, 116]]], ["The test was shown to be sensitive SEROEPIDEMIOLOGIC SURVEY OF CORONAV1RUS 239 and specific, and the results closely parallel those obtained in the NT test.INTRODUCTIONIn this report we describe the application of the IHA test for a seroepidemiologic study of the role of 229E in infections occurring in a children's population over an 8-year period.", [["infections", "DISEASE", 280, 290], ["children", "ORGANISM", 306, 314], ["children", "SPECIES", 306, 314], ["The test", "TEST", 0, 8], ["CORONAV1RUS", "TEST", 63, 74], ["the NT test", "TEST", 144, 155], ["the IHA test", "TEST", 214, 226], ["a seroepidemiologic study", "TEST", 231, 256], ["infections", "PROBLEM", 280, 290], ["infections", "OBSERVATION", 280, 290]]], ["The number and seasonal distribution of illnesses and infections, antibody prevalence, the relation of antibody to protection, and the clinical syndrome were studied.MATERIAL AND METHODSStudy population.", [["infections", "DISEASE", 54, 64], ["illnesses", "PROBLEM", 40, 49], ["infections", "PROBLEM", 54, 64], ["antibody prevalence", "TEST", 66, 85], ["antibody to protection", "TREATMENT", 103, 125], ["the clinical syndrome", "PROBLEM", 131, 152], ["seasonal", "OBSERVATION_MODIFIER", 15, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["illnesses", "OBSERVATION", 40, 49], ["infections", "OBSERVATION", 54, 64]]], ["A longitudinal survey of respiratory illness was conducted from 1960 to 1968 in a church-sponsored children's home in the Atlanta area.", [["respiratory illness", "DISEASE", 25, 44], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["respiratory illness", "PROBLEM", 25, 44], ["respiratory illness", "OBSERVATION", 25, 44]]], ["This population has been described in detail in previous studies (8) .", [["previous studies", "TEST", 48, 64]]], ["For each year-, the total number of children, median age, percentage of turnover, and the number and percentage of children from the original study group are shown in table 1.MATERIAL AND METHODSCollection of specimens.", [["specimens", "ANATOMY", 209, 218], ["children", "ORGANISM", 36, 44], ["children", "ORGANISM", 115, 123], ["children", "SPECIES", 36, 44], ["children", "SPECIES", 115, 123], ["METHODSCollection of specimens", "TEST", 188, 218]]], ["All children with any symptoms of respiratory illness were sent by housemothers to the Home clinic for examination by the attending physician who recorded all signs and symptoms on a standard form.", [["respiratory", "ANATOMY", 34, 45], ["respiratory illness", "DISEASE", 34, 53], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["any symptoms", "PROBLEM", 18, 30], ["respiratory illness", "PROBLEM", 34, 53], ["examination", "TEST", 103, 114], ["symptoms", "PROBLEM", 169, 177]]], ["Acute and convalescent blood specimens were collected 2 to 3 weeks apart.", [["blood specimens", "ANATOMY", 23, 38], ["blood specimens", "ORGANISM_SUBSTANCE", 23, 38], ["Acute and convalescent blood specimens", "PROBLEM", 0, 38]]], ["Control sera were collected from all children three times a year during the first 2 years of this study.", [["sera", "ANATOMY", 8, 12], ["sera", "ORGANISM_SUBSTANCE", 8, 12], ["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["this study", "TEST", 93, 103]]], ["At least twice yearly collections were made in succeeding years.MATERIAL AND METHODSVirus.", [["collections", "OBSERVATION", 22, 33]]], ["The coronavirus strain 229E which had been originally isolated in human embryonic kidney cell culture and then passaged in WI-38 cells was used in this study (9) .MATERIAL AND METHODSAntigen production.", [["embryonic kidney cell culture", "ANATOMY", 72, 101], ["WI-38 cells", "ANATOMY", 123, 134], ["coronavirus strain 229E", "ORGANISM", 4, 27], ["human", "ORGANISM", 66, 71], ["embryonic kidney cell culture", "CELL", 72, 101], ["WI-38 cells", "CELL", 123, 134], ["human embryonic kidney cell culture", "CELL_LINE", 66, 101], ["WI-38 cells", "CELL_LINE", 123, 134], ["coronavirus", "SPECIES", 4, 15], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["The coronavirus strain", "PROBLEM", 0, 22], ["human embryonic kidney cell culture", "TEST", 66, 101], ["this study", "TEST", 147, 157], ["coronavirus strain", "OBSERVATION", 4, 22], ["kidney", "ANATOMY", 82, 88], ["cell culture", "OBSERVATION", 89, 101], ["METHODSAntigen production", "OBSERVATION", 176, 201]]], ["The preparation of antigen for the IHA test has been described in detail elsewhere (7) .", [["the IHA test", "TEST", 31, 43]]], ["Briefly, RU-1 cells (diploid human fetal lung fibroblasts) were grown in 32-oz (960-ml) bottles with Eagle's minimum essential medium (MEM) containing 10 per cent fetal calf serum and aureomycin (25 Mg/100 ml) at 35 C. When monolayers were complete, two-wash cycles were performed with serum-free Eagle's MEM to reduce calf serum proteins.", [["RU-1 cells", "ANATOMY", 9, 19], ["fetal lung fibroblasts", "ANATOMY", 35, 57], ["fetal calf serum", "ANATOMY", 163, 179], ["monolayers", "ANATOMY", 224, 234], ["serum", "ANATOMY", 286, 291], ["serum", "ANATOMY", 324, 329], ["aureomycin", "CHEMICAL", 184, 194], ["Mg", "CHEMICAL", 199, 201], ["aureomycin", "CHEMICAL", 184, 194], ["Mg", "CHEMICAL", 199, 201], ["RU-1 cells", "CELL", 9, 19], ["human", "ORGANISM", 29, 34], ["fetal lung fibroblasts", "CELL", 35, 57], ["calf", "ORGANISM", 169, 173], ["serum", "ORGANISM_SUBSTANCE", 174, 179], ["aureomycin", "SIMPLE_CHEMICAL", 184, 194], ["monolayers", "CELL", 224, 234], ["serum", "ORGANISM_SUBSTANCE", 286, 291], ["calf", "ORGANISM", 319, 323], ["serum", "ORGANISM_SUBSTANCE", 324, 329], ["RU-1 cells", "CELL_LINE", 9, 19], ["diploid human fetal lung fibroblasts", "CELL_TYPE", 21, 57], ["calf serum proteins", "PROTEIN", 319, 338], ["human", "SPECIES", 29, 34], ["calf", "SPECIES", 169, 173], ["calf", "SPECIES", 319, 323], ["human", "SPECIES", 29, 34], ["diploid human fetal lung fibroblasts", "PROBLEM", 21, 57], ["Eagle's minimum essential medium (MEM)", "TREATMENT", 101, 139], ["aureomycin", "TREATMENT", 184, 194], ["serum", "TEST", 286, 291], ["calf serum proteins", "PROBLEM", 319, 338], ["lung", "ANATOMY", 41, 45], ["fetal calf", "ANATOMY", 163, 173]]], ["The cells were then inoculated with 229E, 20 ml of serum-free Eagle's MEM were added, and incubation was continued.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 51, 56], ["MEM", "CHEMICAL", 70, 73], ["cells", "CELL", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["MEM", "ORGANISM_SUBSTANCE", 70, 73], ["serum", "TEST", 51, 56], ["Eagle's MEM", "TREATMENT", 62, 73], ["incubation", "TREATMENT", 90, 100]]], ["When minimal cytopathic effect was detected, all but 2-3 ml of medium was decanted, and the cells were frozen at -70 C. The bottles were frozen and thawed three times, the contents were centrifuged lightly, and the supernatant fluid was collected and stored at -70 C.MATERIAL AND METHODSAntisera production.", [["cells", "ANATOMY", 92, 97], ["supernatant fluid", "ANATOMY", 215, 232], ["cells", "CELL", 92, 97], ["minimal cytopathic effect", "PROBLEM", 5, 30], ["the cells", "TEST", 88, 97], ["the supernatant fluid", "TEST", 211, 232], ["minimal", "OBSERVATION_MODIFIER", 5, 12], ["cytopathic", "OBSERVATION_MODIFIER", 13, 23]]], ["Immune sera were prepared in New Zealand White rabbits by subcutaneous inoculations of partially pu- 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968 1968 All sera had been previously tested by CF and/or hemagglutination inhibition for diagnostic rises in antibody titer to influenza A and B, parainfluenza types 1, 2 and 3, adenovirus, mumps virus, respiratory syncytial virus, herpesvirus, Mycoplasma pneumoniae, and coronavirus OC 43.", [["sera", "ANATOMY", 7, 11], ["subcutaneous", "ANATOMY", 58, 70], ["sera", "ANATOMY", 190, 194], ["pu- 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968", "CHEMICAL", 97, 180], ["parainfluenza", "DISEASE", 324, 337], ["mumps virus", "DISEASE", 368, 379], ["respiratory syncytial virus", "DISEASE", 381, 408], ["Mycoplasma pneumoniae", "DISEASE", 423, 444], ["OC", "CHEMICAL", 462, 464], ["Immune sera", "ORGANISM_SUBSTANCE", 0, 11], ["rabbits", "ORGANISM", 47, 54], ["sera", "ORGANISM_SUBSTANCE", 190, 194], ["influenza A", "ORGANISM", 305, 316], ["B", "ORGANISM", 321, 322], ["parainfluenza types 1", "ORGANISM", 324, 345], ["3", "GENE_OR_GENE_PRODUCT", 353, 354], ["adenovirus", "ORGANISM", 356, 366], ["mumps virus", "ORGANISM", 368, 379], ["respiratory syncytial virus", "ORGANISM", 381, 408], ["herpesvirus", "ORGANISM", 410, 421], ["Mycoplasma pneumoniae", "ORGANISM", 423, 444], ["rabbits", "SPECIES", 47, 54], ["parainfluenza", "SPECIES", 324, 337], ["mumps virus", "SPECIES", 368, 379], ["respiratory syncytial virus", "SPECIES", 381, 408], ["Mycoplasma pneumoniae", "SPECIES", 423, 444], ["coronavirus", "SPECIES", 450, 461], ["pu- 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968 1968", "SPECIES", 97, 185], ["influenza A", "SPECIES", 305, 316], ["mumps virus", "SPECIES", 368, 379], ["respiratory syncytial virus", "SPECIES", 381, 408], ["Mycoplasma pneumoniae", "SPECIES", 423, 444], ["Immune sera", "TREATMENT", 0, 11], ["New Zealand White rabbits", "TREATMENT", 29, 54], ["All sera", "TEST", 186, 194], ["hemagglutination inhibition", "TEST", 235, 262], ["diagnostic rises", "TEST", 267, 283], ["antibody titer", "TEST", 287, 301], ["influenza A and B, parainfluenza types", "TEST", 305, 343], ["adenovirus", "PROBLEM", 356, 366], ["mumps virus", "PROBLEM", 368, 379], ["respiratory syncytial virus", "PROBLEM", 381, 408], ["herpesvirus", "PROBLEM", 410, 421], ["Mycoplasma pneumoniae", "PROBLEM", 423, 444], ["coronavirus OC", "PROBLEM", 450, 464], ["respiratory syncytial", "ANATOMY", 381, 402], ["Mycoplasma pneumoniae", "OBSERVATION", 423, 444]]], ["In this study, sera were tested only for IHA antibody to coronavirus 229E.", [["sera", "ANATOMY", 15, 19], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["coronavirus 229E", "ORGANISM", 57, 73], ["IHA antibody", "PROTEIN", 41, 53], ["coronavirus 229E", "PROTEIN", 57, 73], ["coronavirus", "SPECIES", 57, 68], ["coronavirus 229E", "SPECIES", 57, 73], ["this study", "TEST", 3, 13], ["sera", "TEST", 15, 19], ["IHA antibody", "PROBLEM", 41, 53], ["coronavirus", "PROBLEM", 57, 68]]], ["The CF test was not performed for 229E because of frequency of serum anti-complementary activity which was probably related to length of storage and previous usage.MATERIAL AND METHODSThe IHA test has been previously described (7) .", [["serum", "ANATOMY", 63, 68], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["The CF test", "TEST", 0, 11], ["serum anti-complementary activity", "PROBLEM", 63, 96], ["METHODSThe IHA test", "TEST", 177, 196], ["probably related to", "UNCERTAINTY", 107, 126]]], ["The test was performed on microtiter \"U\" plates.", [["The test", "TEST", 0, 8]]], ["A 0.05 ml volume of 1:150 dilution of normal horse serum in phosphate-buffered saline, pH 7.2, was used as the diluent.", [["serum", "ANATOMY", 51, 56], ["phosphate", "CHEMICAL", 60, 69], ["phosphate", "CHEMICAL", 60, 69], ["horse", "ORGANISM", 45, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 60, 85], ["horse", "SPECIES", 45, 50], ["horse", "SPECIES", 45, 50], ["A 0.05 ml volume", "TREATMENT", 0, 16], ["phosphate-buffered saline", "TREATMENT", 60, 85], ["pH", "TEST", 87, 89]]], ["Each test serum was titrated in 0.05-ml volumes in twofold dilutions beginning with a 1:10 dilution.", [["serum", "ANATOMY", 10, 15], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["Each test serum", "TEST", 0, 15]]], ["Controls consisted of 1) the first four dilutions of each serum plus tannic acidtreated unsensitized erythrocytes, 2) sensitized erythrocytes plus diluent, and 3) 229E rabbit antiserum.", [["serum", "ANATOMY", 58, 63], ["erythrocytes", "ANATOMY", 101, 113], ["erythrocytes", "ANATOMY", 129, 141], ["tannic", "CHEMICAL", 69, 75], ["tannic", "CHEMICAL", 69, 75], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["tannic", "SIMPLE_CHEMICAL", 69, 75], ["erythrocytes", "CELL", 101, 113], ["erythrocytes", "CELL", 129, 141], ["rabbit", "ORGANISM", 168, 174], ["antiserum", "ORGANISM_SUBSTANCE", 175, 184], ["tannic acidtreated unsensitized erythrocytes", "CELL_LINE", 69, 113], ["sensitized erythrocytes", "CELL_TYPE", 118, 141], ["rabbit", "SPECIES", 168, 174], ["rabbit", "SPECIES", 168, 174], ["each serum", "TEST", 53, 63], ["tannic acidtreated unsensitized erythrocytes", "TREATMENT", 69, 113], ["sensitized erythrocytes plus diluent", "TREATMENT", 118, 154], ["229E rabbit antiserum", "TEST", 163, 184]]], ["The plates were shaken and permitted to stand for 3 to 4 hours at room temperature before erythrocyte-setting patterns were read.", [["erythrocyte", "ANATOMY", 90, 101], ["erythrocyte", "CELL", 90, 101]]], ["A fourfold or greater increase in antibody titer was considered to be indicative of infection.", [["infection", "DISEASE", 84, 93], ["A fourfold or greater increase in antibody titer", "PROBLEM", 0, 48], ["infection", "PROBLEM", 84, 93], ["greater", "OBSERVATION_MODIFIER", 14, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["antibody titer", "OBSERVATION", 34, 48], ["considered to be indicative of", "UNCERTAINTY", 53, 83], ["infection", "OBSERVATION", 84, 93]]], ["All sera were inactivated at 56 C for 30 min.RESULTSIncidence of respiratory illness and seroresponse to coronavirus.", [["sera", "ANATOMY", 4, 8], ["respiratory", "ANATOMY", 65, 76], ["respiratory illness", "DISEASE", 65, 84], ["coronavirus", "DISEASE", 105, 116], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["coronavirus", "ORGANISM", 105, 116], ["All sera", "TEST", 0, 8], ["respiratory illness", "PROBLEM", 65, 84], ["seroresponse", "PROBLEM", 89, 101], ["coronavirus", "PROBLEM", 105, 116], ["respiratory illness", "OBSERVATION", 65, 84]]], ["Over the 8-year period 1477 respiratory illnesses were reported; 229E IHA sero-responses were demonstrated for 63.", [["respiratory illnesses", "DISEASE", 28, 49], ["respiratory illnesses", "PROBLEM", 28, 49]]], ["(None of the 63 illnesses could be related by isolation and/or seroresponse to any of the other respiratory disease agents included in previous studies.)", [["respiratory disease", "DISEASE", 96, 115], ["the other respiratory disease agents", "PROBLEM", 86, 122], ["previous studies", "TEST", 135, 151]]], ["An additional 105 sero-responses were detected by fourfold or greater increases in antibody titer between control bleedings.", [["bleedings", "DISEASE", 114, 123], ["antibody titer between control bleedings", "PROBLEM", 83, 123], ["greater", "OBSERVATION_MODIFIER", 62, 69], ["increases", "OBSERVATION_MODIFIER", 70, 79], ["antibody titer", "OBSERVATION", 83, 97]]], ["The total number of seroresponses was 168 (table 2) .", [["seroresponses", "TEST", 20, 33], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["Thirty-one of the 112 were associated with reported illnesses.", [["illnesses", "OBSERVATION", 52, 61]]], ["The remainder (81) represented either unreported disease or subclinical infections.", [["infections", "DISEASE", 72, 82], ["unreported disease", "PROBLEM", 38, 56], ["subclinical infections", "PROBLEM", 60, 82], ["subclinical", "OBSERVATION_MODIFIER", 60, 71], ["infections", "OBSERVATION", 72, 82]]], ["Fifty-six sero-responses were found throughout the other 5 years of the study.", [["the study", "TEST", 68, 77]]], ["Of these, 32 occurred among children who reported respiratory illness.", [["respiratory", "ANATOMY", 50, 61], ["respiratory illness", "DISEASE", 50, 69], ["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36], ["respiratory illness", "PROBLEM", 50, 69], ["respiratory illness", "OBSERVATION", 50, 69]]], ["Forty-eight sero- 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968 1968 responses were found in the fall-winterspring quarters during years other than those previously mentioned.", [["sero- 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968 1968", "SPECIES", 12, 102]]], ["Only 10 seroresponses were found in the summer quarter during the entire study, but 6 of these were in children who reported illness.", [["illness", "DISEASE", 125, 132], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["the entire study", "TEST", 62, 78], ["illness", "PROBLEM", 125, 132]]], ["The 229E sero-responses which could be associated with illness accounted for 5 per cent of the total illnesses seen in the fall quarter, 4 per cent in the winter and spring quarters and 3 per cent in the summer quarter.", [["illness", "DISEASE", 55, 62], ["illness", "PROBLEM", 55, 62], ["the total illnesses", "PROBLEM", 91, 110]]], ["Although the largest number of seroresponses occurred during the three outbreaks mentioned above, percentages for other years are worth noting.", [["largest", "OBSERVATION_MODIFIER", 13, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["seroresponses", "OBSERVATION", 31, 44]]], ["Strain 299E accounted for 9 per cent of the total respiratory illness in the winter quarters of 1963-1964 and 1966-1967 Evidence of preexisting antibody.", [["respiratory illness", "DISEASE", 50, 69], ["the total respiratory illness", "PROBLEM", 40, 69], ["preexisting antibody", "PROBLEM", 132, 152], ["preexisting", "OBSERVATION_MODIFIER", 132, 143], ["antibody", "OBSERVATION", 144, 152]]], ["Of 168 persons with sero-response in the population, 59 (35 per cent) had preexisting antibody titers of 10 or greater in two consecutive serum specimens collected before the rise in antibody titer (table 3) .", [["serum specimens", "ANATOMY", 138, 153], ["persons", "ORGANISM", 7, 14], ["serum specimens", "ORGANISM_SUBSTANCE", 138, 153], ["persons", "SPECIES", 7, 14], ["sero-response", "TEST", 20, 33], ["preexisting antibody titers", "TEST", 74, 101], ["serum specimens", "TEST", 138, 153], ["antibody titer", "TEST", 183, 197]]], ["Preexisting antibody was less frequent in the younger age group (5-9) than in the older age group (15) (16) (17) (18) (19) .", [["Preexisting antibody", "PROBLEM", 0, 20], ["antibody", "OBSERVATION", 12, 20], ["less frequent", "OBSERVATION_MODIFIER", 25, 38]]], ["Almost a third of the 10-to 14-year-old group, which had the highest number of sero-responses, had preexisting antibody.", [["preexisting antibody", "PROBLEM", 99, 119]]], ["Thirteen of the 59 children with sero-responses to 229E had preexisting antibody titers of 20 or greater.RESULTSClinical syndrome.", [["229E", "CHEMICAL", 51, 55], ["RESULTSClinical syndrome", "DISEASE", 105, 129], ["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27], ["sero-responses", "TEST", 33, 47], ["preexisting antibody titers", "TEST", 60, 87], ["RESULTSClinical syndrome", "PROBLEM", 105, 129], ["syndrome", "OBSERVATION", 121, 129]]], ["Clinical histories were available for 61 of the 63 children with reported respiratory illnesses (table 4).", [["respiratory", "ANATOMY", 74, 85], ["respiratory illnesses", "DISEASE", 74, 95], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["reported respiratory illnesses", "PROBLEM", 65, 95]]], ["The major presenting complaints were sore throat (66 per cent), coryza (52 per cent), cough (43 per cent), and fever (21 per cent).", [["sore throat", "DISEASE", 37, 48], ["coryza", "DISEASE", 64, 70], ["cough", "DISEASE", 86, 91], ["fever", "DISEASE", 111, 116], ["sore throat", "PROBLEM", 37, 48], ["coryza", "PROBLEM", 64, 70], ["cough", "PROBLEM", 86, 91], ["fever", "PROBLEM", 111, 116]]], ["The predominant physical findings were pharyngeal injection (82 per cent), coryza (64 per cent), fever >37.6 < 39 C (34 per cent), fever >39 C (8 per cent), and cervical adenitis (30 per cent).", [["pharyngeal", "ANATOMY", 39, 49], ["cervical", "ANATOMY", 161, 169], ["coryza", "DISEASE", 75, 81], ["fever", "DISEASE", 97, 102], ["fever", "DISEASE", 131, 136], ["adenitis", "DISEASE", 170, 178], ["pharyngeal", "ORGANISM_SUBDIVISION", 39, 49], ["cervical", "ORGAN", 161, 169], ["pharyngeal injection", "TREATMENT", 39, 59], ["coryza", "TEST", 75, 81], ["fever", "PROBLEM", 97, 102], ["fever", "PROBLEM", 131, 136], ["cervical adenitis", "PROBLEM", 161, 178], ["pharyngeal", "ANATOMY", 39, 49], ["cervical", "ANATOMY", 161, 169], ["adenitis", "OBSERVATION", 170, 178]]], ["No statistically significant differences were found in the * Fourfold or greater rises in IHA titer between paired acute and convalescent sera, t > 10 in two consecutive serum specimens prior to sero-response.", [["sera", "ANATOMY", 138, 142], ["serum specimens", "ANATOMY", 170, 185], ["IHA", "SIMPLE_CHEMICAL", 90, 93], ["sera", "ORGANISM_SUBSTANCE", 138, 142], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["IHA titer", "TEST", 90, 99], ["paired acute", "PROBLEM", 108, 120], ["convalescent sera", "TEST", 125, 142], ["serum specimens", "TEST", 170, 185], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["differences", "OBSERVATION", 29, 40], ["acute", "OBSERVATION_MODIFIER", 115, 120]]], ["X No. of children in parentheses. clinical aspects of respiratory illness in children with or without preexisting antibody to 229E.", [["respiratory", "ANATOMY", 54, 65], ["respiratory illness", "DISEASE", 54, 73], ["children", "ORGANISM", 9, 17], ["children", "ORGANISM", 77, 85], ["229E", "PROTEIN", 126, 130], ["children", "SPECIES", 9, 17], ["children", "SPECIES", 77, 85], ["respiratory illness", "PROBLEM", 54, 73], ["preexisting antibody", "PROBLEM", 102, 122], ["respiratory illness", "OBSERVATION", 54, 73]]], ["DISCUSSION The development of the IHA test for 229E enabled us to conduct a seroepidemiologic study with a population previously investigated by the hemagglutination inhibition technique for evidence of coronavirus OC 43 infections (10) .RESULTSIHA antibody sero-responses to coronavirus 229E accounted for 63 (4 per cent) of the 1477 respiratory illnesses reported.", [["OC", "CHEMICAL", 215, 217], ["infections", "DISEASE", 221, 231], ["coronavirus 229E", "DISEASE", 276, 292], ["respiratory illnesses", "DISEASE", 335, 356], ["coronavirus", "ORGANISM", 203, 214], ["coronavirus 229E", "ORGANISM", 276, 292], ["coronavirus", "SPECIES", 276, 287], ["coronavirus OC 43", "SPECIES", 203, 220], ["coronavirus 229E", "SPECIES", 276, 292], ["the IHA test", "TEST", 30, 42], ["a seroepidemiologic study", "TEST", 74, 99], ["the hemagglutination inhibition technique", "TEST", 145, 186], ["coronavirus OC 43 infections", "PROBLEM", 203, 231], ["RESULTSIHA antibody", "TEST", 238, 257], ["coronavirus", "PROBLEM", 276, 287], ["respiratory illnesses", "PROBLEM", 335, 356]]], ["Twenty-nine of the 63 reported illnesses were found in three distinct outbreaks occurring in the fall, winter, and spring quarters of the years [1961] [1962] [1965] [1966] and the fall and winter of 1968.", [["distinct", "OBSERVATION_MODIFIER", 61, 69], ["outbreaks", "OBSERVATION", 70, 79]]], ["Another 80 sero-responses were found in children who were asymptomatic or did not report illness during these same periods.", [["illness", "DISEASE", 89, 96], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["illness", "PROBLEM", 89, 96]]], ["In this study, unlike previous studies, a large number of sero-responses were found during the fall quarters.", [["this study", "TEST", 3, 13], ["previous studies", "TEST", 22, 38], ["large", "OBSERVATION_MODIFIER", 42, 47]]], ["In the fall of the year 1961-1962, for example, diagnostic 229E antibody rises were detected in 12 per cent of all the reported illnesses.RESULTSThe nature of the 229E outbreaks was cyclical and closely resembled that of the OC 43.", [["OC", "CHEMICAL", 225, 227], ["229E antibody", "PROTEIN", 59, 72], ["diagnostic 229E antibody rises", "TEST", 48, 78], ["illnesses", "OBSERVATION", 128, 137]]], ["Outbreaks of OC 43 were found in our previous study in the years 1960-1961, 1964-1965, and 1966-1967 .", [["OC", "CHEMICAL", 13, 15]]], ["Low numbers of 229E sero-responses were also found during periods of high OC 43 prevalence.", [["OC", "CHEMICAL", 74, 76], ["229E", "GENE_OR_GENE_PRODUCT", 15, 19]]], ["This has been observed by others as well (1, 5) .RESULTSIn our study, the combined total of 229E (4 per cent) and OC 43 (3 per cent) infections accounted for 7 per cent of all illness reported over an 8-year period.", [["OC", "CHEMICAL", 114, 116], ["infections", "DISEASE", 133, 143], ["illness", "DISEASE", 176, 183], ["our study", "TEST", 59, 68], ["OC", "TEST", 114, 116], ["infections", "PROBLEM", 133, 143], ["all illness", "PROBLEM", 172, 183]]], ["This was higher than the 4 per cent found by Hendley et al. (1) over a comparable length of time.", [["higher", "OBSERVATION_MODIFIER", 9, 15]]], ["However, they found that OC 43 and 229E accounted for 8 per cent of all respiratory illness, if seasons other than spring and winter were excluded.", [["respiratory", "ANATOMY", 72, 83], ["OC 43 and 229E", "CHEMICAL", 25, 39], ["respiratory illness", "DISEASE", 72, 91], ["all respiratory illness", "PROBLEM", 68, 91], ["respiratory", "ANATOMY", 72, 83], ["illness", "OBSERVATION", 84, 91]]], ["The comparative ages of the populations under study could also have accounted for these differences in findings.RESULTSThe prevalence of 229E IHA antibody in the total population stayed relatively constant over the 8-year period.", [["229E IHA antibody", "PROTEIN", 137, 154], ["229E IHA antibody", "TEST", 137, 154], ["constant", "OBSERVATION_MODIFIER", 197, 205]]], ["Previous studies have demonstrated the persistence of NT antibody to 229E, and a close relationship has been noted between IHA and NT antibody for 229E (7) or for other animal coronaviruses (11) .", [["NT antibody", "GENE_OR_GENE_PRODUCT", 54, 65], ["NT antibody", "GENE_OR_GENE_PRODUCT", 131, 142], ["NT antibody", "PROTEIN", 54, 65], ["229E", "PROTEIN", 69, 73], ["NT antibody", "PROTEIN", 131, 142], ["Previous studies", "TEST", 0, 16], ["NT antibody", "PROBLEM", 54, 65], ["IHA", "TEST", 123, 126], ["NT antibody", "TEST", 131, 142], ["other animal coronaviruses", "PROBLEM", 163, 189]]], ["Despite the presence of such antibody, two infections with 229E occurred in 20 individuals during our study.", [["infections", "DISEASE", 43, 53], ["such antibody", "PROBLEM", 24, 37], ["two infections", "PROBLEM", 39, 53], ["our study", "TEST", 98, 107], ["infections", "OBSERVATION", 43, 53]]], ["Reinfection with coronaviruses had also been noted in previous studies (1, 10, 12) .RESULTSPrevious studies of experimental and natural infections with human and animal coronaviruses have revealed heterologous antibody responses (13) (14) (15) (16) (17) (18) .", [["infections", "DISEASE", 136, 146], ["coronaviruses", "ORGANISM", 17, 30], ["human", "ORGANISM", 152, 157], ["animal coronaviruses", "ORGANISM", 162, 182], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["Reinfection", "PROBLEM", 0, 11], ["coronaviruses", "PROBLEM", 17, 30], ["previous studies", "TEST", 54, 70], ["RESULTSPrevious studies", "TEST", 84, 107], ["experimental and natural infections", "PROBLEM", 111, 146], ["human and animal coronaviruses", "PROBLEM", 152, 182], ["heterologous antibody responses", "TEST", 197, 228], ["coronaviruses", "OBSERVATION", 17, 30], ["infections", "OBSERVATION", 136, 146]]], ["In our earlier study (7) of antibodies to 229E and OC 43 in human sera, simultaneous seroresponses were not found among 103 of 104 paired sera with a diagnostic antibody rise to either virus, despite the fact that over 30 per cent of these pairs had preexisting antibody to the other virus.", [["sera", "ANATOMY", 66, 70], ["sera", "ANATOMY", 138, 142], ["OC", "CHEMICAL", 51, 53], ["229E", "GENE_OR_GENE_PRODUCT", 42, 46], ["OC 43", "GENE_OR_GENE_PRODUCT", 51, 56], ["human", "ORGANISM", 60, 65], ["sera", "ORGANISM_SUBSTANCE", 66, 70], ["sera", "ORGANISM_SUBSTANCE", 138, 142], ["antibodies", "PROTEIN", 28, 38], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["our earlier study", "TEST", 3, 20], ["antibodies", "TEST", 28, 38], ["OC", "TEST", 51, 53], ["human sera", "TEST", 60, 70], ["simultaneous seroresponses", "TEST", 72, 98], ["a diagnostic antibody", "TEST", 148, 169], ["virus", "PROBLEM", 185, 190], ["preexisting antibody to the other virus", "PROBLEM", 250, 289]]], ["Hendley et al.RESULTS(1) also reported that antibody increases to either of these two coronaviruses were not accompanied by an increase in antibody to the other.", [["coronaviruses", "ORGANISM", 86, 99], ["antibody increases", "PROBLEM", 44, 62], ["these two coronaviruses", "PROBLEM", 76, 99], ["an increase in antibody", "PROBLEM", 124, 147], ["coronaviruses", "OBSERVATION", 86, 99], ["increase", "OBSERVATION_MODIFIER", 127, 135]]], ["Our observations apply only to 229E and OC 43.", [["OC", "CHEMICAL", 40, 42]]], ["Heterotypic antibody rises caused by unknown or uncharacterized strains cannot be excluded.", [["Heterotypic antibody", "PROTEIN", 0, 20], ["Heterotypic antibody rises", "PROBLEM", 0, 26], ["uncharacterized strains", "PROBLEM", 48, 71], ["antibody rises", "OBSERVATION", 12, 26], ["uncharacterized strains", "OBSERVATION", 48, 71], ["cannot be excluded", "UNCERTAINTY", 72, 90]]], ["Our findings, as well as those of other investigators, must be interpreted with caution, particularly in view of the absence of isolation of etiologic agents responsible for tht illness, the lack of comparable serologic methods for assaying 229E and OC 43 antibodies, and the present knowledge of the serologic interrelationships of other possible human and animal coronaviruses.RESULTSIn previous clinical studies reported by Kapikian et al. (3) , the chief complaint of patients shedding 229E-like virus was coryza or nasal congestion followed by sneezing, sore throat, headache, cough, muscular aches, chills and fever in that order.", [["nasal", "ANATOMY", 520, 525], ["muscular", "ANATOMY", 589, 597], ["nasal congestion", "DISEASE", 520, 536], ["sneezing", "DISEASE", 549, 557], ["sore throat", "DISEASE", 559, 570], ["headache", "DISEASE", 572, 580], ["cough", "DISEASE", 582, 587], ["muscular aches", "DISEASE", 589, 603], ["chills", "DISEASE", 605, 611], ["fever", "DISEASE", 616, 621], ["OC 43 antibodies", "GENE_OR_GENE_PRODUCT", 250, 266], ["human", "ORGANISM", 348, 353], ["animal coronaviruses", "ORGANISM", 358, 378], ["patients", "ORGANISM", 472, 480], ["229E-like virus", "ORGANISM", 490, 505], ["nasal", "ORGANISM_SUBDIVISION", 520, 525], ["229E", "PROTEIN", 241, 245], ["OC 43 antibodies", "PROTEIN", 250, 266], ["human", "SPECIES", 348, 353], ["patients", "SPECIES", 472, 480], ["human", "SPECIES", 348, 353], ["etiologic agents", "TREATMENT", 141, 157], ["tht illness", "PROBLEM", 174, 185], ["serologic methods", "TEST", 210, 227], ["OC 43 antibodies", "TEST", 250, 266], ["human and animal coronaviruses", "PROBLEM", 348, 378], ["clinical studies", "TEST", 398, 414], ["patients shedding 229E", "PROBLEM", 472, 494], ["virus", "PROBLEM", 500, 505], ["coryza", "PROBLEM", 510, 516], ["nasal congestion", "PROBLEM", 520, 536], ["sneezing", "PROBLEM", 549, 557], ["sore throat", "PROBLEM", 559, 570], ["headache", "PROBLEM", 572, 580], ["cough", "PROBLEM", 582, 587], ["muscular aches", "PROBLEM", 589, 603], ["chills", "PROBLEM", 605, 611], ["fever", "PROBLEM", 616, 621], ["coronaviruses", "OBSERVATION", 365, 378], ["nasal", "ANATOMY", 520, 525], ["congestion", "OBSERVATION", 526, 536], ["sore throat", "ANATOMY", 559, 570], ["cough", "OBSERVATION", 582, 587], ["muscular aches", "ANATOMY", 589, 603], ["chills", "OBSERVATION", 605, 611]]], ["Hendley et al. (1) found that illness due to 229E in adults was characterized mainly by nasal symptoms with little or no fever.", [["nasal", "ANATOMY", 88, 93], ["illness", "DISEASE", 30, 37], ["fever", "DISEASE", 121, 126], ["nasal", "ORGANISM_SUBDIVISION", 88, 93], ["nasal symptoms", "PROBLEM", 88, 102], ["fever", "PROBLEM", 121, 126], ["illness", "OBSERVATION", 30, 37], ["nasal", "ANATOMY", 88, 93]]], ["They also found that illnesses due to OC 43 resembled colds caused by rhinoviruses and were characterized by pharyngitis, cough and nasal congestion.", [["nasal", "ANATOMY", 132, 137], ["OC", "CHEMICAL", 38, 40], ["colds", "DISEASE", 54, 59], ["rhinoviruses", "DISEASE", 70, 82], ["pharyngitis", "DISEASE", 109, 120], ["cough", "DISEASE", 122, 127], ["nasal congestion", "DISEASE", 132, 148], ["rhinoviruses", "ORGANISM", 70, 82], ["nasal", "ORGANISM_SUBDIVISION", 132, 137], ["illnesses", "PROBLEM", 21, 30], ["colds", "PROBLEM", 54, 59], ["rhinoviruses", "PROBLEM", 70, 82], ["pharyngitis", "PROBLEM", 109, 120], ["cough", "PROBLEM", 122, 127], ["nasal congestion", "PROBLEM", 132, 148], ["rhinoviruses", "OBSERVATION", 70, 82], ["pharyngitis", "OBSERVATION", 109, 120], ["nasal", "ANATOMY", 132, 137], ["congestion", "OBSERVATION", 138, 148]]], ["Our findings, based on patients with sero-response to 229E, indicate a close parallel in regard to nasal involvement.", [["nasal", "ANATOMY", 99, 104], ["patients", "ORGANISM", 23, 31], ["nasal", "ORGAN", 99, 104], ["patients", "SPECIES", 23, 31], ["nasal involvement", "PROBLEM", 99, 116], ["nasal", "ANATOMY", 99, 104], ["involvement", "OBSERVATION", 105, 116]]], ["Our attending physicians saw more fever than that described by Hendley et al. (1) , although the frequency of fever with 229E was less than that described in our previous study with OC 43.", [["fever", "DISEASE", 34, 39], ["fever", "DISEASE", 110, 115], ["OC", "CHEMICAL", 182, 184], ["fever", "PROBLEM", 34, 39], ["fever", "PROBLEM", 110, 115], ["fever", "OBSERVATION", 110, 115]]], ["The presence of preexisting antibody seemed to have no significant ameliorating effect on respiratory illness caused by 229E.", [["respiratory", "ANATOMY", 90, 101], ["respiratory illness", "DISEASE", 90, 109], ["preexisting antibody", "PROBLEM", 16, 36], ["respiratory illness", "PROBLEM", 90, 109], ["antibody", "OBSERVATION", 28, 36], ["no", "UNCERTAINTY", 52, 54], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["ameliorating", "OBSERVATION_MODIFIER", 67, 79], ["effect", "OBSERVATION", 80, 86], ["respiratory illness", "OBSERVATION", 90, 109]]]], "a8b0b9ef444b8ddeeff4d0015076f4a5c34c0bf7": [["Ghanaian children (2176) aged <5 years who presented with undifferentiated acute respiratory distress were tested for respiratory pathogens using a BioFire FilmArray polymerase chain reaction assay.", [["respiratory", "ANATOMY", 81, 92], ["acute respiratory distress", "DISEASE", 75, 101], ["respiratory pathogens", "DISEASE", 118, 139], ["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["undifferentiated acute respiratory distress", "PROBLEM", 58, 101], ["respiratory pathogens", "PROBLEM", 118, 139], ["a BioFire FilmArray polymerase chain reaction", "TREATMENT", 146, 191], ["undifferentiated", "OBSERVATION_MODIFIER", 58, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory distress", "OBSERVATION", 81, 101]]], ["Rhinovirus and/or enterovirus was detected in 36% of the assays, respiratory syncytial virus in 11%, and parainfluenza in 7%.", [["respiratory syncytial virus", "DISEASE", 65, 92], ["parainfluenza", "DISEASE", 105, 118], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["enterovirus", "ORGANISM", 18, 29], ["respiratory syncytial virus", "ORGANISM", 65, 92], ["parainfluenza", "ORGANISM", 105, 118], ["respiratory syncytial virus", "SPECIES", 65, 92], ["parainfluenza", "SPECIES", 105, 118], ["respiratory syncytial virus", "SPECIES", 65, 92], ["Rhinovirus", "PROBLEM", 0, 10], ["enterovirus", "PROBLEM", 18, 29], ["the assays", "TEST", 53, 63], ["respiratory syncytial virus", "TEST", 65, 92], ["parainfluenza", "PROBLEM", 105, 118], ["enterovirus", "OBSERVATION", 18, 29], ["respiratory syncytial", "ANATOMY", 65, 86]]], ["Respiratory syncytial virus and metapneumovirus were detected more frequently in the rainy season than in the dry season.", [["Respiratory syncytial virus and metapneumovirus", "DISEASE", 0, 47], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["metapneumovirus", "ORGANISM", 32, 47], ["Respiratory syncytial virus and metapneumovirus", "SPECIES", 0, 47], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["metapneumovirus", "PROBLEM", 32, 47], ["syncytial virus", "OBSERVATION", 12, 27], ["metapneumovirus", "OBSERVATION", 32, 47]]]], "PMC7172604": [["Author contributionsB.A.O., D.S.W. and W.Y.L. wrote the letter.Declaration of Competing InterestB.A.O. is an inventor named on a Canadian patent (2852978), a US patent (9517265), and a pending US patent (62/268,137).", [["a US", "TEST", 156, 160], ["a pending US", "TEST", 183, 195], ["patent", "OBSERVATION", 138, 144], ["patent", "OBSERVATION", 161, 167], ["patent", "OBSERVATION", 196, 202]]], ["D.S.W. and W.Y.L have no competing interests.", [["no", "UNCERTAINTY", 22, 24], ["competing interests", "OBSERVATION", 25, 44]]]]}